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ABSTRACT 
Human pancreatic beta cells are susceptible to infection by enteroviruses, 
especially Coxsackie B viruses, and such infections could contribute to the 
development of Type 1 diabetes. Enteroviruses gain entry via cell surface 
receptors, one of which, the Coxsackie and Adenovirus receptor (CAR), is a 
transmembrane cell adhesion protein which serves as a key entry receptor for 
Coxsackie B viruses and is thought to be localised mainly within regions where 
contacts are formed between adjacent cells. CAR exists as at least 5 isoforms 
and this study has examined their expression profile and distribution in the human 
pancreas utilising; formalin-fixed paraffin-embedded pancreatic sections from 
non-diabetic individuals, type 1 diabetes patients and a human tissue microarray. 
Isolated human islets, human pancreatic beta and ductal cell lines were also 
studied. Immunological and molecular approaches were employed to examine 
the expression and cellular localisation of the known CAR isoforms in human 
pancreas. 
One specific isoform of CAR (CAR-SIV) with a unique C terminal PDZ binding 
domain, was highly expressed in human beta cells at the protein level. 
Surprisingly, it was distributed in a punctate manner mainly within the cytoplasm 
of the cells, rather than at the cell surface. In human beta cells, within the 
cytoplasm CAR-SIV co-localised with ZnT8, PC1/3 and insulin but less so with 
proinsulin suggesting that CAR-SIV is associated with insulin secretory granules. 
Immunogold labelling and electron microscopic analysis revealed that CAR-SIV 
is localised both to maturing insulin secretory granules and to fully mature, dense-
core (insulin) secretory granules. Intriguingly, CAR-SIV colocalises and interacts 
with a cytosolic protein, PICK1, which plays a role in the budding, maturation and 
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trafficking of insulin secretory granules. On this basis, a model is proposed 
whereby CAR-SIV and PICK1 interact to regulate the maturation and trafficking 
of insulin secretory granules. Overall, this study suggests that the specialised role 
and subcellular localisation of CAR-SIV in human beta cells may contribute to 
their sensitivity to enteroviral infection following externalisation of the protein at 
the cell surface, during insulin exocytosis. 
 
 
 
  
5 | P a g e  
 
Table of Contents 
ABSTRACT .................................................................................................................. 3 
LIST OF FIGURES ..................................................................................................... 11 
LIST OF TABLES ....................................................................................................... 15 
ACKNOWLEDGEMENT ............................................................................................. 17 
ABBREVIATIONS ....................................................................................................... 18 
PUBLICATIONS ......................................................................................................... 23 
CHAPTER 1 
Introduction…………………………………………………………………………………..24 
1.1 Brief history of diabetes mellitus ........................................................................ 25 
1.2 Diabetes mellitus ............................................................................................... 26 
1.2.1 Type 1 diabetes (T1D) .................................................................................... 27 
1.2.2 Other forms of diabetes ............................................................................... 28 
1.2.3 Immune mediated Type 1 diabetes ................................................................. 31 
1.3 Pancreas ........................................................................................................... 34 
1.3.1 Islets of Langerhans .................................................................................... 35 
1.3.2 Studying the beta cell .................................................................................. 38 
1.3.3 Insulin granule biogenesis ........................................................................... 38 
1.3.4 Insulin secretion .......................................................................................... 41 
1.3.5 Alternate signals for insulin secretion .......................................................... 44 
1.3.6 Insulin granule pools ................................................................................... 45 
1.3.7 Exocytosis................................................................................................... 46 
1.3.7.1 Fusion pore opening ................................................................................ 47 
1.3.8 Endocytosis ................................................................................................ 50 
1.4 Human enteroviruses and Type 1 diabetes ....................................................... 52 
1.5 Mechanism of virus-induced autoimmune T1D .................................................. 57 
1.5.1 Direct beta cell damage .............................................................................. 57 
1.5.2 Persistent enteroviral infection .................................................................... 58 
1.5.3 Molecular mimicry ....................................................................................... 59 
1.6 Enterovirus receptors ........................................................................................ 59 
1.7 The Coxsackievirus and adenovirus receptor (CAR) ......................................... 61 
1.7.1 Structure of CAR ......................................................................................... 64 
1.7.2 CAR expression in cells and tissues ........................................................... 67 
1.7.3 CAR Post-translational modifications .......................................................... 68 
1.7.9 CAR interacting protein partners ................................................................. 70 
1.7.10 Mechanism of Coxsackievirus entry through CAR ..................................... 73 
6 | P a g e  
 
1.8 AIMS ................................................................................................................. 75 
CHAPTER 2 
Materials and Methods……………………………………………………………………..76 
2.1 Source of reagents ............................................................................................ 77 
2.2 Cell culture ........................................................................................................ 79 
2.2.1 Passaging of cell line .................................................................................. 80 
2.3 Isolated human Islets......................................................................................... 80 
2.4 Tissue samples ................................................................................................. 81 
2.4.1 Microtomy ................................................................................................... 82 
2.5 Immunostaining reagents .................................................................................. 83 
2.6 Immunocytochemistry (ICC) .............................................................................. 84 
2.6.1 Cells and fixation ......................................................................................... 84 
2.6.2 Staining ....................................................................................................... 84 
2.7 Immunohistochemistry (IHC) ............................................................................. 85 
2.8 Immunofluorescence microscopy ...................................................................... 87 
2.8.1 Imaging ....................................................................................................... 87 
2.9 Cryoimmunogold electron microscopy (Cryo-EM) .............................................. 88 
2.10 RNA analysis ................................................................................................... 88 
2.10.1 RNA purification ........................................................................................ 88 
2.10.2 RNA or DNA estimation ............................................................................ 89 
2.10.3 cDNA (Complementary DNA) synthesis .................................................... 89 
2.10.4 Primer design ............................................................................................ 89 
2.11 polymerase chain reaction (PCR) .................................................................... 90 
2.12 DNA sequencing ............................................................................................. 90 
2.13 RT-Real Time PCR.......................................................................................... 91 
2.14 Laser capture microdissection of human islets ................................................ 91 
2.15 RNAseq ........................................................................................................... 93 
2.16 Protein analysisby Western blotting ................................................................. 93 
2.16.1 Sample preparation ................................................................................... 93 
2.16.2 Protein estimation ..................................................................................... 94 
2.16.3 Electrophoresis and protein transfer .......................................................... 94 
2.16.4 Antibody probing ....................................................................................... 95 
2.16.5 Detection of proteins ................................................................................. 96 
2.17 Flow cytometry ................................................................................................ 96 
2.17.1 Cell preparation......................................................................................... 97 
2.17.2 Extracellular staining of surface antigen .................................................... 97 
2.17.3 Intracellular staining of antigen .................................................................. 97 
7 | P a g e  
 
2.18 Proximity ligation assay (PLA) ......................................................................... 98 
2.19 Co-immunoprecipitation ................................................................................... 99 
2.19.1 Cell lysate preparation .............................................................................. 99 
2.19.2 Precipitation of Immune complexes ........................................................... 99 
2.20 DNA cloning .................................................................................................. 100 
2.20.1 Agar plates .............................................................................................. 100 
2.20.2 Bacterial transformation and plasmid purification .................................... 100 
2.20.3 Glycerol storage ...................................................................................... 101 
2.21 Transient transfection of purified plasmid ...................................................... 101 
2.21.1 Identification of a suitable transfection reagent for the human pancreatic 
beta cell line 1.1B4 ............................................................................................ 102 
2.21.2 Transient transfection of CAR-SIV Myc construct into the human pancreatic 
beta cell line 1.1B4. ........................................................................................... 106 
2.22 Site directed mutagenesis ............................................................................. 111 
2.22.1 Restriction digest .................................................................................... 113 
2.22.2 Direct sequencing confirming successful site directed mutagenesis ........ 114 
2.23 Human growth hormone assay (HGH) ........................................................... 116 
2.24 Statistical analysis ......................................................................................... 119 
CHAPTER 3 
Characterisation of CAR isoforms in the human beta cell and pancreas……….120 
3.1 Introduction ..................................................................................................... 121 
3.2 Results ............................................................................................................ 123 
3.2.1 RT-PCR detection of mRNA encoding specific CAR isoforms in human 
pancreatic islets and human beta cell lines ........................................................ 123 
3.2.2 TaqMan qRT-PCR detection of mRNA encoding specific CAR isoforms in 
isolated and laser captured micro-dissected human pancreatic islets ................ 128 
3.2.3 RNAseq and RT-PCR detection of mRNA encoding specific CAR isoforms 
and effect on cytokine treatment in human pancreatic islets and human beta cell 
lines ................................................................................................................... 133 
3.2.4 Detection of CAR isoform protein expression in human pancreatic tissue by 
immunohistochemistry ....................................................................................... 139 
3.2.5 Detection of CAR isoform protein expression by immunofluorescence 
analysis in human pancreatic tissue................................................................... 145 
3.2.6 Detection of other CAR isoforms by immunofluorescence analysis in human 
pancreatic tissue ................................................................................................ 148 
3.2.7 CAR isoform expression by Western blotting ............................................ 152 
3.2.8 Detection of ADAM10 expression in isolated human islets, human pancreatic 
tissue and beta cell line EndoC-βH1 .................................................................. 155 
8 | P a g e  
 
3.2.9 Comparison of CAR CT and CAR RmcB antisera in human pancreatic tissue 
and the human pancreatic beta cell line 1.1B4 ................................................... 157 
3.2.10 CAR-SIV isoform expression in the human pancreas .............................. 159 
3.2.11 CAR-SIV isoform expression in the pancreas of Type 1 diabetes patients
 .......................................................................................................................... 164 
3.2.12 CAR-SIV isoform expression in the pancreas of Type 2 diabetes patients
 .......................................................................................................................... 167 
3.2.13 Differential staining of CAR-SIV isoform in mouse and human pancreas 
tissue ................................................................................................................. 168 
3.3 Discussion ....................................................................................................... 173 
3.3.1 Expression of transmembrane CAR isoform in isolated human islets and beta 
cell lines ............................................................................................................. 173 
3.3.2 Expression of soluble CAR isoform in isolated human islets and pancreatic 
beta cell lines ..................................................................................................... 174 
3.3.3 Cytokine treatment has no effect in CAR isoform expression in the isolated 
human islets and EndoC-βH1 cells .................................................................... 175 
3.3.4 CAR isoform expression in the human pancreatic tissue ........................... 176 
3.3.5 CAR isoform protein expression in the isolated human islets and pancreatic 
beta cell lines ..................................................................................................... 177 
3.3.6 CAR isoform expression in autoantibody positive individuals without diabetes 
and individuals with Type 2 Diabetes ................................................................. 179 
3.3.7 Differential CAR isoform expression in mouse and human pancreatic tissue
 .......................................................................................................................... 180 
3.3.8 Summary: ................................................................................................. 181 
CHAPTER 4 
Characterisation of CAR antisera using human pancreas tissue beta and ductal 
cells…………………………………………………………………………………..182 
4.1 Introduction ..................................................................................................... 183 
4.2 Results ............................................................................................................ 185 
4.2.1 Trial of CAR antisera in human pancreatic ductal cell line ......................... 185 
4.2.2 Detection of CAR surface expression in the human pancreatic beta and 
ductal cell line model ......................................................................................... 188 
4.2.3 Detection of intracellular CAR expression in the human pancreatic beta and 
ductal cell line models ........................................................................................ 191 
4.2.4 Bioinformatics prediction of CAR-SIV isoform structural orientation within a 
cell ..................................................................................................................... 193 
4.2.5. Flow cytometry detection of CAR orientation in the human pancreatic beta 
cell model (EndoC-βH1)..................................................................................... 195 
4.2.6 CAR-SIV isoform immunolabelling in normal and cancerous human tissues
 .......................................................................................................................... 200 
4.3 Discussion ....................................................................................................... 205 
9 | P a g e  
 
4.3.1 CAR CT, CAR ECD and CAR RmcB antisera differentially label the human 
pancreatic ductal cell (PANC-1) ......................................................................... 205 
4.3.2 The extracellular domain of CAR is present on the surface of human 
pancreatic beta and ductal cell lines .................................................................. 205 
4.3.3 CAR CT antiserum staining suggests that CAR-SIV is present in intracellular 
compartments in human pancreatic beta and ductal cells .................................. 208 
4.3.4 CAR orientation in EndoC-βH1 cell line ..................................................... 208 
4.3.5 CAR-SIV is differentially expressed in normal and cancerous human tissues
 .......................................................................................................................... 210 
4.3.6 Differential CAR-SIV and CAR-TVV expression in normal and cancerous 
human tissues by RNAseq ................................................................................. 210 
CHAPTER 5 
Subcellular localisation of CAR-SIV in human beta cell of the pancreas……….214 
5.1 Introduction ..................................................................................................... 215 
5.2 Results ............................................................................................................ 216 
5.2.1 Cellular localisation of CAR-SIV in the human pancreatic beta cell ........... 216 
5.2.2 Co-localisation of CAR-SIV with insulin secretory granule (ISG) proteins in 
the beta cell ....................................................................................................... 219 
5.2.3 Pearson’s correlation coefficient (PCC) quantifies the colocalisation between 
CAR-SIV and the secretory granule proteins ..................................................... 223 
5.2.4 Manders correlation coefficient (MCC) quantifies the colocalisation between 
CAR-SIV and the secretory granule proteins ..................................................... 225 
5.2.5 Cryo-immunogold electron microscopy (Cryo-EM) of CAR-SIV and ZnT8 in 
the insulin granule .............................................................................................. 229 
5.2.6 Morphometric quantification of CAR-SIV labelling density ......................... 232 
5.2.7 CAR-SIV immunogold labelling at different stages of insulin granule 
maturation .......................................................................................................... 233 
5.2.8 Detection of PICK1 protein expression in human pancreatic tissue by 
immunohistochemistry ....................................................................................... 236 
5.2.9 PICK1 detection by immunofluorescence and confocal immunofluorescence 
microscopy ........................................................................................................ 239 
5.2.10 Pearson’s correlation coefficient and Mander's correlation coefficient 
quantifies the colocalisation of PICK1, CAR-SIV and Insulin .............................. 242 
5.2.11 PICK1 expression by Western blotting analysis ...................................... 244 
5.2.12 Do PICK1 and CAR-SIV interact in the human pancreatic beta cell? ...... 246 
5.3 Discussion ....................................................................................................... 251 
5.3.1 CAR-SIV colocalises with insulin in human pancreatic beta cells .............. 251 
5.3.2 CAR-SIV is present in both immature and mature insulin secretory granule 
proteins .............................................................................................................. 251 
10 | P a g e  
 
5.3.3 CAR-SIV colocalises and interacts with PICK1 in the insulin secretory 
granule .............................................................................................................. 255 
CHAPTER 6 
Investigation of the role of CAR-SIV in the human beta cell………………...........264 
6.1 Introduction ..................................................................................................... 265 
6.2 Results ............................................................................................................ 265 
6.2.1 Confirming the generated wildtype CAR-SIV and truncated CAR-SIV mutant 
constructs .......................................................................................................... 265 
6.2.2 Detection of CAR CT and CAR RmcB antisera binding in transfected cells 
using a proximity ligation assay ......................................................................... 270 
6.2.3 CAR-SIV colocalises with insulin in wild-type CAR-SIV construct in the 
human pancreatic beta cell line 1.1B4 ............................................................... 273 
6.2.4 Investigating insulin secretion in transfected 1.1B4 cells ........................... 275 
6.2.5 Effects of transfection with CAR-SIV on human growth hormone (hGH) 
release from 1.1B4 cells .................................................................................... 277 
6.2.6 Investigation of the human growth hormone (hGH) system in the rodent 
pancreatic INS-1E cell line ................................................................................. 281 
6.2.7. Immunocytochemical detection of human growth hormone (hGH) and CAR-
SIV in the human pancreatic beta cell line 1.1B4 ............................................... 285 
6.3 Discussion ....................................................................................................... 287 
6.3.1 Generation of wild-type and mutant CAR-SIV constructs .......................... 287 
6.3.2 Validation of the specificity of the CAR CT antiserum using the mutant CAR-
SIV construct ..................................................................................................... 287 
6.3.3 CAR-SIV overexpression did not impact on insulin granule secretion in this 
model-but is it the right model? .......................................................................... 288 
6.3.4 Future work to assess the effect of CAR-SIV in insulin secretion .............. 289 
CHAPTER 7 
Conclusion………………………………………………………………………………….291 
7.0 Summary ......................................................................................................... 292 
7.0.1 The localisation of CAR-SIV may explain the susceptibility of human beta 
cells to enteroviral infection ................................................................................ 293 
7.0.2 CAR-SIV may have a role in vesicle maturation and trafficking in human 
pancreatic beta cells .......................................................................................... 295 
7.1 Limitation of study ........................................................................................... 298 
7.2 Future Work .................................................................................................... 298 
APPENDIX ............................................................................................................ 301 
REFERENCES ...................................................................................................... 306 
 
  
11 | P a g e  
 
LIST OF FIGURES 
CHAPTER 1 
Figure 1.1 Worldwide current and projected cases of diabetes. .................................. 26 
Figure 1.2 Architectural difference in islet organisation of beta and alpha cells in human 
and mouse pancreas .................................................................................................. 37 
Figure 1.3 Biogenesis of insulin granules. ................................................................... 40 
Figure 1.4 Insulin secretion pathway. .......................................................................... 43 
Figure 1.5 Exocytosis mechanism of insulin secretion ................................................ 49 
Figure 1.6 Endocytosis proposed mechanism ............................................................. 51 
Figure 1.7 Structure and genome of Enterovirus. ........................................................ 53 
Figure 1.8 Structure of the CAR protein and isoform. .................................................. 63 
Figure 1.9 Similarities and differences between the protein sequence of CAR-SIV and 
CAR-TVV .................................................................................................................... 66 
Figure 1.10 CAR and interacting protein partners. ...................................................... 72 
Figure 1.11 Mechanism of CVB entry into cells. .......................................................... 74 
 
CHAPTER 2 
Figure 2.1 Morphology of isolated human islets .......................................................... 81 
Figure 2.2 Immunocytochemical staining with chromogranin and insulin antisera in 
EndoC-βH1 cell line .................................................................................................... 85 
Figure 2.3 Immunocytochemical analysis showing pMax-GFP vector transfected in 
1.1B4 cells utilising different transfection reagents .................................................... 103 
Figure 2.4 Avalanche-Omni reagent has a 20% transfection efficiency when compared 
to Fugene transfection reagent in the 1.1B4 ............................................................. 105 
Figure 2.5 RT-PCR confirms the overexpression of CAR-SIV and not CAR-TVV in 
1.1B4 cells transfected with CAR SIV-Myc. ............................................................... 107 
Figure 2.6 Immunocytochemical analysis demonstrates low expression of CAR-SIV in 
transfected CAR-SIV Myc 1.1B4 cells ....................................................................... 108 
Figure 2.7 Western blot analysis confirms low expression of CAR-SIV in transfected 
CAR-SIV Myc-tag 1.1B4 cells ................................................................................... 110 
Figure 2.8 Pipeline of site directed mutagenesis ....................................................... 112 
Figure 2.9 Restriction digest confirms the wild-type CAR-SIV vector. ....................... 114 
Figure 2.10 Direct sequencing confirmation of the generation of CAR-SIV wild type and 
truncated CAR-SIV constructs by insertion of mutation ............................................. 115 
Figure 2.11 Pictorial diagram of human Growth Hormone secretion process. ........... 118 
 
CHAPTER 3 
Figure 3.1 CAR-SIV or CAR-TVV transmembrane isoforms are amplified in isolated 
human islet and 1.1B4. ............................................................................................. 124 
Figure 3.2 Isoform specific RT-PCR analysis revealed that CAR-SIV is more abundant 
than CAR-TVV from two independent isolated human islets. .................................... 126 
Figure 3.3 CAR-SIV and CAR-TVV isoform is confirmed in isolated human islets. .... 127 
Figure 3.4 Schematic diagram displaying the location of TaqMan probes and primers 
for each of the five CAR isoforms.............................................................................. 129 
Figure 3.5 CAR-SIV and CAR-TVV is expressed in both isolated and LCM human islets
 ................................................................................................................................. 131 
Figure 3.6 Visualisation of human islets for laser capture microdissection (LCM) ..... 132 
12 | P a g e  
 
Figure 3.7 RNAseq analysis demonstrates higher expression of CAR-SIV compared to 
CAR-TVV and low expression of CAR4/7 ................................................................. 134 
Figure 3.8 RT-PCR confirms the soluble CAR4/7 isoform expression in isolated human 
islets and 1.1B4 cell line ........................................................................................... 136 
Figure 3.9 RNAseq analysis confirms no effect of cytokines on levels of mRNA of CAR 
isoforms .................................................................................................................... 138 
Figure 3.10 Schematic diagram of CAR antisera immunoreactivity against CAR protein
 ................................................................................................................................. 139 
Figure 3.11 CAR isoforms are detected in the islet and exocrine pancreas  utilising 
CAR (NT and ECD) antisera in NDA pancreas. ........................................................ 141 
Figure 3.12 CAR isoform is detected in the islet and not in the exocrine tissue utilising 
CAR CT antiserum in NDA pancreas. ....................................................................... 142 
Figure 3.13 CAR isoform expression estimated by reciprocal intensity demonstrates 
that staining with CAR CT antisera detects high levels of CAR expression in the islets 
and not in the exocrine .............................................................................................. 144 
Figure 3.14 The CAR-SIV isoform is absent in some endocrine cells of the islets. .... 145 
Figure 3.15 Immunofluorescence images demonstrate that CAR-SIV is present in the 
beta cells .................................................................................................................. 147 
Figure 3.16 Representative immunofluorescence microscopy images of CAR isoforms 
in the islet ................................................................................................................. 150 
Figure 3.17 Immunofluorescence images provide independent confirmation of CAR-SIV 
isoform in the beta cells from an autoantibody positive non-diabetic case ................. 151 
Figure 3.18 Western blot analysis utilising the CAR CT and CAR ECD antisera detects 
CAR-SIV in isolated human islets, 1.1B4, EndoC-βH1 and PANC-1 cell lines .......... 153 
Figure 3.19 ADAM10 is expressed in isolated human islets and EndoC-βH1 ............ 156 
Figure 3.20 CAR RmcB antiserum epitope recognises the extracellular domain of CAR 
protein ...................................................................................................................... 157 
Figure 3.21 Comparison of the CAR CT and CAR RmcB antisera in the human 
pancreatic tissue and in the human pancreatic beta cell line 1.1B4 ........................... 158 
Figure 3.22 Consistent expression of CAR-SIV isoform in the islets of non-diabetes 
cases from neonates to adulthood. ........................................................................... 160 
Figure 3.23 Consistent expression of CAR-SIV isoform and insulin in beta cells in non 
diabetic pancreas. ..................................................................................................... 161 
Figure 3.24 CAR isoforms expression in the ductal cells of the human pancreas. ..... 163 
Figure 3.25 CAR-SIV is expressed in only the insulin containing islets of Type 1 
diabetes cases and not in insulin deficient islets. ...................................................... 165 
Figure 3.26 CAR-SIV is present only in insulin containing islet (ICI) and is absent in 
insulin deficient islets (IDI) ........................................................................................ 166 
Figure 3.27 Expression of CAR-SIV is not altered in a pancreas from a Type 2 diabetes 
case .......................................................................................................................... 168 
Figure 3.28 Differential enteroviral VP1 protein expression in CVB infected human and 
mouse pancreatic tissue ........................................................................................... 169 
Figure 3.29 Differential immunostaining with CAR CT and CAR ECD antisera in mouse 
pancreas tissue. ........................................................................................................ 171 
Figure 3.30 Alignment of the human and mouse CAR-SIV isoform ........................... 172 
 
 
 
13 | P a g e  
 
CHAPTER 4 
Figure 4.1 Schematic diagram of CAR antisera (CAR NT, CAR ECD, CAR RmcB and 
CAR CT) immunoreactivity against CAR protein ....................................................... 184 
Figure 4.2 Staining with CAR RmcB and CAR CT, but not CAR ECD, antisera detects 
CAR in PANC-1 cell line ........................................................................................... 187 
Figure 4.3 CAR expression is detected on the surface of cells by staining with CAR 
RmcB antisera .......................................................................................................... 190 
Figure 4.4 CAR-SIV isoform is detected intracellularly by staining with the CAR CT 
antisera in EndoC-βH1, 1.1B4 and PANC-1 cells. ..................................................... 192 
Figure 4.5 Bioinformatics prediction of the orientation of the CAR-SIV isoform with 
bioinformatic tool (Protter). ........................................................................................ 194 
Figure 4.6 CAR orientation is detected utilising staining with anti-CAR RmcB and anti-
CAR CT in the human pancreatic beta cell EndoC-βH1. ........................................... 197 
Figure 4.7 Staining with CAR RmcB suggests that the CAR-SIV isoform is present both 
on the surface of the cells and in an intracellular compartment ................................. 198 
Figure 4.8 CAR-SIV isoform distribution and cellular localisation in normal and 
cancerous human tissues. ........................................................................................ 201 
Figure 4.9 CAR-SIV isoform expression in normal and cancerous human tissues. ... 202 
Figure 4.10 RNAseq analysis confirming the expression profile of CAR-SIV, CAR-TVV 
and CAR4/7. ............................................................................................................. 204 
Figure 4.11 A model of CAR proteolysis, with molecular weights of the resulting 
fragments indicated. ................................................................................................. 207 
Figure 4.12 CAR-SIV orientation in the beta cell…. .................................................... 209 
 
CHAPTER 5 
Figure 5.1 CAR-SIV colocalises with insulin in FFPE isolated human islets .............. 217 
Figure 5.2 CAR-SIV colocalises with insulin in insitu human pancreas ..................... 218 
Figure 5.3 CAR-SIV colocalises with insulin secretory granule proteins in the beta cell.
 ................................................................................................................................. 220 
Figure 5.4 CAR-SIV shows a partial colocalisation with proinsulin and no colocalisation 
with glucagon secretory granule proteins in the human islet. .................................... 222 
Figure 5.5 Pearson’s correlation coefficient (PCC) demonstrating an association 
between CAR-SIV and insulin secretory granule protein ........................................... 224 
Figure 5.6 Mander’s correlation coefficient (MCC) demonstrating the proportion of 
CAR-SIV that associates with insulin secretory granule proteins .............................. 226 
Figure 5.7 Mander’s correlation coefficient (MCC) demonstrates that CAR-SIV 
associates more with insulin but less with proinsulin ................................................. 228 
Figure 5.8 Cryo-immunogold electron microscopy revealed that CAR-SIV and ZnT8 is 
localised to the insulin granule .................................................................................. 230 
Figure 5.9 Cryo-immunogold electron microscopy. ................................................... 231 
Figure 5.10 Cryo-immunogold electron microscopy quantification. ............................ 233 
Figure 5.11Cryo-immune EM analysis of insulin granules at different stages of 
maturation. ................................................................................................................ 235 
Figure 5.12 Cryo-EM analysis of pancreatic tissue with unconjugated gold particles 236 
Figure 5.13 PICK 1 is expressed in the islet of normal human pancreatic tissue. ...... 238 
Figure 5.14 CAR-SIV colocalises with PICK1 and insulin in the beta cell in normal 
pancreas tissues. ...................................................................................................... 240 
14 | P a g e  
 
Figure 5.15 Confocal microscopy coupled with hyvolution imaging demonstrates a 
close association of CAR-SIV and PICK1 in insulin granule of normal human pancreas.
 ................................................................................................................................. 241 
Figure 5.16 Pearson correlation coefficient and Manders correlation coefficient 
demonstrating the extent of CAR-SIV colocalisation with PICK1 and insulin. ............ 243 
Figure 5.17 Schematic diagram of PICK1 antisera with epitope recognition sites against 
the PICK1 protein. Adapted from (Xu and Xia, 2006) ................................................ 245 
Figure 5.18 Confirmation of PICK1 expression in isolated human islets and pancreatic 
beta cell lines EndoC-βH1 and 1.1B4. ...................................................................... 245 
Figure 5.19 Immunoprecipitation of PICK1 and CAR-SIV independently from EndoC-
βH1 with different antisera. ....................................................................................... 247 
Figure 5.20 Co-immunoprecipitation of CAR pulls down PICK1. ............................... 249 
Figure 5.21 Co-immunoprecipitation of PICK1 weakly pulls down CAR. ................... 250 
Figure 5.22 Proposed CAR-SIV orientation in the insulin secretory granule. ............. 258 
Figure 5.23 Pictorial diagram of CAR-SIV and PICK1 binding ................................... 260 
Figure 5.24 Model for CAR-SIV, PICK1 and ICA69 insulin granule maturation and 
trafficking. ................................................................................................................. 262 
 
CHAPTER 6 
Figure 6.1 Full length CAR-SIV isoform is overexpressed in wild-type CAR-SIV and not 
in truncated CAR-SIV mutant constructs in 1.1B4 cell line ........................................ 266 
Figure 6.2 Confirmation of the CAR CT antiserum detecting only the full length CAR-
SIV isoform. .............................................................................................................. 267 
Figure 6.3 Representative flow scatter plot confirming labelling with CAR RmcB and 
CAR CT antisera in CAR-SIV transfected 1.1B4 cells ............................................... 269 
Figure 6.4 Proximity ligation assay demonstrates the binding of CAR CT and CAR 
RmcB in the different CAR-SIV constructs ................................................................ 271 
Figure 6.5 Schematic diagram of both CAR constructs ............................................. 272 
Figure 6.6 CAR-SIV co-localises with insulin in the wild-type CAR-SIV transfected 
1.1B4 cells. ............................................................................................................... 274 
Figure 6.7 Effect of different combinations of insulin secretion stimuli on human Growth 
Hormone (hGH) release in hGH transfected 1.1B4 cells. .......................................... 276 
Figure 6.8 Effect of the different CAR-SIV constructs on human growth Hormone (hGH) 
release in 1.1B4 cells ................................................................................................ 278 
Figure 6.9 Effect of the equal ratio of human growth hormone (hGH) and different CAR-
SIV constructs on hGH release in 1.1B4 cells ........................................................... 280 
Figure 6.10 hGH is released in INS1E cells co-transfected with 0.5μg of hGH and 0.3μg 
empty constructs. ...................................................................................................... 281 
Figure 6.11 The hGH release from the hGH transfected 1.1B4 cells is similar to the 
INS1-E cells. ............................................................................................................. 282 
Figure 6.12 Insulin is present in many more INS-1E cells than expressed hGH. ....... 283 
Figure 6.13 hGH co-localises with insulin in some, but not in all INS-1E cells. .......... 284 
Figure 6.14 ICC staining reveals hGH partial co-localisation with CAR-SIV in insulin 
containing beta cells in 1.1B4 cells. .......................................................................... 286 
 
 
 
15 | P a g e  
 
 
CHAPTER 7 
Figure 7.1 Proposed model of enteroviral entry in the beta cell through CAR-SIV. .... 294 
Figure 7.2 CAR-SIV and PICK1 interaction in the beta cell may be involved in the 
maturation and trafficking of the insulin secretory vesicle. ......................................... 297 
 
CHAPTER 8 
Figure 8.1 Map of the pCMV6 vector ........................................................................ 302 
Figure 8.2 Map of the pCMV6 empty vector .............................................................. 303 
Figure 8.3 Site directed mutagenesis strategy creating the Wild-type CAR-SIV and 
truncated CAR-SIV mutant construct ........................................................................ 305 
LIST OF TABLES 
CHAPTER 1 
Table 1.1 Summary of mutations, conditions and agents that can lead to diabetes ..... 30 
Table 1.2 Endocrine and exocrine cells of the pancreas and specific hormone secreted. 
(↑) increase (↓) decrease ............................................................................................ 36 
Table 1.3 Receptors utilised by enterovirus serotypes ................................................ 61 
Table 1.4 CAR isoforms from NCBI and UniProt database ......................................... 63 
 
CHAPTER 2 
Table 2.1 Buffer-solutions and components ................................................................ 78 
Table 2.2 Cell lines and sources ................................................................................. 79 
Table 2.3 List of primary antibodies utilised in this study ............................................. 83 
Table 2.4 Secondary antibodies and DAPI utilised for immunofluorescence and 
immunocytochemistry ................................................................................................. 83 
Table 2.5 List of immunostaining reagents .................................................................. 84 
Table 2.6 List of secondary antibodies for Western blotting ........................................ 96 
 
CHAPTER 3 
Table 3.1 Primer sequence to target both CAR-SIV and CAR-TVV ........................... 124 
Table 3.2 Primer sequence specific for CAR-SIV and CAR-TVV isoform .................. 126 
Table 3.3 TaqMan probe sequence for the five CAR isoforms .................................. 128 
Table 3.4 Isolated human islet donors ...................................................................... 129 
Table 3.5 RIN values of LCM human islets (nPOD) donor ........................................ 132 
Table 3.6 Primer sequence targeting the CAR soluble isoforms ............................... 135 
Table 3.7 CAR antisera and their predicted CAR isoforms ........................................ 148 
Table 3.8 Summary of CAR antisera staining pattern using the semi-quantitative 
method ..................................................................................................................... 151 
Table 3.9 Autoantibody positive, type1 diabetes and normal cases .......................... 151 
 
 
16 | P a g e  
 
 
CHAPTER 4 
Table 4.1 Summary of the utility of CAR antisera in different assays (+ suitable, -not 
suitable) .................................................................................................................... 183 
Table 4.2 Validation of CAR antisera with different assays ....................................... 199 
 
CHAPTER 5 
Table 5.1 Secretory granule proteins and their localisation in endocrine cells ........... 219 
Table 5.2 PCC analysis of CAR-SIV and secretory granule proteins ......................... 225 
Table 5.3 MCC analysis of CAR-SIV, insulin and proinsulin proteins ........................ 228 
Table 5.4 Pearson and Manders correlation coefficient of CAR-SIV association with 
PICK1 and insulin ..................................................................................................... 244 
Table 5.5 Proteins interacting with CAR-SIV ............................................................. 255 
 
CHAPTER 6 
Table 6.1 Summary of the validation of the specificity of CAR CT antiserum with the 
wild-type and truncated CAR-SIV constructs ............................................................ 272 
 
APPENDIX 
Table 8.1 Tissue Samples, Patient Information ......................................................... 301 
Table 8.2 Primers used for site directed mutagenesis ............................................... 304 
 
 
 
 
 
 
 
 
  
17 | P a g e  
 
ACKNOWLEDGEMENT 
I would like to wholeheartedly thank my supervisors Dr Sarah Richardson and 
Prof. Noel Morgan for their mentorship and guidance in the entirety of this project. 
With their enthusiasm and passion for research, both have inspired me and 
taught me grit and resilience in order to evolve as a scientist. Thank you for the 
extensive feedback and constructive criticisms while writing my thesis. 
I am utterly grateful to Dr Mark Russell and Dr Pia Leete for their support from 
the very first day I started my PhD and Dr Shalinee Dhayal who assisted me 
through the last stage. 
To our collaborators (in Finland, Belgium and Italy) and funders “FFWG, UEMS, 
JDRF, nPOD, Diabetes UK” as well as the donors and their family, thank you. 
I would also like to thank every single member of the IBEX team both past and 
present for the pleasant and friendly vibrant lab environment; Afi, Trish, Nikki, the 
entire team and level 4 labs. 
I would like to specially thank Felice Dileo for his kindness, immense support and 
encouragement. 
To my lovely siblings (Mamu, Ochuko, Nyerhovwo and Ejiro), words cannot 
express my deepest gratitude for your support throughout this journey. 
Finally, I would love to thank my dearest parents Mr and Mrs U.N Ifie who are 
irreplaceable and have gone beyond to make this dream become a reality. For 
believing in me when I found it so difficult to believe in myself. I am extremely 
grateful for your sacrifices and investment in me. 
To God almighty for the strength and grace to start and complete this degree.  
18 | P a g e  
 
ABBREVIATIONS 
 
ADS Antibody diluting solution 
ADST Antibody diluting solution with Triton X-100 
ATP Adenosine triphosphate 
BCA Bicinchoninic acid 
BSA Bovine serum albumin 
BT-IgSF Brain-testis Immunoglobulin superfamily 
cAMP Cyclic adenosine monophosphate 
CAR Coxsackie and adenovirus receptor 
CLMP CAR like membrane protein 
CD Cluster of differentiation 
CCR5 C-C chemokine receptor type 5 
CHO Chinese hamster ovary 
CPE Carboxypeptidase 
CT C terminus 
CTLA4 Cytotoxic T lymphocyte associated protein 4 
CTX Cortical thymocyte marker in Xenopus 
CVB Coxsackievirus B 
DAF Decay accelerating factor 
DiviD Diabetes virus detection  
DKA                  Diabetic ketoacidosis 
EADB Exeter Archival Diabetes Biobank 
EBV Epstein-Barr virus 1 
ECD Extracellular domain 
EDTA               Ethylenediaminetetraacetic acid 
19 | P a g e  
 
 
EM Electron microscopy 
EPAC Exchange protein directly activated by cAMP 
ER Endoplasmic reticulum 
ESAM Endothelial cell selective adhesion molecule 
FACS Fluorescence activated cell sorting 
FBS Fetal bovine serum 
Fd Forward 
FFPE Formalin fixed paraffin embedded 
GADA Glutamic acid decarboxylase 
 
GIP Glucose dependent insulinotropic peptide 
GLUT  Glucose transporter  
GLP1 Glucagon like peptide 1 
GLP2 Glucagon like peptide 2 
HEV Human enteroviruses 
hGH Human growth hormone 
HLA                  Human Leucocyte Antigen 
HRP Horseradish peroxidase 
IAA     Insulin autoantibody 
IAPP Islet amyloid polypeptide 
IA-2A Protein tyrosine phosphatase related IA-2 molecule 
 
IBMX 3-isobutyl-1-methylxanthine 
ICA Islet cell autoantibodies 
ICAM-1 Intercellular Adhesion Molecule 1 
ICC Immunocytochemistry 
ICD Intracellular cytoplasmic domain 
20 | P a g e  
 
IDF International diabetes federation 
IF Immunofluorescence 
IGSF Immunoglobulin superfamily 
IHC     Immunohistochemistry 
IL2RA Interleukin-2-receptor alpha chain 
INS Insulin 
IP3 Inositol triphosphate 
ISG Insulin secretory granule 
JAMs Junctional adhesion molecules 
KATP  ATP sensitive potassium  
LADA Latent autoimmune diabetes 
LB Luria broth 
LCM Laser captured micro-dissected 
LDCV Large dense core vesicles 
LDS Lithium dodecyl sulfate 
MCC Manders correlation coefficient 
MDCK Madin-Darby Canine Kidney Cells 
MHC   Major histocompatibility complex 1 
MODY Maturity onset diabetes of the young 
NDA Non diabetes adult  
NOD     Non obese diabetes  
nPOD network of Pancreatic Organ donor  
NT N terminus 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffered saline 
PC Prohormone convertase  
21 | P a g e  
 
 
PCC Pearson’s correlation coefficient 
PDZ PSD-95 (Post Synaptic Density Protein), DIgA (Drosophila Disc 
Large Tumor Suppressor) and ZO-1(Zonula Occludens-1 Protein) 
 
PE Phycoerythrin 
PFA Paraformaldehyde 
PKA Protein kinase A 
PP Pancreatic polypeptide 
PTPN22 Protein tyrosine phosphatase non-receptor type 22 
PVDF polyvinylidene difluoride 
PVR Poliovirus receptor 
RIN RNA integrity number 
RRP Readily releasable pool 
RER Rough endoplasmic reticulum 
RT-PCR Reverse transcriptase polymerase chain reaction 
SEM Standard error of the mean 
STWS Scott’s tap water substitute 
SNARE Soluble NSF Attachment protein Receptor 
T1D   Type 1 diabetes 
T2D Type 2 diabetes 
TAE Tris base, acetic acid, EDTA 
TBE Tris, borate, EDTA 
TBS Tris-buffered saline 
TBST Tris-buffered saline with Tween 20 
TCR T cell receptor 
TGN trans-Golgi network 
TM Transmembrane 
22 | P a g e  
 
 
 
 
 
 
  
RER Rough endoplasmic reticulum 
RRP Readily releasable pool 
RV   Reverse 
 
SEM Standard error of the mean 
 
SJL/J Swiss Jim Lambert 
SNAP25 Synaptosomal associated protein of 25kDa 
TBST Tris buffered saline + tween 
TIRF Total internal reflection fluorescence 
UAG Unacylated Ghrelin 
UTR      Untranslated region 
VAMP2 vesicle associated membrane protein 2 
VDCC Voltage gated Ca2+ channels 
VP Viral capsid protein 
ZO-1 Zonula occludens-1 
ZnT8 Zinc transporter 8 
23 | P a g e  
 
PUBLICATIONS 
Ifie E, Russell M.A, Dhayal S, LeeteP, Sebastiani G, Nigi L, Dotta F, Marjomäki 
V, Eizirik D.L, Morgan N.G &. RichardsonS.J (2018) Unexpected subcellular 
distribution of a specific isoform of the Coxsackie and Adenovirus Receptor, CAR-
SIV, in human pancreatic beta cells. Diabetologia Nov; 61(11): 2344-2355 
 
Jmii H, Halouani A, Elmastour F, Ifie E, Richardson S.J, Sane F, Mokni M, Aouni 
M, Hober D, Jaïdane H (2016) Central nervous system infection following vertical 
transmission of Coxsackievirus B4 in mice. FEMS Pathogens and Disease Sep 
20; 74 (8).ftw096. 
 
  
24 | P a g e  
 
 
 
 
 
 
 
 
 
CHAPTER 1 
Introduction 
 
 
 
 
 
 
  
25 | P a g e  
 
1.1 Brief history of diabetes mellitus 
In 400 B.C Sushruta, an Indian physician described polyuria (a symptom of type 
1 diabetes) as sweet urine disease and documented “that black ants were 
attracted to the urine” of affected individuals. This was recognised as the first 
recorded symptom of diabetes. The term “diabetes” originated from a Greek word 
(meaning “to syphon”), reflecting how individuals with the disease produce large 
volumes of urine. The term “Diabetes Mellitus” was later coined by a physician 
Thomas Willis in 1674, he described the word “Mellitus” (Latin to mean “sweet 
like honey”) as a feature of the urine of people with diabetes (von Engelhardt, 
1989).  
It was not until the late 1800’s that a connection between diabetes and the 
pancreas was established after German physicians Joseph von Mering and 
Oskar Minkowski noticed that dogs developed diabetes after the pancreas was 
surgically removed. This breakthrough discovery led to research centred on the 
isolation of pancreatic extract from animals that could treat diabetes (v. Mering 
and Minkowski, 1890). The extract now known as “insulin” was isolated by a 
surgeon, Fredrick Banting, and a medical student Charles Best, in the laboratory 
of Prof. John Macloed in Toronto, Canada. Experiments on diabetic dogs showed 
that this extract caused a drop in blood glucose levels and the disappearance of 
glucose in urine (Banting et al., 1922). 
In 1922, the first patient, an extremely ill young boy received insulin which 
lowered his blood glucose levels and he began to gain weight (Banting et al., 
1922). Over the next 60 years, our understanding of the insulin molecule was 
refined, and insulin collected from animals to treat humans was terminated due 
to the advancement of recombinant human insulin (Ahmed, 2002).  
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1.2 Diabetes mellitus 
Diabetes mellitus is “a complex metabolic disorder characterised by abnormally 
high levels of blood glucose (hyperglycaemia) as a result of dysfunction in either 
insulin secretion, insulin signalling or both” (American Diabetes Association, 
2010). In 2013, the International Diabetes Federation (IDF) https://www.idf.org/ 
predicted that globally, 1 in 10 people will be diagnosed with some form of 
diabetes and that about 382 million people were living with the disease, this is 
expected to markedly increase to 600 million by 2035. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1.1 Worldwide current and projected cases of diabetes. 
 
 
 
 
Chart showing diabetes cases in 2013 and an estimated increase of diabetes cases in 
the world by 2035 (white arrow represent estimated % increase). International Diabetes 
Federation (IDF), Diabetes Atlas 6th edition (2013), https://www.idf.org/e-
library/epidemiology-research/diabetes-atlas/19-atlas-6th-edition.html 
 
2013 2035 
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The Diabetes UK charity in 2017 https://www.diabetes.org.uk/professionals/position-
statements-reports/statistics, reported that in the UK alone, 3.7million people aged 
17yrs or older had been diagnosed with the disease with an estimated 10% with 
Type 1 diabetes and 90% with Type 2 diabetes. Interestingly, there were large 
variations within the country with some cities having the highest prevalence of 
type 1 and type 2 diabetes. 
Previously, it was indicated that there were two forms of diabetes mellitus; 
autoimmune type 1 diabetes (T1D) and non-autoimmune type 2 diabetes (T2D) 
(Canivell and Gomis, 2014). However, as research advances many forms of 
diabetes mellitus are emerging. The American Diabetes Association recently 
classified diabetes into type 1 diabetes, type 2 diabetes, gestational diabetes 
mellitus and other specific forms of diabetes (American Diabetes Association 
2010, 2018) which are summarised in Table 1.1 
 
1.2.1 Type 1 diabetes (T1D) 
Type 1 diabetes is subdivided into immune mediated, latent autoimmune 
diabetes (LADA) and idiopathic diabetes. Immune mediated type 1 diabetes 
previously termed “insulin dependent” or “juvenile-onset diabetes” occurs as a 
result of autoimmune destruction of the pancreatic beta cells. The terms were 
abolished when it became evident that not all individuals with autoimmune 
diabetes were either juvenile or exhibited an absolute insulin requirement (Leslie 
et al., 2006). Immune mediated type 1 diabetes is the focus of this thesis and is 
described in more detail in section 1.2.3.  
LADA refers to individuals with adult onset autoimmune diabetes who may not 
initially require insulin treatment. This type of diabetes has also been called a 
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slow progressing insulin dependent diabetes (Kobayashi et al., 1993) or type 1.5 
diabetes (Naik and Palmer, 2003). Three features have been defined for the 
diagnosis of LADA; adult age at diagnosis, the presentation of circulating 
autoantibodies and the delay from diagnosis for the requirement of insulin dosage 
to manage hyperglycaemia (Leslie et al., 2006). 
Individuals with idiopathic T1D have no evidence of autoantibodies presentation 
but have strong genetic association, mostly observed in African and Asian 
lineage. Individuals also have almost complete insulin deficiency and are liable 
to diabetic ketoacidosis (American Diabetes Association, 2010) 
 
1.2.2 Other forms of diabetes 
Other forms of diabetes include Type 2 diabetes, gestational diabetes, neonatal 
and maturity onset diabetes of the young (MODY).  
Type 2 diabetes is reported to account for 90-95% of all diabetes and was termed 
“non-insulin dependent diabetes” or “adult onset diabetes”. People with type 2 
diabetes generally present as overweight or obese with relative insulin deficiency 
and peripheral insulin resistance (American Diabetes Association 2010, 2018). 
Type 2 diabetes results from a defect in beta cell insulin secretory function which 
is insufficient to compensate for insulin resistance (Lebovitz, 1999). In some 
individuals, T2D diagnosis may be missed for many years because 
hyperglycaemia may develop gradually over decades.  
Gestational diabetes mellitus (GDM) is defined as glucose intolerance diagnosed 
during pregnancy, and it is characterised by the insufficiency of the pancreatic 
beta secretory function to meet the body’s insulin requirement (Buchanan et al., 
2007). Women with gestational diabetes are at an increased risk of also 
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developing type 2 diabetes, cardiovascular disease and other metabolic 
syndromes (Poola-Kella et al., 2018).  
Neonatal diabetes is a form of monogenic diabetes that occurs from the 
inheritance of a mutation in a single gene. These mutations are found in genes 
that regulate beta cell function and are diagnosed in children within the first 6 
months of life (Hattersley et al., 2009). Maturity onset diabetes of the young 
(MODY) is also a form of monogenic diabetes that comprises of a group of 
clinically heterogeneous mutations that trigger beta cell dysfunction, with an 
autosomal dominant mode of inheritance (Shields et al., 2010), normally 
diagnosed before 25years of life. The subtypes of Neonatal and Maturity onset 
diabetes of the young with known mutations as well as other conditions that can 
lead to diabetes are summarised in Table 1.1 below 
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Table 1.1Summary of mutations, conditions and agents that can lead to diabetes 
Known 
mutations 
in 
Neonatal 
Diabetes 
Known 
mutations 
associated 
with MODY 
Diseases of the 
exocrine 
pancreas 
Endocrinopathies Drugs or 
chemicals that 
can induce 
diabetes 
KCNJ11 HNF-4α  
(MODY 1) 
Pancreatitis Acromegaly Nicotinic acid 
INS GCK 
(MODY 2) 
Cystic fibrosis Cushing's 
syndrome 
Glucocorticoids 
ABCC8 HNF-1α 
(MODY 3) 
Neoplasia Glucagonoma Diazoxide 
FOXP3 IPF-1 
(MODY4) 
Hemochromatosis Hyperthyroidism β-adrenergic 
agonist 
GATA6 HNF-1β 
(MODY 5) 
Pancreatectomy Aldosteronoma Thiazides 
EIF2AK3 NeuroD1 
(MODY6) 
  
Pentamidine 
Adapted from (Carmody et al., 2015, Association, 2010)  
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1.2.3 Immune mediated Type 1 diabetes 
Globally, about 500,000 young people under the age of 15 are estimated to have 
type 1 diabetes and the incidence is rising, in Europe this increase is most clear 
in young children (Patterson et al., 2014).  It has been forecast that the incidence 
of T1D in developed countries will double in children under the age of 5 between 
2005 and 2020 (Patterson et al., 2009). 
Type 1 diabetes develops from the selective destruction of the insulin producing 
pancreatic beta cells by autoimmune attack (Anderson and Bluestone, 2005). 
Analysis of post mortem pancreas tissue samples from recent onset T1D patients 
revealed that the destruction is linked to the infiltration of CD8+ cytotoxic T cells, 
CD4+ helper T  cells, CD20+ B lymphocytes cells and CD68+ macrophages termed 
“insulitis” (Willcox et al., 2009). CD8+ T cells have long been known as the major 
effectors of pancreatic beta cell destruction from studies of non-obese diabetes 
(NOD) mice (a rodent model of Type 1 diabetes), which demonstrates that mice 
do not progress to diabetes in the absence of cytotoxic CD8+ T cells (Katz et al., 
1993). These CD8+ T cells are activated by the interaction of their T-cell receptors 
(TCRs) with the MHC1 (Major histocompatibility complex 1), expressed on all 
nucleated cells. These activated CD8+ T cells can directly kill cells by the 
production of perforins, pore forming proteins, and granzymes, proteases that 
digest intracellular proteins or by Fas-Fas ligand mediated pathway (Trivedi et 
al., 2016, Graham et al., 2012). 
The classical symptoms of T1D are polyuria, polyphagia, polydipsia, weight loss, 
weakness and recurrent infections (Atkinson and Eisenbarth, 2001). One major 
complication of T1D especially for some children and adolescents is the initial 
presentation with diabetic ketoacidosis (DKA). Adults may have modest 
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hyperglycaemia, which may be exacerbated by environmental factors triggering 
severe hyperglycaemia and diabetic ketoacidosis (Dabelea et al., 2014). The 
consequence of the disease is that patients have to rely on lifelong exogenous 
insulin administration due to the failure in insulin production from the destroyed 
beta cells. 
In most individuals, the preclinical phase of the disease is usually characterised 
by the presence of one or more circulating autoantibodies (early immunological 
markers) in the serum which can appear between a few weeks to several years 
before onset (Ziegler et al., 2013). These circulating autoantibodies are targeted 
against beta cell autoantigens including those reactive to insulin (IAA), glutamic 
acid decarboxylase (GADA), protein tyrosine phosphatase-related IA-2 molecule 
(IA-2A) and Zinc transporter 8 (ZnT8) (Hyöty, 2002). 
Genetic predisposition plays an important role, with more than 50 candidate 
genes associated with risk of disease development (Santin and Eizirik, 2013). 
About 40-50% of the genetic risk of T1D derives from human leucocyte antigen 
(HLA) alleles located on chromosome 6. The HLA class II haplotypes (HLA-
DRB1, HLA-DQA1 and HLA-DQB1 loci) in particular show the strongest 
association with T1D (Noble and Erlich, 2012, de Beeck and Eizirik, 2016).The 
HLA class II region encodes membrane proteins expressed on the surface of 
antigen presenting cells (B lymphocytes, macrophages and dendritic cells) that 
are involved in the processing and presentation of exogenous antigens to CD4+ 
T helper cells (Gillespie, 2006). Other mapped candidate genes across the 
genome include cytotoxic T lymphocyte associated protein 4 (CTLA4); protein 
tyrosine phosphatase non-receptor type 22 (PTPN22), insulin (INS), interleukin-
2-receptor alpha chain (IL2RA),C-C chemokine receptor type 5 (CCR5) e.t.c 
(Todd, 2010) 
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Importantly though, the 1.5% annual increase in disease incidence cannot be 
explained by genetics alone as only a proportion of individuals with the genetic 
risk eventually go on to develop the disease (Atkinson et al., 2015). Also, the 
concordance rate observed between monozygotic twin study is only 30-50% and 
less than 5% of genetically predisposed individuals develop T1D (Redondo et al., 
1999, Patterson et al., 2012) implying that both genetic and environmental factors 
may contribute to the disease. A range of potential environmental factors have 
been linked to triggering T1D, such as; enhanced reactivity to cow’s milk 
introduced early in infancy which was evident in children who later went on to 
develop T1D (Luopajärvi et al., 2008), greater weight gain in early life (Hyppönen 
et al., 2001, Elding Larsson et al., 2016) and lower serum levels of vitamin D 
binding protein (Blanton et al., 2011).  
Recently, it has also been suggested that a correlation exists between the gut 
microbiome and type 1 diabetes. This was shown in a study where analysis of 
the microbiome from duodenal mucosa biopsied from people with type 1 diabetes 
was composed of reduced levels of Proteobacteria (Escherichia, Salmonella, 
Helicobacter) and increased Firmicutes (Bacilli and Streptococcus) when 
compared to healthy control individuals (Pellegrini et al., 2017). 
Viruses such as Epstein-Barr virus 1 (EBV), cytomegaloviruses, parechoviruses, 
rotaviruses, mumps virus, reovirus, retroviruses, rubella virus, enteroviruses and 
congenital rubella have also been implicated (Jun and Yoon, 2004, Coppieters et 
al., 2012). In particular, the human enterovirus family seem to have the strongest 
association (Yeung et al., 2011, Rodriguez-Calvo et al., 2016) and are considered 
by many, the prime environmental trigger for the disease. What is clear though is 
that there is a complex interplay between genetic predispositions, a dysregulated 
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immune system and environmental factors, each of which contribute in part to 
type 1 diabetes disease pathogenesis. 
 
1.3 Pancreas 
The pancreas is an organ with a head, neck, body and tail and is part of the 
gastrointestinal system that lies in the upper abdomen behind the stomach 
(Longnecker, 2014). It is highly vascularised and is innervated with sympathetic, 
parasympathetic and afferent nerve fibres that are closely associated together as 
they move through the pancreas (Love et al., 2007, Ahrén, 2000, Rodriguez-Diaz 
and Caicedo, 2013, Lindsay et al., 2006). 
The pancreas has two distinct tissues (endocrine and exocrine) that have 
important metabolic and digestive functions. The endocrine pancreas is 
organised into the islets of Langerhans, and these structures comprise 
approximately 1-2% of the pancreas mass. The islets produce and secrete 
hormones into the blood to regulate energy metabolism (Longnecker, 2014). The 
exocrine tissue is composed of lobules with acinar cells surrounded by ducts 
(Pandol, 2011). These cells synthesize and secrete digestive enzymes and 
bicarbonate, respectively, into the duodenum (initial part of the small intestine). 
Importantly, most studies of the pancreas come from extensive research in mice 
models which is still the most studied animal model due to the difficulties in 
obtaining human pancreas tissues. 
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1.3.1 Islets of Langerhans 
The islets of Langerhans were originally described as “small cells of almost 
perfect homogeneous content and of a polygonal form, with round nuclei without 
nucleoli, mostly lying together in pairs or small groups” by Paul Langerhans, a 
medical student in Berlin in 1869 (Sakula, 1988). 
The islets of Langerhans are highly vascularised micro-organs which are supplied 
with approximately 10-fold more volume of blood than the entire exocrine tissue. 
The intra-islet microcapillary comprises 7-8% of the total islet volume (Henderson 
and Moss, 1985, Saito et al., 1979). It is estimated that the average adult human 
pancreas contains one to two million islets (Hellman, 1959, Stefan et al., 1982), 
and these structures are more concentrated in the tail compared to the head or 
neck (Mann and Bellin, 2016). 
Five different endocrine cells make up the islets and respond to changes in 
plasma nutrient level by releasing a balanced mixture of specific hormones into 
the portal vein (Smeets, 2015). These cell types and their distribution in the islet 
include the alpha (α) cells (20%), beta (β) cells (70%), delta (δ) cells (<10%), 
ghrelin or epsilon (ε) cells (<1%) and F or pancreatic polypeptide (PP) cells 
(<5%). Upon receiving an appropriate stimulus these cells would secrete 
glucagon, insulin, somatostatin, ghrelin and pancreatic polypeptide respectively 
(Elayat et al., 1995, El-Gohary and Gittes, 2018). Apart from specific hormone 
product, non-hormonal products with varying functions are also secreted by these 
cells (Marrif and Al-Sunousi, 2016) described in Table 1.2 
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Table 1.2 Endocrine and exocrine cells of the pancreas and specific hormone secreted. 
(↑) increase (↓) decrease 
Pancreatic 
Cells 
Hormone Secreted Function 
Beta (β) Insulin 
Amylin or Islet Amyloid polypeptide 
(IAPP) 
↓plasma glucose 
↓pancreatic enzymes 
↓gut gastric emptying 
Alpha(α) Glucagon 
Glucagon like peptide (GLP1 and 
GLP2) 
↑plasma glucose 
↑insulin secretion and 
sensitivity 
↓glucagon secretion 
Delta(δ) Somatostatin Inhibits insulin and 
glucagon 
secretion  
F PP Pancreatic polypeptide Reduces food intake and 
the rate of gastric 
emptying 
Epsilon (ε) Ghrelin (AG).  
Unacylated Ghrelin (UAG) 
Inhibits insulin release 
and increases appetite 
Acinar cells Alpha-amylase, proteases and 
lipases 
 
Promote digestion in the 
gut 
 
Duct cells Secrete mucus, bicarbonate Promotes digestion  
Adapted from (Marrif and Al-Sunousi, 2016)  
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Importantly, the overall islet architecture may differ between human and rodent 
islets. Human islets are composed of layers of beta cells sandwiched between 
alpha cells. These are then folded in structures with vessels circulating along both 
sides. The beta cells also have cytoplasmic extensions (yellow arrows; 
Figure1.2A) intercalated between alpha cells implying that beta cells are able to 
reach the vasculature (Figure 1.2A). Also, either a heterologous beta-alpha cell 
contact or homologous beta-beta cell contact is predominant in human islets 
(Bosco et al., 2010). In contrast, rodents islets tend to be organised into a core-
mantle unit favouring homologous beta-cell to beta-cell contacts in the core and 
alpha-alpha cell contacts in the mantle surrounding the periphery which are in 
close association with vasculature (Bosco et al., 2010) as shown in Figure 1.2B. 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.2 Architectural difference in islet organisation of beta and alpha cells in human 
and mouse pancreas 
 
A B 
Immunofluorescence images showing (A) Human islets displaying layers of beta cells 
(light blue) sandwiched between alpha cells (red) enriched layers, beta cells also have 
cytoplasmic extensions intercalated between alpha cells (yellow arrows) (B) mouse 
islet organised with beta-beta cell in the core and alpha cells in the mantle surrounding 
the periphery. Nuclei are in dark blue. Scale bar 25μm       
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1.3.2 Studying the beta cell 
In 1908, Lane identified the “beta cells” by staining guinea pig pancreas sections 
with an alcoholic solution, Bensley’s neutral gentian (Lane, 1907, Bensley, 1914). 
It is estimated that about a 100 x 106 beta cells are present in the pancreas (Weir 
and Bonner‐Weir, 2013). The pancreatic beta cell functions as a sensor of 
extracellular glucose and produces appropriate amounts of insulin to decrease 
the blood glucose to a physiological level (Marrif and Al-Sunousi, 2016). As 
shown previously in Table 1.2, the beta cell also produces islet amyloid 
polypeptide (IAPP) also known as amylin. Amylin reduces food intake by slowing 
gastric emptying and promoting satiety (Reda et al., 2002). In mouse islet 
studies, amylin was shown to be packaged in and released from insulin granules 
(Kahn et al., 1990). Insulin and IAPP gene promoters have both been shown to 
be regulated by the transcription factor, PDX1 (MacFarlane et al., 1994, 
MacFarlane et al., 2000).  
 
1.3.3 Insulin granule biogenesis 
Studies with electron microscopy analysis estimated that about 11,000 insulin 
granules are present in a single beta cell of mouse pancreas (Dean, 1973, 
Olofsson et al., 2002) and the characteristic morphological feature of the insulin 
secretory granule has been observed by transmission electron microscopy to 
have a central dense core with a surrounding halo (Olofsson et al., 2002, Orci et 
al., 1986). 
The biogenesis of insulin (see Figure 1.3) begins with the synthesis of 
preproinsulin on the ribosomes in the rough endoplasmic reticulum (RER) and 
proinsulin is formed when the signal peptide sequence is cleaved off (by signal 
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peptidase) (Dodson and Steiner, 1998). According to Yang et al (2010), it is in 
the ER (endoplasmic reticulum) lumen that proinsulin is folded into a globular 
protein, a disordered structure comprising of native-like insulin and C-peptide 
(Yang et al., 2010). Properly folded proinsulin is then assembled in COPII 
vesicles which are subsequently transported from the ER to the trans-Golgi 
network (Fang et al., 2015). Here, proinsulin is assembled into Zn2+ and Ca2+ 
containing hexamers (Dunn, 2005) and packaged in clathrin coated vesicles 
before budding off as an immature granule to begin the maturation process.  
An ATP-dependent proton pump in the granule is reported to be responsible for 
the acidification of the insulin secretory vesicle (Davidson et al., 1988).  As the 
vesicles mature they become more acidic which facilitates the sequential 
proteolytic cleavage of proinsulin by the endoprotease PC1/3 (which cleaves the 
B-C junction of the proinsulin peptide sequence), and then PC2 (which cleaves 
the A-C junction of the proinsulin peptide sequence) (Furuta et al., 1997, Goodge 
and Hutton, 2000). Carboxypeptidase E enzyme (CPE) trims the carboxyl 
terminal two-basic amino acids yielding mature insulin and C peptide (Hutton, 
1994, Tokarz et al., 2018). This process converts proinsulin to mature insulin and 
C peptide (Naggert et al., 1995). Following the actions of prohormone convertase 
and carboxypeptidase, the insulin within the secretory granule binds to zinc 
enabling the crystallisationof insulin and the formation of dense core insulin 
structures (Ashcroft and Ashcroft, 1992, Dunn, 2005).   
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   Figure 1.3 Biogenesis of insulin granules. 
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Preproinsulin synthesis initiates on the ribosomes of the rough endoplasmic reticulum 
(RER). The signal peptide is cleaved and proinsulin is translocated into the ER lumen 
and proinsulin is then transported to the trans-Golgi network (TGN). Immature insulin 
granules then bud off the trans-Golgi network. Pro-insulin within the immature 
granules undergoes proteolytic cleavage to form insulin which forms insulin crystals 
when bound to zinc.  
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1.3.4 Insulin secretion 
Insulin secretion has been intensively studied in rodent and human pancreas and 
it is well established that the beta cell is a glucose sensor with a physiological 
function to secrete insulin (Ashcroft and Rorsman, 1989, Ashcroft and Rorsman, 
2012, Doyle and Egan, 2007). 
The process of insulin secretion (Figure 1.4) initiates when there is a postprandial 
rise in plasma glucose levels which elicits the uptake of glucose into the beta cell 
through the low affinity glucose transporter (GLUT1/3) in humans and (GLUT2) 
in mouse (Thorens, 1992). Cytosolic glucose is then metabolised through the 
glycolytic pathway to generate glucose-6-phosphate by glucokinase through an 
ATP dependent reaction. Glucokinase catalyses the rate limiting step in the 
process (Newgard and McGarry, 1995, De Vos et al., 1995) and thus is described 
to play a central role as a “glucose sensor” (Matschinsky, 1990). The production 
of glucose-6-phosphate then drives further metabolism leading to the generation 
of an increase in the ATP:ADP ratio (Rorsman et al., 2000, Cook et al., 1988).  
Studying ionic currents using patch clamp experiments has established that two 
types of ion channels are present in the pancreatic beta cell. These ion channels 
are pivotal for insulin secretion initiation in response to glucose: ATP sensitive K+ 
channels (KATP-channels) and voltage-gated Ca2+ channels (VDCC) (Rorsman 
and Renström, 2003). 
At low glucose, the KATP channel maintains the membrane potential at its resting 
potential (-70mv) and an increase in ATP generation induces the closure of the 
KATP channels which prevents K+ efflux and causes depolarisation of the plasma 
membrane. This change in membrane potential initiates the opening of the 
voltage dependent Ca2+ channels which facilitates the influx of extracellular 
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calcium (Ca2+) into the beta-cell. The increase in cytosolic Ca2+ induces insulin 
granule release, the key step in exocytosis (Rorsman and Braun, 2013, Shibasaki 
et al., 2004).  
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    Figure 1.4 Insulin secretion pathway. 
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Glucose enters into the human beta cell through the GLUT1/3 transporter and 
becomes metabolised via the glycolytic pathway facilitating an increase in 
intracellular ATP. This increase leads to the closure of the KATP channels inducing 
depolarisation of the membrane. This change in membrane potential initiates the 
opening of the voltage-gated Ca2+ channels, Ca2+ then enters leading to rise in 
cytosolic Ca2+ levels for insulin granule release. Another pathway that potentiates 
insulin secretion is the cAMP pathway, where an activation of GLP-1R leads to 
increase in cAMP facilitating the activation of protein kinase A (PKA) and exchange 
protein directly activated by cAMP (Epac) which then induces biphasic insulin 
secretion. Alternatively, activation of the GqR induces an increase in phospholipase 
C (PLC) activity thereby increasing the intracellular levels of inositol triphosphate 
(IP3) leading to Ca
2+ release from the calcium store in the ER.  
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1.3.5 Alternate signals for insulin secretion 
Insulin release from beta cells can be regulated by secretagogues such as 
endogenously produced hormones, neurotransmitters and pharmacological 
agents which can either enhance or negatively regulate insulin secretion. This 
section will focus more on the potentiation of insulin secretion through cyclic 
adenosine monophosphate (cAMP) signalling pathway. 
After the absorption of a meal, two main incretin hormones GLP-1 (glucagon like 
peptide-1) and GIP (glucose dependent insulinotropic peptide) are secreted by 
the intestinal L- and K-cells respectively in response to the local rise in glucose 
and these have been shown to potentiate insulin secretion (Doyle and Egan, 
2007). GLP-1 and GIP act on specific G protein coupled receptors expressed on 
the plasma membrane of beta cells, which when activated increase adenylyl 
cyclase activity and enhance the subsequent activity of cAMP dependent second 
messenger pathway members, protein kinase A (PKA) and exchange protein 
directly activated by cAMP (EPAC) (Holz, 2004).  These factors then act to 
regulate protein phosphorylation and increase the recruitment of secretory 
granules resulting in the potentiation of biphasic insulin release (Henquin and 
Nenquin, 2014). The biphasic insulin secretion includes a first phase rapid 
release of insulin followed by a second sustained phase of insulin secretion 
(Henquin et al., 2002). Importantly, pharmacological agents such as forskolin and 
IBMX (3-isobutyl-1-methylxanthine) can be used to raise cyclic AMP levels 
(Alasbahi and Melzig, 2012, Fehmann and Habener, 1992) and artificially 
stimulate the potentiation pathway. 
Additional agents known to amplify insulin secretion by alternate pathways, 
include acetylcholine, which is a non-fuel secretagogue released by intra-
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pancreatic nerves. Acetylcholine acts through the Gq coupled receptor (GqR) and 
activates phospholipase C (PLC), which subsequently leads to the generation of 
inositol triphosphate (IP3), and results in the release of calcium stores from the 
endoplasmic reticulum. This elevation in cytosolic calcium levels increases the 
number of readily releasable insulin granules at the plasma membrane (Ahrén, 
2000, Gilon and Henquin, 2001)(Figure 1.4) 
Whilst all of the above pathways absolutely require ATP generation in order to 
amplify secretion, the addition of a compound such as KCl bypasses the need for 
glucose metabolism and the ATP induced K+ channel. KCl acts by directly 
inducing membrane depolarisation enabling the opening of the voltage gated 
dependent Ca2+ channel to permit Ca2+ influx (Hatlapatka et al., 2009).  
 
1.3.6 Insulin granule pools 
It is proposed that there are two populations of intracellular insulin secretory 
granule; a readily releasable pool (RRP) which are docked close to the plasma 
membrane for immediate insulin release (Rorsman and Renström, 2003) 
(Figure1.4). The second population of granules, which are important for 
maintaining secretion over an extended period, are known as “the reserve pool”. 
These are situated in the cytoplasm and are recruited in an AMPK and kinesin-1 
dependent manner to the cell periphery (McDonald et al., 2009)(Figure 1.4). For 
insulin granules to reach the plasma membrane, depolymerisation (coordinated 
reorganisation and remodelling) of the cytoskeleton F-actin network has to occur 
(Kalwat and Thurmond, 2013) before granules are docked to the plasma 
membrane for eventual secretion.  
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The readily releasable pool accounts for about 1-5% of the insulin granules which 
undergo release without further modification after stimulation and is thought to be 
responsible for the rapid release (the first phase) of insulin secretion (Neher, 
1998). This pool is closely aligned to the plasma membrane and undergoes a 
calcium dependent release. 
The reserve pool (mediating the second phase of insulin secretion) occurs at a 
much slower rate and accounts for 95-99% of the granules. These granules must 
first undergo priming/mobilization which requires ATP, Ca2+ and time dependent 
reactions prior to their release.  
These two phases of glucose stimulated insulin secretion are said to yield 
“biphasic” insulin secretion. In the first phase, glucose stimulated insulin secretion 
last between 4 to 15mins (Nesher and Cerasi, 2002, Gaisano, 2014) and once 
depleted, the second phase insulin secretion occurs (Rorsman et al., 2000).  
 
1.3.7 Exocytosis 
Exocytosis of insulin secretory granules involves distinct steps; the tethering of 
the insulin secretory granules to the release site of the plasma membrane 
(Verhage and Sørensen, 2008, Lang, 1999, Barg et al., 2008), docking, referring 
to the movement of the granule and priming, which entails the assembly of 
SNARE complexes in preparation for the release of insulin (Eliasson et al., 2008). 
It is established that the SNARE proteins such as v-SNARE protein VAMP2 
(vesicle associated membrane protein2) associate with the insulin granules and 
form complexes that attach to the plasma membrane proteins syntaxin, 
synaptosomal associated protein of 25kDa (SNAP25) and t-SNARE proteins 
(Hou et al., 2009). The  zippering of the complex allows for the overall opening of 
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the fusion pore (Lou and Shin, 2016). Very recently, with high resolution total 
internal reflection fluorescence (TIRF) microscopy, the voltage dependent K+ 
channel, KV2.1 was shown not only to be involved in the depolarisation of the 
membrane but to form clusters on the plasma membrane and also bind with the 
C terminus of syntaxin 3 to recruit secretory granules from the reserve pool 
(Greitzer-Antes et al., 2018) 
The SNARE proteins aid in exocytosis by bringing the vesicle membrane into 
close contact with the plasma membrane (Bruns and Jahn, 2002). The 
conformational changes that occur provide the energy to elicit membrane fusion, 
but it has been noted that the SNARE proteins are not sufficient to account for 
the Ca2+ dependent exocytosis in secretory cells. Synaptotagmin has been 
implicated in calcium regulated exocytosis in the beta cell (Gut et al., 2001). 
However, it remains unclear which isoform of this protein is involved as some 
synaptogamin isoforms have been shown by peptide inhibition experiments to 
mediate calcium regulated exocytosis and knock down experiments have shown 
that other isoforms may exert the same effect implying that many isoforms could 
be involved in this process (Gut et al., 2001, Iezzi et al., 2004) 
 
1.3.7.1 Fusion pore opening 
As discussed in the previous section the secretory vesicles have to fuse with the 
plasma membrane for insulin to be released and there are two general fusion 
mechanisms proposed which include: “Full fusion” and “Kiss and Run” shown in 
Figure 1.5. 
Full fusion entails the complete fusion of the insulin secretory vesicle membrane 
with the exterior of the beta cell plasma membrane resulting in the complete 
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emptying of the granule contents (Akerblom and Knip, 1998, Hastoy et al., 2017). 
Granule fusion has been studied extensively in pancreatic beta cell using two 
main methods. Studies using two photon excitation imaging techniques have 
involved the incubation of isolated mice islets in an extracellular dye that will not 
be taken up until stimulation of these islet cells. Stimulation then causes the 
extracellular dye to be taken up through the fusion pore which occurs when the 
secretory granule fuses with the plasma membrane. The granule then emits a 
bright fluorescence spot signifying exocytosis (Hoang Do and Thorn, 2015, 
Takahashi et al., 2002). Secondly, capacitance measurements analyse single 
beta cells and fusion of the plasma membrane and secretory membrane lead to 
an increase in membrane area which can be monitored electrically. Since insulin 
granules are estimated to be about 300-400nm in diameter the changes in 
membrane capacitance can be measured when vesicle fusion occurs (Neher, 
1998). Both methods are powerful tools but they have met with some criticism in 
that no differentiation can be made between exocytosis and endocytosis 
mechanism (Hou et al., 2009) 
The ‘kiss and run’ mechanism is a form of partial fusion in which transient pores 
open between the insulin secretory granule membrane and beta cell plasma 
membrane allowing only partial release of the granule contents and an abrupt 
closing of the pore (Tsuboi and Rutter, 2003, MacDonald et al., 2006). By utilising 
TIRF microscopy Rutter and Tsuboi (2003) demonstrated the formation of 
transient fusion pores without any fusion of the secretory granules and plasma 
membrane. Studies by Macdonald et al (2006) in rat beta cells also revealed the 
formation of transient fusion pores and these allowed the passage of ATP but not 
insulin, which was too big to penetrate. The authors suggested that kiss and run 
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exocytosis may serve to mediate selective release of small vesicles rather than 
large vesicles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 1.5 Exocytosis mechanism of insulin secretion 
 
 
A. Full fusion
B. Kiss and Run
Insulin secretory vesicle
Insulin secretory vesicle
(A) full fusion depicting the complete fusion of the insulin membrane vesicle 
with the exterior of the beta cell plasma membrane resulting in the complete 
removal of the granule content (black circle) (B) kiss and run displaying partial 
fusion of the insulin membrane vesicle with the beta cell plasma membrane 
resulting in only partial release of the granule content (small black circle) 
followed by an abrupt closure of the pore   
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1.3.8 Endocytosis 
Once insulin is released, the secreted membrane must be recaptured back into 
the beta cell by endocytosis and three mechanisms which are similar to 
exocytosis have been suggested (Figure 1.6) 
The first type is the “kiss and run” where there is a transient fusion pore opening 
between the granule membrane and the plasma membrane allowing only a partial 
release of the granule contents. This is immediately followed by the closure and 
retrieval of the granule membrane back inside the cell (Tsuboi and Rutter, 2003).  
Alternatively, there may be a complete integration of granule membrane and the 
plasma membrane (termed “full fusion”) and this extra membrane is recaptured 
as a clathrin coated vesicle into the cell by clathrin mediated endocytosis. 
A third mechanism “Semi-fusion” has also been proposed in which there is a large 
opening between the granule lumen and the outside of the cell without disrupting 
the granule membrane for the eventual retrieval of its membrane after insulin is 
secreted (Taraska et al., 2003) 
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   Figure 1.6 Endocytosis proposed mechanism 
 
 
 
 
  
 
Insulin secretory vesicle
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Clathrin mediated endocytosis
 
C. Kiss and Run endocytosis
Insulin secretory vesicle
(A) Semi-fusion entails a large opening between the granule lumen and the 
exterior of the beta cell membrane without disrupting the granule membrane for 
the retrieval of its membrane (B) Full fusion displays a complete integration of 
the plasma membrane through a clathrin mediated endocytosis (C) Kiss and 
Run entails the partial release of the granule content followed by an immediate 
closure and retrieval of the granule membrane back into the cell.  
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1.4 Human enteroviruses and Type 1 diabetes 
Human enteroviruses (HEV) are ubiquitous and circulate commonly, especially 
in young children. Most infections are asymptomatic, however, these viruses can 
cause serious illness such as post poliomyelitis syndrome, amyotrophic lateral 
sclerosis, chronic myocarditis and pancreatitis and in the worst cases they can 
be lethal (Rhoades et al., 2011). They are easily transmitted through the faecal-
oral route replicating mostly in the intestine and secondarily in the pancreas 
(Jaidane and Hober, 2008). 
HEV belong to the Picornaviridae family and are non-enveloped with a single-
stranded positive (+) sense RNA genome of roughly 7500bases. The virion RNA 
has a viral protein (VPg) covalently linked to it and this acts as a primer for RNA 
replication. The genome contains a single open reading frame with a 5’ 
untranslated region (UTR), that contains a type 1 internal ribosome entry site 
(IRES) for cap-independent translation; the P1 region, which encodes the 
structural polypeptides; the P2 and P3 regions, which encode the non-structural 
proteins required for replication and a 3’-end poly(A) tail. The structural proteins 
include (VP1-4) in the P1 region and the non-structural proteins (2A-2C and 3A-
3D) in the P2 and P3 region.  
In an acute lytic infection, after the delivery of the positive sense (+) viral RNA 
genome into the cytosol, the viral genome is translated to the single polyprotein 
which then undergoes cleavage by viral proteases (2Apro and 3Cpro) to release 
structural and non-structural viral proteins (Linden et al., 2015). The four 
structural proteins adopt an icosahedral capsid structure with four viral capsid 
proteins consisting of VP1, VP2, VP3 (making up the outer surface of the capsid) 
and VP4 located inside the capsid (Figure 1.7). The icosahedral capsid protein 
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protects the viral RNA genome and is important in mediating cellular attachment 
(Hober et al., 2013). The non-structural proteins (2A-2C and 3A-3D) mediate the 
replication of the viral RNA genome to produce a negative-strand which is used 
as a template for the synthesis of positive-strand RNA. Newly synthesized 
positive stranded RNA molecules then either undergo another round of 
translation and replication or are packaged into viral capsid proteins to form new 
infectious particles (Linden et al., 2015). 
 
 
 
 
 
 
 
 
 
 
Circumstantial epidemiological evidence suggests that enteroviruses, particularly 
members of the Coxsackievirus B family, may be involved in the development of 
type 1 diabetes (Coppieters et al., 2012). As far back as the late 1960’s, human 
enteroviruses were implicated in the development of type 1 diabetes when 
Gamble and Taylor (1969) demonstrated an increased frequency of neutralising 
antibodies to Coxsackievirus B4 (CVB4) in newly diagnosed patients (Gamble et 
al., 1969). Then in 1979, a strain of CVB4 was isolated from the pancreas of a 
 
 
Figure 1.7 Structure and genome of Enterovirus. 
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Left panel displays the closed viral capsid comprising of the structural proteins VP1-
3 present on the outside with VP4 inside. Right panel displays the open viral capsid 
with genome linked to a Vpg protein 
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child who died from diabetic ketoacidosis, which was able to induce T1D in mice 
(Yoon et al., 1979). A later study with Swiss Jim Lambert (SJL/J) mice, showed 
that 6 weeks after CVB4 infection, mice developed hyperglycaemia and 
importantly this correlated with GAD autoantigen positivity in 90% of the mice, 
implying that Coxsackie B viruses may trigger and/ or amplify islet autoimmunity 
(Gerling et al., 1991). 
Serological and epidemiological studies in children from five European countries 
reported that antibodies against CVB1, another member of the CVB family, were 
more frequent in diabetic children than amongst carefully matched control 
children (Oikarinen et al., 2014). Moreover, enteroviral RNA has been detected 
in the peripheral blood of recent-onset T1D patients (Schulte et al., 2010). 
Coxsackie B virus infection has also been linked to the initiation of islet 
autoimmunity in several studies (Hyöty, 2016). Recently, for example, the 
appearance of neutralising antibodies against CVB1, which is indicative of a 
recent infection with this virus, were identified more frequently in the serum of 
children who later (in the next few months) developed IAA (insulin autoantibodies) 
(Sioofy-Khojine et al., 2018). 
A meta-analysis of 24 studies with 4,448 participants prompted the conclusion 
that enteroviral infection is detected ten-times more frequently in patients with 
recent-onset T1D than in matched controls. Importantly, it was elevated four-fold 
in autoantibody positive (non-diabetic) patients, suggesting that such infections 
may be causal to, rather than a secondary consequence of islet autoimmunity 
(Yeung et al., 2011).  
The human pancreatic beta cells are known to be susceptible to enteroviral 
infection and this has been demonstrated in several in vitro and in vivo studies. 
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The study by Elshebani et al (2007) revealed that infection of isolated human 
islets with four enterovirus strains isolated from families with T1D, resulted in 
increased enterovirus replication (EV-RNA), evident from three days to seven 
days post-infection (Elshebani et al., 2007). Importantly, they also reported that 
glucose stimulated insulin secretion in infected cells, 3 days after infection, was 
reduced when compared to non-infected control islets (Elshebani et al., 2007). 
In mice, it was shown that when isolated human islets were transplanted in mice 
and later infected with a CVB4 strain, that diabetes was developed in these mice 
after three weeks (Gallagher et al., 2014). In addition, analysis of the human islets 
from infected mice revealed statistical significant decrease in insulin at both the 
RNA and protein level (Gallagher et al., 2014). In neonates, it was also shown 
that islets are susceptible to CVB infection when in situ hybridization with a CVB-
specific probe detected the presence of an acute coxsackievirus infection in the 
pancreas particularly in the islets of five of the nine cases of these infants 
examined (Foulis et al., 1997). Interestingly, infection was observed mostly in the 
islets with limited restriction to the exocrine pancreas (Foulis et al., 1997). In 
contrast, a study in neonatal mouse, showed that infection with CVB was found 
specifically in the exocrine pancreas (Hilton et al., 1992) implying that there is 
differential CVB tissue tropism in the human (targeting the islets) and mouse 
pancreas (targeting the exocrine tissue). 
More direct evidence of pancreas infection in human type 1 diabetes was 
provided by utilising in situ hybridization in pancreases from type 1 diabetes 
patients which revealed the presence of enteroviral RNA in the islets which was 
absent in non-diabetes cases (Ylipaasto et al., 2004). This was also confirmed, 
in 2009 when pathological studies provided evidence that a small number of beta 
cells express the enteroviral capsid protein VP1, in 44 of 72 (61%) recent-onset 
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T1D post mortem pancreas samples from the Exeter Archival Diabetes Biobank 
(Richardson et al., 2009). In contrast, VP1 positive cells were seen only rarely in 
control cases (Richardson et al., 2009). These findings have since been 
replicated in two further cohorts, the nPOD collection which uses a standard 
procedure to ensure consistency in recovery and processing of samples. In these 
pancreas sections, VP1 positive cells were detected in 80% of cases in islet cells 
in which insulin containing islets were present (Richardson et al., 2013). In 
addition, in the Norwegian DiViD cohort, Krogvold et al (2015) revealed the 
presence of enteroviral RNA and capsid protein (VPI) in pancreatic islet cultures 
and islet tissue from living people recently diagnosed (3-9 weeks) with T1D  
(Krogvold et al., 2015).  
In the above studies, the low level of infection observed in type 1 diabetes 
patients (i.e very few viral protein positive cells and/ or low levels of viral RNA) 
contrasts with the levels observed in an acute infection setting (e.g. CVB-infected 
neonates) and the results are indicative of a low level persistent infection. One 
mechanism, through which persistent infection can occur, is via naturally 
occurring deletions of the 5’ terminal end of the coxsackievirus genome resulting 
in a loss of cytopathic effect (Kim et al., 2005, Chapman et al., 2008, Tracy et al., 
2015). This phenomenon has been observed in human heart samples and results 
in a reduced replication rate of the virus when compared to the full length virus 
(Tracy et al., 2015). It was further shown that inoculation of the NOD mouse with 
CVB3 resulted in an initial acute infection and that the terminally deleted virus 
could however be detected from day 21 onwards in the heart and pancreas. In 
contrast, the full length virus levels dropped over time, with only the terminally 
deleted virus still detectable on day 35. Despite the persistence of the viral RNA 
in the pancreas, no cytolytic virus activity could be detected (Tracy et al., 2015). 
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This terminally deleted 5’ form of the virus genome has also been demonstrated 
in other tissues such as the heart, in both mice and humans (Kim et al., 2005, 
Chapman et al., 2008). These “terminally deleted viruses” have replicative-
defective ability that rarely forms functional infectious virions that can infect 
adjacent cells. In non-lytic slow replication, there are equal numbers of positive 
and negative strand viral RNA with very little synthesis of the complete viral 
particles expressing the structural capsid proteins (Cunningham et al., 1990, 
Klingel et al., 1992, Tam and Messner, 1999). For this reason, these viruses 
persist in the host cells replicating very slowly over a long duration which concurs 
to what is observed in type 1 diabetes islets where a low number of VP1 
immunopositive beta cells are detected with no extensive cell lysis (Morgan and 
Richardson, 2014).  
 
1.5 Mechanism of virus-induced autoimmune T1D 
1.5.1 Direct beta cell damage 
Enterovirus infection can directly lead to the malfunction of the insulin producing 
beta cell and can induce beta cell lysis. In vitro studies in isolated human islets 
infected with enterovirus have revealed efficient viral replication in the beta cells 
that coincided with a significant increase in cytopathic effect and a reduction in 
insulin gene expression. No effect on glucagon gene expression was observed, 
confirming the susceptibility of beta cells to enteroviral infection (Frisk and 
Diderholm, 2000, Anagandula et al., 2014b). Lysis of infected beta cells will 
release beta cell antigens that in vivo will be taken up by phagocytic cells and 
antigen presenting cells and can subsequently lead to the activation of an 
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autoimmune response against beta cell antigens in at-risk individuals 
(Richardson and Horwitz, 2014) 
 
1.5.2 Persistent enteroviral infection 
A series of events by which a persistent infection in the beta cells could lead to 
autoimmune type 1 diabetes has been proposed. Following an initial acute 
infection with an enterovirus which causes direct damage to beta cells (described 
above), release of beta cell antigens and the appearance of islet autoimmunity 
occur in individuals who are at risk of developing type 1 diabetes. It is proposed 
that in certain individuals (potentially determined by their genetic background) 
that they are unable to efficiently clear the infection and a slowly replicative 
persistent infection of the pancreatic beta cells can occur. This infection can be 
sensed by intracellular pattern recognition receptors (PRRs), which subsequently 
activate antiviral signalling pathways, which includes the secretion of anti-viral 
interferons (IFNs). These IFNs can, amongst other functions, induce the 
hyperexpression of MHC class 1 on the surface of beta cells and other 
neighbouring endocrine cells. This is a hallmark feature in the pancreas of 
individuals with Type 1 diabetes (Richardson et al., 2016). Hyperexpression of 
MHC1 can lead to the aberrant presentation of beta cell antigen and the 
recruitment of the islet auto-reactive immune cells to the islets and the 
subsequent destruction of the beta cells, facilitating the progression towards type 
1 diabetes (Richardson et al., 2014, Morgan and Richardson, 2014).  
 
59 | P a g e  
 
1.5.3 Molecular mimicry 
This hypothesis proposes that there may be potential cross reactivity between 
the epitopes of islet cell autoantigens and viral proteins. This happens as a result 
of similarities in amino acid sequence. There are speculations that the immune 
response directed against the viral antigen results in the production of cytotoxic 
T lymphocytes which can also recognise the islet cells, evoking beta cell death. 
In support of the potential for molecular mimicry, a study by Atkinson et al (1994) 
revealed that PBMCs (peripheral blood mononuclear cell) from individuals at 
increased risk of diabetes or with recent onset type 1 diabetes had 
responsiveness to GAD (an islet autoantigen) peptides (amino acid region 247-
279) which was not observed in healthy controls. Interestingly, this region shared 
similarity to the Coxsackie B virus protein P2-C (Atkinson et al., 1994). However, 
it was later shown that the homology between these two epitopes was not 
associated with any functional consequence (Schloot et al., 2001).The role of 
molecular mimicry in Type 1 diabetes is still under debate, but many believe it to 
be an unlikely scenario (Coppieters et al., 2012) 
 
1.6 Enterovirus receptors 
Very early on in the 1960’s it was reported that the presence of specific surface 
receptors (virus attachment sites) on the cell membrane was an important feature 
for virus sensitive cells and tissue tropism (Kunin, 1964). It was further 
demonstrated that these viral receptors may be essential for viral tropism; since 
in aged mice the enterovirus receptor expression was downregulated and this 
correlated directly with decreased viral sensitivity, with most of the adult mice 
tissues being resistant, except for limited infection in the brain (Kunin, 1964). In 
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contrast, new born mice tissues, which exhibited higher enterovirus receptor 
expression were exquisitely sensitive to infection with multiple Coxsackie virus 
strains (Kunin, 1964).  
A number of cell surface receptors utilised for viral attachment and entry have 
been identified for different enterovirus serotypes (Table 1.3). Importantly, the 
enteroviral receptor known as the Coxsackievirus and adenovirus receptor (CAR) 
is expressed in host cells and mediates infection by Coxsackie B viruses (CVB1-
6). An additional cell surface receptor decay accelerating factor (DAF) has also 
been identified to facilitate the binding of some members of the CVB viruses, but 
it is not sufficient to sustain a productive infection (Bergelson et al., 1997, Tomko 
et al., 1997, Shafren et al., 1995). Chinese hamster ovary (CHO) cells are not 
normally permissive to CVB infection, however, Bergelson et al (1997) 
demonstrated that if CAR was transfected into these cells that they became 
susceptible to these viruses (Bergelson et al., 1997). In another study, 
radiolabelled experiments with CVB3 and CVB4 showed that murine CAR 
transfected CHO cells (homologous to human CAR), resulted in increased virus 
titre and viral cytopathic effect which was not evident in control integrin α2 subunit 
transfected CHO cells (Bergelson et al., 1997). Also, Martino et al (2000) 
demonstrated that CAR transfected CHO cells sustained high levels of viral 
production when infected with CVB1-6 reference strains and clinical isolates 
which was not observed in non-CAR transfected CHO cells  (Martino et al., 2000).  
As many of the molecular and epidemiological studies implicate CVB viruses in 
type 1 diabetes and CAR plays a significant role in mediating viral attachment, 
entry and infection of these, I felt it was fundamentally important to investigate 
the presence of CAR in the human pancreas.   
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Table 1.3 Receptors utilised by enterovirus serotypes 
Receptors Enterovirus and serotypes References 
PVR Poliovirus(PV)1-3 (Mendelsohn et al., 1989) 
CAR Coxsackievirus B1-6 (Bergelson et al., 1997) 
ICAM-1 Coxsackievirus A21, A13,A18 (Shafren et al., 1997) 
αVβ3 integrin Coxsackievirus A9 (Berinstein et al., 1995) 
DAF Coxsackievirus B1,B3 and B5 
Echovirus 
3,6,7,11,13,20,21,24,29,33 
(Bergelson et al., 1994, 
Shafren et al., 1995) 
 
 
1.7 The Coxsackievirus and adenovirus receptor (CAR) 
CAR is a type 1 transmembrane cell adhesion and tight junction protein that is 
utilised as a primary viral receptor by two distinct types of viruses; the Coxsackie 
B viruses (CVB) and most adenoviruses (Tomko et al., 1997, Cohen et al., 2001b, 
Bergelson et al., 1997, Excoffon et al., 2004). 
Human CAR was first isolated by Bergelson et al (1997) as a protein encoded by 
a gene (CXADR) with 7 exons (Bergelson et al., 1997). Through a process of 
alternative splicing, CAR can be spliced into at least 5 different isoforms in 
humans (Figure 1.8, Table 1.4) and 3 isoforms in mice (Bergelson et al., 1998, 
Thoelen et al., 2001, Chen et al., 2003).  
In humans, only two of the splice variants have a transmembrane domain; these 
two variants are retained by cells within membranes and can bind other CAR 
molecules, viruses and are able to sustain a productive infection. These two 
isoforms include “CAR-SIV” (also named CAR EX7, HCAR1, SIV or α CAR) a 7 
exon encoded isoform, which is the mice equivalent of mCAR2 and an 8 exon 
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encoded isoform “CAR-TVV” (also named CAREX8, HCAR5 or TVV), which is the 
mice equivalent of mCAR1. The two transmembrane isoforms in humans were 
named according to the terminal end of their amino acids (“SIV” and “TVV”) which 
harbours a specific protein-protein interaction domain. This domain is known as 
PDZ, which signifies the first letter of the initial three proteins discovered (post-
synaptic density protein (PSD95), drosophila disc large tumor suppressor (DIG1) 
and zonula occludens-1 proteins (ZO-1) binding domain.The mouse isoforms 
were named according to the order they were discovered (Bergelson et al., 1998, 
Excoffon et al., 2010).The other three isoforms are generated by exon skipping 
and are soluble, as they do not contain the transmembrane domain, and are 
called CAR 4/7(CAR β), CAR 3/7(γ) and CAR 2/7(δ) dependent on the exon 
splicing events. These isoforms can be secreted from cells, are capable of 
binding extracellular CAR and can prevent CVB3 infection (Dörner et al., 2004, 
Thoelen et al., 2001, Excoffon et al., 2014) by binding the sequestering virus 
away from susceptible cells 
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Table 1.4 CAR isoforms from NCBI and UniProt database 
CAR 
Isoforms 
NCBI nucleotide ID UniProt ID 
CAR-SIV NM_001338.4 P78310-1 
CAR-TVV NM_001207066.1 P78310-6 
CAR 4/7 NM_001207063.1 P78310-5 
CAR 3/7 NM_001207064.1 P783104 
CAR 2/7 NM_001207065.1 P783103 
  
 
 
Figure 1.8 Structure of the CAR protein and isoform. 
 
1-19
Signal peptide
1a
1b
2 3 4 5 6 7 CAR-SIV, hCAR1, CAREx7; 40kDa
2
3
7
2
3
73
2
2 4
4 7
5 6 7a 8 CAR-TVV, hCAR2, CAREx8; 39kDa
CAR4/7; 28 kDa
CAR3/7; 22 kDa
CAR2/7; 10kDa
20-237 Extracellular domain
238-258 
Transmembrane 
domain
259-365 Cytoplasmic 
domain
20-134 Ig-like C2 type 1 141-228 Ig-like C2 type 2 360-365 
PDZ binding
259 and 260
Palmitoylated
site
N C
(1a) In CAR protein structure the signal peptide in the N terminus (red box, broken 
lines) is cleaved off to yield a mature protein with an extracellular domain (ECD) 
comprising 2 immunoglobulin (Ig)-like domains, type 1 and type 2 (blue and green). 
The transmembrane domain (TM; yellow) bridges the ECD and cytoplasmic domain 
(light salmon) terminating with a PDZ binding domain (brick red) (1b) CAR exon 
maps for the 5 differentially spliced isoforms. Isoforms CAR-SIV and CAR-TVV 
contain the transmembrane domain. The soluble isoforms CAR4/7, CAR3/7 and 
CAR2/7 reflect exons inclusion or exclusion and they all lack the transmembrane 
domain.    
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1.7.1 Structure of CAR 
CAR is a 46kDa protein composed of an N-terminus signal peptide (ND), an 
extracellular domains (ECD) consisting of two Ig-like domain, transmembrane 
region (TM) and an intracellular cytoplasmic domain (ICD) shown in Figure 1.8 
(Bergelson et al., 1997, Tomko et al., 1997).  
CAR is classified as a member of the proteins belonging to the CTX (cortical 
thymocyte marker in Xenopus) subfamily of the immunoglobulin superfamily 
(Igsf) (Chrétien et al., 1998). Members of the subfamily include junctional 
adhesion molecules (JAMs), endothelial cell selective adhesion molecule 
(ESAM), brain-testis IgSF (BT-IgSF), CAR like membrane protein (CLMP), CTX 
and A33 (Schreiber et al., 2014, Matthäus et al., 2017). This family is structurally 
composed of an extracellular domain with a variable (V-type) D1 and a constant 
(C-type) D2, a single transmembrane domain followed by a cytoplasmic domain 
of varying length (Philipson and Pettersson, 2004) 
Similarity exists between the human and mouse CAR protein with 91% amino 
acid identity within the extracellular domain, 77% within the transmembrane and 
up to 95% within the cytoplasmic domain (Cohen et al., 2001b). 
CAR-SIV is the principal isoform of CAR encoding 365aa which differs from CAR-
TVV (352aa) only within the last portion of their cytoplasmic domain (Figure 1.9). 
The C’ terminus end of CAR-SIV contains 26 unique amino acids encoded by 
exon 7, while CAR-TVV contains 13 unique amino acids encoded by exon 7a and 
exon 8. The C terminus of both transmembrane isoforms encodes a consensus 
type 1 PDZ binding domain, a motif enclosing four amino-acid protein interaction 
sites at the terminal end (X-(S/T)-X-φ) where X represents any amino acid and φ 
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any hydrophobic aminoacid; GSIV (Gly-Ser-Ile-Val) and ITVV (Ile-Thr-Val-Val) 
(Excoffon et al., 2010, Excoffon et al., 2014). 
The C terminus also encodes a peptide recognition site for the clathrin adaptor 
protein (AP), 318YNQV321, which is common to both CAR-SIV and CAR-TVV and 
a distinct basolateral sorting motif 345LSRMG349 only found in CAR-SIV, which is 
essential for basolateral targeting. This was confirmed in a study where truncated 
CAR mutants were shown to be localised to the apical surface of polarised Madin-
Darby canine Kidney Cells (MDCK cells) (Cohen et al., 2001a). In that study, a 
tyrosine residue based at position 318 was also demonstrated as a sorting signal 
318YNQV321. Mutation of that tyrosine residue resulted in differential targeting to 
the apical membrane of polarised MDCK cells, confirming its importance in 
basolateral sorting (Cohen et al., 2001a). The differences between CAR-SIV and 
CAR-TVV protein sequence is displayed in Figure 1.9 below. 
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CAR-SIV   MALLLCFVLLCGVVDFARSLSITTPEEMIEKAKGETAYLPCKFTLSPEDQGPLDIEWLIS 
60 
CAR-TVV   MALLLCFVLLCGVVDFARSLSITTPEEMIEKAKGETAYLPCKFTLSPEDQGPLDIEWLIS 
60                         
          ************************************************************ 
 
CAR-SIV   PADNQKVDQVIILYSGDKIYDDYYPDLKGRVHFTSNDLKSGDASINVTNLQLSDIGTYQC 
120 
CAR-TVV   PADNQKVDQVIILYSGDKIYDDYYPDLKGRVHFTSNDLKSGDASINVTNLQLSDIGTYQC 
120 
          ************************************************************ 
 
CAR-SIV   KVKKAPGVANKKIHLVVLVKPSGARCYVDGSEEIGSDFKIKCEPKEGSLPLQYEWQKLSD 
180 
CAR-TVV   KVKKAPGVANKKIHLVVLVKPSGARCYVDGSEEIGSDFKIKCEPKEGSLPLQYEWQKLSD 
180 
          ************************************************************ 
 
CAR-SIV   SQKMPTSWLAEMTSSVISVKNASSEYSGTYSCTVRNRVGSDQCLLRLNVVPPSNKAGLIA 
240 
CAR-TVV   SQKMPTSWLAEMTSSVISVKNASSEYSGTYSCTVRNRVGSDQCLLRLNVVPPSNKAGLIA 
240 
          ************************************************************ 
 
CAR-SIV   GAIIGTLLALALIGLIIFCCRKKRREEKYEKEVHHDIREDVPPPKSRTSTARSYIGSNHS 
300 
CAR-TVV   GAIIGTLLALALIGLIIFCCRKKRREEKYEKEVHHDIREDVPPPKSRTSTARSYIGSNHS 
300 
          ************************************************************ 
 
CAR-SIV   SLGSMSPSNMEGYSKTQYNQVPSEDFERTPQSPTLPPAKVAAPNLSRMGAIPVMIPAQSK 
360 
CAR-TVV   SLGSMSPSNMEGYSKTQYNQVPSEDFERTPQSPTLPPAKFKYPYKTDG--ITVV------ 
352 
          ***************************************.  *  :    * *:       
 
CAR-SIV   DGSIV 365 
CAR-TVV   ---- 
 
 
KEY  
PDZ domain 362SIV365, 349TVV352 
C 259 & 260-palmitoylation 
N 106 D1 DOMAIN, N201 D2 DOMAIN- glycosylation on asparagine residues 
Tyrosine Y269,294,313,318& Threonine T290, serine S293 residues, S306, 
323, 332 
YNQV peptide recognition for basolateral targetting 
345 LSRMG 349 Sorting motiv 
D1 c41-c120disulfide bounds 
D2 c162-c212 disulfide bounds 
 
Figure 1.9 Similarities and differences between the protein sequence of CAR-SIV and 
CAR-TVV 
  
67 | P a g e  
 
1.7.2 CAR expression in cells and tissues 
A recent review by Matthaus et al (2017) concluded that CAR is developmentally 
regulated with tissue-specific expression in several organs, such as the heart, 
brain, testis, pancreas, kidney and intestine (Matthäus et al., 2017). In mice, CAR 
can be detected by IHC in the ectoderm, as early as embryonic day (ED) 6.5 
(Hotta et al., 2003). As the embryonic mice develop CAR can be found 
abundantly in the brain, skeletal and heart muscles (Honda et al., 2000a, 
Loustalot et al., 2016) but expression becomes more restricted at later 
developmental stages. This pattern of expression may explain the extreme 
sensitivity of neonatal mice to CVB-infection (Hilton et al., 1992, Jmii et al., 2016). 
Knockout of CAR (Dorner et al., 2005) resulted in embryonic death between 
ED11.5 and ED13.5, highlighting the critical importance of CAR in early 
developmental events, particularly within the heart. Additionally, cardiac specific 
CAR knockout mice resulted in abnormal atrioventricular conduction in the heart, 
which is essential in regulating blood flow in the heart (Lim et al., 2008). In adult 
mice, CAR expression is predominantly found on polarised epithelial cells lining 
the body cavities (Raschperger et al., 2006) which fits with its role as a tight 
junction protein. In terms of CAR expression in the pancreas, studies of CAR 
knockout adult mice revealed dilated intestines and atrophy of the exocrine 
tissue, with an almost complete lack of acinar cells. The islets, however, 
appeared unaffected (Pazirandeh et al., 2011).  
CAR developmental importance in human brain has not been reported but it has 
been shown to be present abundantly in the brain, specifically in the hippocampus 
region, responsible for long term memory (Yonelinas, 2013). In contrast, CAR 
was shown to be downregulated in the hippocampus in patients with Alzheimer’s 
disease (Zussy et al., 2016). In another study, CAR was detected in the choroid 
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plexus cells of the brain, which are involved in the synthesis of cerebrospinal fluid 
circulating the brain (Persson et al., 2006). In addition, CAR has also been shown 
to be expressed in the human pituitary gland (Persson et al., 2006).  
CAR expression in the human heart is similar to the situation in mice, in that there 
is a low-level expression in the normal adult heart. In contrast, CAR expression 
was observed to be higher in patients with dilated cardiomyopathy (Noutsias et 
al., 2001) implying that patients with this disease could be more susceptible to 
CVB infection. CAR has also been demonstrated to be localised to cell-cell 
junctions in polarised human airway epithelial cells (Cohen et al., 2001b, Excoffon 
et al., 2010). Due to CAR’s localisation to cell-cell contact it has been shown to 
play a structural role in cell adhesion (Excoffon et al., 2004).  
In cancerous cells, low levels of CAR have been revealed, for example in normal 
bladder tissue, CAR have been shown to be downregulated at both the RNA and 
protein level in cancerous bladder tissue (Sachs et al., 2002, Jee et al., 2002). 
The consequence of low-level CAR expression in cancer cells may result in a 
loss in cell adhesion giving an advantage for cancerous cells to easily 
metastasise. In support of this, when CAR was overexpressed in human bladder 
cancer cells, there was an inhibition in further cell proliferation (Okegawa et al., 
2001) implying that an increase in CAR expression may negatively regulate 
proliferation in cancerous cells. 
 
1.7.3 CAR Post-translational modifications 
Many proteins undergo palmitoylation which facilitate targeting to lipid rafts that 
are enriched in cholesterol and sphingomyelin (Levental et al., 2010). Using 
radiolabelled fatty acids it was demonstrated that the cysteine residues, C259 and 
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C260, in the cytoplasmic tail of CAR can be palmitoylated (van't Hof and Crystal, 
2002). It was further shown in COS7 cells that if these cysteine residues were 
mutated that labelling by radiolabelled palmitate was prevented. MDCK cells 
expressing these mutants showed altered localisation, being found more 
prominently in the perinuclear region and throughout the plasma membrane, in 
contrast to the basolateral localisation of CAR that was normally observed in 
these cells with wild-type CAR (van't Hof and Crystal, 2002). Although, the 
cytoplasmic tail is essential for palmitoylation, another study observed that CAR 
was still localised to lipid rich microdomains when the transmembrane and 
cytoplasmic tail were replaced with a non-lipid raft protein (Excoffon et al., 2003) 
suggesting that the CAR ECD may be, in part, mediating CAR localisation. 
N-Glycosylation plays pivotal roles in protein folding, conformation and stability 
(Mitra et al., 2006) and there are two N-glycosylation sites in the CAR ECD 
domain “N106 in D1” and “N201 in D2”. These have been confirmed by the 
generation of single and double glycosylation deficient mutants at these sites in 
COS-7 cells. Western blotting confirmed the loss of glycosylation by the detection 
of lower fragments in the mutants when compared to the glycosylated wild-type 
CAR which migrated at 46kDa (Excoffon et al., 2007). Cell adhesion assays 
revealed that mutations of both these glycosylation sites prevented CAR-CAR 
homophilic interactions, as evidenced by the lack of clumping cells in double 
deficient mutants when compared to wild type or single glycosylation deficient 
mutants. However, the lack of glycosylation did not alter CAR junctional 
localisation (Excoffon et al., 2007). 
In addition, CAR also has two potential phosphorylation sites, threonine 290 and 
serine293, within the C terminus. Protein kinase C delta (PKCδ) has been shown 
to phosphorylate these residues in human bronchial epithelial cells, and this 
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process is augmented by treatment of the cells with the phosphatase inhibitor 
(Calyculin A, CalA) and activator of protein kinase, phorbol 12,13-dibutyrate 
(PDBu) (Morton et al., 2013). In addition, pull down assays revealed that CAR 
binds directly to PKCδ. Importantly, knockdown of PKCδ reduced CAR’s 
molecular weight in cells treated with Cal A or PDBu, indicative of a lack of 
phosphorylation at these residues. The phosphorylation of CAR has been shown 
to mediate the recruitment of E-cadherin, an adhesion protein, to cell-cell 
junctions (Morton et al., 2013). This was further shown using CAR mutants that 
could not be phosphorylated which significantly disrupted E-cadherin junctional 
localisation (Morton et al., 2013) 
Recently, CAR was also found to undergo ubiquitination when cells were treated 
with cycloheximide (a protein translation inhibitor) and cytokines (IFNγ + TNF). 
This induced down regulation of CAR levels by ~40% in GC-2spd cells (a mouse 
germ cell line). This suggests that cytokines can promote CAR degradation via a 
ubiquitin-mediated pathway (Gao and Lui, 2014). In support of this, blocking of 
the proteasome pathway, using lactacystin (a proteasome inhibitor) 
demonstrated that when cells were pre-treated with IFNγ + TNF, that CAR could 
be immunoprecipitated with ubiquitin antibody. The specific residues that are 
ubiquitinated have still not yet been identified (Gao and Lui, 2014) 
 
1.7.9 CAR interacting protein partners 
A range of scaffolding PDZ containing proteins (Figure 1.10) are known to interact 
with the PDZ binding domain of CAR-SIV and CAR-TVV in several cells and a 
selection of these are described below. 
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Co-immunoprecipitation and cryo-EM studies have revealed that the CAR-SIV 
isoform interacts with and colocalises with ZO-1 at the apical region of tight 
junctions in the human colonic cell line (T84) (Cohen et al., 2001b). Furthermore, 
in CAR-CHO cells, CAR was found to recruit ZO-1 to cell-cell junctions (Cohen 
et al., 2001b). CAR-SIV also interacts with MAGI-1b and PSD-90; 
immunocytochemical analysis revealed a shift from cytoplasmic to the junctional 
colocalisation (Excoffon et al., 2004). The CAR-TVV isoform also interacts with 
PSD90, however interaction with MAGI-1b results in a loss of CAR-TVV 
expression and implies that binding to MAGI-1b targets this particular isoform for 
degradation (Excoffon et al., 2010).  
The Ligand of Numb protein X2 (LNX2) which is important in Notch signalling also 
has been shown to interact with CAR in human embryonic kidney cells (HEK 293) 
(Mirza et al., 2005). CAR-SIV has also been shown to interacts with PICK1 in 
polarised COS-7cells and immunocytochemistry revealed significant 
colocalisation of both proteins at the perinuclear and membrane regions which 
was lost when the terminal PDZ-binding domain of “SIV” was deleted (Excoffon 
et al., 2004). In contrast, CAR-TVV does not interact with PICK1 and 
immunocytochemistry revealed a lack of colocalisation of both proteins in the 
same polarised COS-7 cells (Excoffon et al., 2010) 
Utilising pull down and mutation analysis, murine CAR1 (TVV) and connexin 45 
(a gap junction protein) were shown to interact in whole murine heart extracts. 
This interaction was confirmed to be mediated by the PDZ binding domain 
because deletions of either mCAR1 PDZ-binding domain (TVV) or deletions of 
connexin 45 PDZ domain prevented their interaction with one another (Lim et al., 
2008).  
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CAR also binds to a series of different proteins involved in cell adhesion for 
example junctional adhesion molecules (JAMs) which include (JAM-L and JAM-
C), but this interaction involves the extracellular domain. These interactions play 
an important role in maintaining cell-cell contacts, facilitate cell migration across 
tight junctions and can regulate neutrophil trans-epithelial migration across 
epithelial tight junctions (Zen et al., 2005, Mirza et al., 2012). Importantly, the 
interacting partners for CAR-SIV and CAR-TVV can differ and so this will likely 
impart different functional properties for each of the isoforms. 
 
 
   Figure 1.10 CAR and interacting protein partners. 
 
 
 
 
 
 
 
 
 
The CAR protein structure includes a signal peptide in the N terminus (red box, 
broken lines) which is cleaved off to yield mature CAR protein. This includes an 
extracellular domain (ECD) comprising 2 immunoglobulin (Ig)-like domains, D1 (blue) 
and D2 (green). The transmembrane domain (TM; yellow) bridges the ECD and 
cytoplasmic domain (light salmon) terminating with a PDZ binding domain in the C 
terminus (brick red). JAM-L and JAM-C proteins can bind to domain D1 of CAR 
protein while ZO-1, MAGI-1b, PSD-90, LNX-2, PICK1 and Connexin 45 can bind to 
the PDZ binding domain (red box) in the C terminus 
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1.7.10 Mechanism of Coxsackievirus entry through CAR 
Coxsackievirus B members interact with cell surface receptor CAR via a canyon-
like depression region on the infectious viral capsid. This interaction forms the 
initial CVB-CAR binding complex. At physiological temperatures, the binding of 
CAR to this region induces a conformational change in the capsid that initiates 
tighter binding (Fields et al., 2007, Organtini et al., 2014). This conformational 
change of the native infectious virion involves the movement of the three capsid 
proteins (VP1, VP2 and VP3) resulting in the formation of particle called the “A 
particle” (destabilised infectious particle). This process induces the expansion of 
the capsid and the extension of the N terminus of VP1 which inserts into the 
membrane to form a channel composed of five amphipathic helixes (allowing the 
virion to interact with the membrane). The release of a myristate VP4 group then 
results in pore formation (Baggen et al., 2018). Viral RNA is then released from 
the virion through these pores (yielding an empty particle) and is translocated into 
the cytoplasm for initiation, translation and replication (Hogle, 2002) as described 
in section 1.4 and Figure 1.11 
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Figure 1.11 Mechanism of CVB entry into cells. 
 (A) CVB binds to CAR present on the cell plasma membrane forming a CVB-CAR 
binding complex (B) The binding of the complex then induces a conformational 
change in the capsid that involves the movement of the capsid proteins (VP1-4) 
resulting in “A particle” formation and the extension of VP1 initiates tighter 
binding. (C) A myristate VP4 group is released resulting in pore formation for the 
viral genome to be released into the cell 
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1.8 AIMS 
The Coxsackievirus and adenovirus receptor serves as a key entry receptor for 
CVBs. These viruses have a clear propensity to infect human pancreatic beta 
cells and mounting evidence implicates them in the development of type 1 
diabetes. Relatively little is known about CAR expression in human pancreas and 
as CAR exists in multiple different isoforms, each with a different subcellular 
localisation and function, it is imperative that this be investigated further. The 
overall aim of this thesis was to investigate the expression of CAR isoforms in 
human pancreas with the following sub-aims: 
 To study the profile of CAR isoform expression at the RNA and protein 
level in human pancreas in situ and in cultured pancreatic beta and ductal 
cell lines (Chapter 3) 
 To characterise the isoform specificity of various antisera raised against 
CAR and to evaluate their utility as tools to explore CAR expression in 
cells and tissues (Chapter 4) 
 To examine the subcellular localisation of CAR in human islet cells and to 
develop a model explaining its normal physiological role (Chapter 5 & 6). 
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CHAPTER 2 
Materials and Methods 
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2.1 Source of reagents 
This chapter describes the range of general materials and scientific methods 
used in this study but more specific details concerning primers, antibodies and 
chemicals are described in subsequent chapters. 
Cell culture solutions were mostly from Sigma-Aldrich (Dorset, UK), Lonza 
(Slough, UK), and Fisher Scientific (Loughborough, UK). Plastic wares for cell 
culture and other experiments were acquired from Greiner Bio-One (Stonehouse, 
UK). Alcohols were purchased from Honey-well laboratory (Seelze, Germany). 
General laboratory consumables were purchased from Alpha laboratories 
(Eastleigh, UK) and Fisher scientific (Loughborough, UK) or Sterilin (Newport, 
UK).   
Reagents for sample preparation for immunostaining were mostly from Sigma-
Aldrich, except for Histoclear (National Diagnostic, Nottingham, UK) and Xylene 
(Genta Medical, York, UK)  
The kit for cDNA synthesis was from Promega (Southampton, UK), PCR gels, 
Master Mix (Fisher Scientific) and ladders (DNA, Protein) for electrophoresis and 
Western blotting were purchased from Fermentas (York, UK) and Geneflow 
(Lichfield, UK) respectively. Restriction enzymes were supplied by Promega 
(Southampton, UK) and New England Biolabs (Hitchen, UK). 
All components of the buffer-solutions including concentration and pH are 
presented in Table 2.1 
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Table 2.1 Buffer-solutions and components 
 
  
Buffer Components 
FACS buffer 2% (v/v) FBS in PBS  
4% PFA 4% (w/v)PFA in PBS pH 7.4 
ADS 100mmol/l lysine, 10% donor calf 
serum and 0.02% sodium azide  
ADST 100mmol/l lysine, 10% donor calf 
serum, 0.02% sodium azide and 0.2% 
(v/v) Triton X-100 
1% Saponin  
(Permeabilisation buffer) 
1% (w/v) saponin in PBS 
Lysis buffer 
(Western blotting) 
20mmol/l Tris, 150mmol/l Nacl, 
1mmol/l EDTA and 1% (v/v)Triton X-
100 (pH 7.4) 
Lysis buffer  
(Co-immunoprecipitation) 
50mmol/l Tris (pH7.5), 137mmol/l 
NaCl, 5mmol/l EDTA, 1mmol/l EGTA, 
1% Triton, 10μg/ml protease inhibitor 
and 10μg/ml phosphatase inhibitor 
cocktail 2 & 3 
BCA protein assay Solution A: Na2CO3, NaHCO3, 
biocinchoninic acid and Na2C4H4O6 in 
0.1 N NaOH 
Solution B: 4% CuSO4.5H2O 
LDS sample buffer(4x) 4000mmol/l glycerol, 560mmol/l Tris 
Base, 420mmol/l Tris HCL, 300mmol/l 
lithium dodecyl sulphate, 2mmol/l 
EDTA, 0.075% Serva Blue G250, 
0.025% Phenol red 
Transfer buffer 25mmol/l Tris, 190mmol/l glycine, 
20% (v/v) methanol (pH 8.3) 
TBS 137mmol/l NaCl, 2.6mmol/l KCl, 49.5 
mmol/l Tris (pH 7.6) 
TBST TBS and 0.05% (v/v)Tween 20 (pH 
7.6) 
DreamTaq Green PCR Master 
Mix(2X) 
DreamTaq DNA Polymerase, 2X 
DreamTaq Green buffer, dNTPs and 4 
mmol/l MgCl2, 4 x 1.25ml Nuclease 
free water 
TBE buffer 80mmol/l Tris, 40mmol/l boric acid and 
0.2mmol/l EDTA (pH8.0) 
TAE buffer 40mmol/l Tris, 18mmol/l acetic acid, 1 
mmol/l EDTA (pH 8.0) 
Krebs Ringer Buffer 125mmol/l NaCl, 4.74mmol/l KCl, 
1mmol/l CaCl2, 1.2mmol/l KH2PO4, 
1.2mmol/l MgSO4, 5mmol/l NaHCO2, 
25mmol/l HEPES 
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2.2 Cell culture 
Details of the cell lines used in the present study are provided in Table 2.2 
Table 2.2 Cell lines and sources 
Cell lines Source 
EndoC-βH1 Pancreatic β cell line derived from a human fetal 
pancreatic bud initially transfused with a lentiviral 
vector expressing the viral protein SV40LT and then 
transplanted for differentiation into functional islets 
under the kidney capsules of the SCID mice model 
(Ravassard et al., 2011) 
1.1B4 
ECACC 10012801 
Hybrid cell line generated from the fusion of isolated 
human beta cells and PANC-1 ductal cells 
(McCluskey et al., 2011) 
PANC-1 
ECACC 87092802 
Epithelial ductal cell line derived from a pancreatic 
carcinoma of a 56 year old Caucasian male (Lieber 
et al., 1975) 
HeLa 
ECACC 93021013 
Immortalized cell line from a 30 year old black female 
who died of cervical cancer (Lucey et al., 2009) 
HEK293T 
ECACC 14050801 
Derived from the exposure of human primary 
embryonic kidney cells to fragments of adenovirus 
type 5 DNA (Graham et al., 1977) 
INS-1E 
 
Isolated beta cells from induced rat transplantable 
insulinoma (Asfari et al., 1992) 
 
 
The human beta cell line EndoC-βH1 (kindly provided by Dr. Robert Scharfmann, 
University of Paris, France) was cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) low glucose 1g/L (5.5mmol/l glucose), 2%(w/v) bovine serum albumin 
(fraction V), 50μmol/l β-mercaptoethanol, 5.5μg/ml transferrin, 6.7ng/ml sodium 
selenite, 10mmol/l nicotinamide supplemented with penicillin (100units/ml) and 
streptomycin (100μg/ml). Cells were seeded at 1.75 x 106/ml on an extracellular 
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matrix (ECM) with fibronectin coated T25 flasks and were sub-cultured every 7-9 
days. Half of the culture medium was replaced every 3-4 days.  
The 1.1B4 cell line was a gift (from Prof. Peter Flatt, University of Ulster, Ireland) 
and was cultured in 2g/L glucose (11mmol/l RPMI 1640 medium supplemented 
with 10%(v/v) fetal bovine serum (FBS), 2mmol/l glutamine, 100U/ml penicillin 
and 100μg/ml streptomycin. This cell line was routinely cultured in a filter screw 
cap flask on a growth area of 75cm2 in which the surface had been treated for 
improved cell adhesion. INS-1E cell was cultured similarly to the 1.1B4 cells but 
with the addition of 50μm β-mercaptoethanol. 
All other cell lines were cultured in DMEM medium containing 10% (v/v) FBS, 
2mmol/l glutamine, 100U/ml penicillin and 100µg/ml streptomycin. Cell lines were 
maintained in an incubator set at 5% CO2, 370C and 100% humidity. All cells were 
mycoplasma negative. 
2.2.1 Passaging of cell line 
All cell lines (except EndoC-βH1, which is described above) were sub-cultured 
upon reaching 70-80% confluency. Cells were washed in warm sterile phosphate 
buffered saline (PBS) from (Lonza, Slough, UK), incubated with 0.25% Trypsin-
EDTA (Fisher Scientific) for 5mins at 370C to detach adhered cells from flask 
bottom. Cells were then centrifuged at 1500rpm for 5mins and one tenth of cells 
were seeded in new culture vessel. 
2.3 Isolated human Islets 
Isolated human islets were obtained from either Oxford or Worcester centre for 
islet transplantation. On arrival, islets (Figure 2.1) were cultured for 24hrs at 370C 
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for their recovery before being fixed in 4% (w/v) PFA in PBS overnight at 4oC for 
immunostaining or stored at 80oC for RNA extraction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4 Tissue samples 
Formalin-fixed paraffin embedded (FFPE) pancreas sections were available from 
three cohorts: the Exeter Archival Diabetes Biobank (http://foulis.vub.ac.be/), the 
network of Pancreatic Organ donor with Diabetes (nPOD; 
https://www.jdrfnpod.org/) and the Diabetes virus detection study (DiViD). Analysis 
was performed on tissue from 21 non-diabetic controls (age range: 4-47years) 
and 10 individuals with type 1 diabetes (age range: 6-47years) detailed in 
Appendix, Table 8.1. 
 
Figure 2.1 Morphology of isolated human islets 
Bright field image showing islets obtained from the Oxford islet transplantation 
centre. Scale bar 25µm  
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The Exeter archival diabetes biobank consists of a large UK cohort of post 
mortem fixed paraffin embedded (FFPE) pancreas tissue collected in the 1980’s 
by Prof. Alan Foulis (Glasgow). These samples consist of patients recently 
diagnosed (<18 months) with type 1 diabetes at the time of autopsy and it remains 
the largest collection of “recent onset” T1D patients samples in the world. 
nPOD was initiated in 2007 by the Juvenile Diabetes Research Foundation 
(JDRF), it consists of organs from heart beating donors that cannot be used for 
transplantation. The materials consist of donors with diabetes, at risk of diabetes 
(detected by the presence of autoantibodies) and no diabetes (control cases). 
DiViD cohort is a collection of pancreatic tail tissue harvested using laparoscopic 
techniques from 6 living type 1 diabetes patients at the Oslo University hospital 
in Norway. The study was terminated as a result of the complications that 
developed in a few of the patients post-surgery. 
The Tissue microarray (TMA) was provided as a kind gift from Prof. Alan Foulis 
(Glasgow) comprising of normal and cancerous human tissues. 
2.4.1 Microtomy 
Formalin fixed paraffin embedded tissues embedded in blocks were sliced at 4μm 
thickness to yield serial sections. Sections were then allowed to float on a water 
bath (Raymond A. Lamb, Eastbourne, UK) at 370C and tissues were fixed on 
SuperFrost Plus slides (Fisher scientific) harbouring a positive charge that will 
attract the negative charge of the proteins in the tissues. Slides were allowed to 
dry in the slide drier (Raymond A. Lamb) for 24hrs. 
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2.5 Immunostaining reagents 
Reagent sources, primary and secondary antibodies utilised are listed in the 
tables below. 
Table 2.3 List of primary antibodies utilised in this study 
Primary Antibodies Company Catalogue 
Number 
species 
CAR CT Abcam Ab100811 Rabbit 
CAR ECD Abcam Ab180761 Rabbit 
CAR NT Abcam Ab189216 Rabbit 
Insulin Dako A056401-2 Guinea pig 
Glucagon Abcam Ab10988 Mouse 
Proinsulin Abcam Ab8301 Mouse 
ZnT8 R & D MAB7936 Mouse 
PC1/3 Abcam Ab55543 Mouse 
CAR RmcB Merck 05-644 Mouse 
PICK1 Santa Cruz SC-7452 Mouse 
PICK1 Abcam Ab133773 Rabbit 
PICK1  Abcam Ab3420 Rabbit 
PICK1 L20/8 Biolegend 830901 Mouse 
Chromogranin Abcam Ab15160 Rabbit 
MYC  Sigma M4439 Mouse 
Mouse IgG Dako  X0931 Mouse 
Rabbit IgG Vector  Rabbit 
GAPDH Proteintech 60004-1-Ig mouse 
Β-ACTIN Sigma A5441 Mouse 
 
Table 2.4 Secondary antibodies and DAPI utilised for immunofluorescence and 
immunocytochemistry 
AlexaFluor 
Secondary antibodies 
Company Catalogue  
number 
568 Goat Anti-Guinea pig IgG Invitrogen A11075 
488 Goat Anti-Mouse IgG Abcam Ab150113 
488 Goat Anti-Rabbit IgG Abcam Ab150077 
555 Goat Anti-Mouse IgG Abcam Ab150114 
555 Goat Anti-Rabbit IgG Invitrogen A21429 
647 Goat Anti-Guinea pig Invitrogen A21450 
DAPI (4’6 diamidino-2-phenylindole) Fisher D1306 
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Table 2.5 List of immunostaining reagents 
 
 
2.6 Immunocytochemistry (ICC) 
2.6.1 Cells and fixation 
Cells in routine culture were counted and seeded at a density of 1 x105 cells/ml 
onto sterilised glass coverslips in a 24 well plate. Cells were then left to adhere 
between 4hrs to 24hrs. Thereafter, cells were treated and incubated 
appropriately. After incubation, cells were fixed by the addition of cold 4% (w/v) 
paraformaldehyde (PFA) for 10mins, washed in PBS twice and left in PBS at 4oC 
until required. 
2.6.2 Staining 
Cells were removed from PBS and either permeabilised with ADST or non-
permeabilised with ADS (Table 2.1) for 30mins. The ADST/ADS was removed 
and cells were incubated with primary antibody for overnight at 40C. Cells were 
washed five times in PBS and incubated with secondary antibody and DAPI (4’6 
Product and Supplier Catalogue  
number 
Dako Real peroxidase blocking solution S2023 
Dako envision HRP Rabbit Mouse A  K5007 
Dako Substrate buffer B K5007 
Dako envision DAB Chromogen C K5007 
Dako Antibody Diluent S2022 
Dako Normal Goat Serum S1000 
Dako Haemotoxylin S2020 
Dako Fluorescent mounting medium S3023880 
DPX Mounting medium  S06522 
85 | P a g e  
 
diamidino-2-phenylindole; stains the nuclei) at the appropriate concentration. 
Slides were washed in PBS (5 times) and mounted with cells facing downwards 
onto a small drop of Dako fluorescent mountant. Samples were left to dry in a 
dark box and viewed under an Upright fluorescence microscope. Figure 2.2 
(below) shows an immunohistochemical staining of anti-insulin and anti-
chromogranin in EndoC-βH1 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Immunocytochemical staining with chromogranin and insulin antisera in 
EndoC-βH1 cell line 
 
 
 
 
2.7 Immunohistochemistry (IHC) 
In preparation for staining, formalin-fixed paraffin-embedded (FFPE) tissue was 
first de-waxed by immersing slides in 2x5min steps of histoclear in glass coplin 
staining jars (Fisher) or samples fixed with mercuric chloride were placed in 0.5% 
(v/v) iodine in xylene followed by a further 5min incubation with xylene. Tissue 
samples were then re-hydrated in a series of ethanol (100% ethanol, 90% (v/v) 
ethanol, 70% (v/v) ethanol, 100% methanol) respectively and in distilled water for 
 Chromogranin A Insulin Overlay 
EndoC-βH1 cells express both chromogranin A (green) and insulin (red) in the EndoC-
βH1. Nuclei were stained using DAPI (blue). Data are representative of images from 
three replicates. Scale bar 25µm 
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5mins. For antigen retrieval (AR), tissue samples were immersed in an aqueous 
solution of 10mmol/l citrate buffer (pH 6) and incubated for 20mins at high 
temperature in the microwave. AR is a critical step which is thought to revive the 
immunoreactivity of tissue samples previously dampened by fixation technique 
(Shi et al., 1991). Although, the exact mechanism of how AR facilitates this 
recovery is still not well understood. After AR, slides were left to cool for at least 
20mins and then blocked with normal goat serum to minimise background 
staining (Daneshtalab et al., 2010). After which tissues were incubated with 
primary antibody at the optimised dilution in antibody diluent solution for 1hour or 
overnight as appropriate. Tissues were washed three times in TBS (Tris buffered 
saline and incubated with peroxidase block to inhibit any endogenous peroxidase 
activity in tissues thereby preventing non-specific staining.  The secondary 
antibody conjugated to horseradish peroxidase (HRP) enzyme was added to 
tissues for 30mins. Slides were washed three times in TBS and 3,3’ 
diaminobenzidine (DAB) substrate solution was added to the tissue for 10mins. 
DAB reacts with HRP to produce a precipitate (brown in colour) that is insoluble 
in alcohol and water. Slides were then washed in ddH20 for 5mins, nuclei were 
counter-stained with haematoxylin for 1min and washed for 5 mins in running 
H20. Blueing was achieved with STWS (Scott’s tap water substitute) followed by 
a 5 mins incubation with ddH20, then copper sulphate and finally ddH20. 
Dehydration of slides was carried out in 50%(v/v), 70%(v/v), 90%(v/v), 100% 
(twice in) ethanol and Histoclear (twice). Mounting media (DPX) was then 
mounted on slides with tissues and left to dry overnight and visualised under the 
bright field microscope (Nikon eclipse, Surrey, UK) 
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2.8 Immunofluorescence microscopy 
To examine multiple antigens within the same section, samples were probed in a 
sequential manner with either two or three primary antibodies after samples had 
undergone dewaxing and blocking (normal goat serum) step as detailed in 
(Section 2.7). Primary antibody in antibody diluent was incubated for 1 hour at 
room temperature; tissues were washed in PBS (thrice) in plastic slide staining 
jars. Secondary antibody conjugated to fluorescent dyes incubated in antibody 
diluent was added onto slides for 1hr in the dark at room temperature. DAPI was 
used to stain the nuclei and slides were washed in PBS before being mounted 
with the Dako fluorescent mounting media. Labelling of the antigen-antibody 
complex was visualised by a fluorescence microscope. 
2.8.1 Imaging 
For the visualisation of stained antigens in immunohistochemical images, bright 
field image acquisition was performed on a Nikon 50i Microscope (Surrey, UK). 
For immunofluorescence, images were captured either with a Leica AF6000 
microscope (Leica, Milton Keynes, UK) or a Leica SP8 confocal microscope. With 
the Leica AF6000 microscope, images were processed using the standard LASX 
Leica software platform or the Leica SP8 confocal microscope coupled with 
Hyvolution 2 deconvolution software (Scientific Volume Imaging bv, 
Netherlands). Colocalisation analysis of the stained antigen was measured using 
a JACoP plugin from image J version 1.48, Java 1.6.0_20; 
(https://imagej.nih.gov/ij/plugins/track/jacop2.html) 
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2.9 Cryoimmunogold electron microscopy (Cryo-EM) 
For Cryo-EM, human samples were treated as described (Slot and Geuze, 2007).  
Briefly, human pancreas tissue samples from nPOD (6227, 6229 and 6330) were 
fixed in 4% (w/v) PFA, cut into small pieces and immersed in 2300mmol/l sucrose 
in PBS at 4°C. The samples were placed on metal stubs, frozen in liquid nitrogen 
and thin cryosections were cut and protected with sucrose/methyl cellulose films. 
For immunogold labeling, the protective layer was first melted in gelatin coated 
dishes at 37°C and then washed with 0.1%(w/v) glycine in PBS. Then grids were 
incubated in PBS containing 1%(w/v) BSA with the anti-CAR CT, anti-insulin, anti-
proinsulin and anti-ZnT8 antibodies for 45 minutes at room temperature. Protein 
A-gold (diameters 10 or 5 nm; G. Posthuma, Utrecth) diluted in 0.1%(w/v) BSA in 
PBS was added onto the grids for 20 min followed by washes with 0.1%(w/v) 
BSA/PBS and PBS alone. In double labeling studies, antibodies were added 
sequentially with their respective protein A gold conjugate, between incubations 
the sections were incubated briefly with 1% glutaraldehyde. The sections were 
then stained with 2% neutral uranyl acetate in water for 5min and then embedded 
for 10 min on ice with 2% methyl cellulose containing 0.4% uranyl acetate. The 
stained sample was examined with a Jeol 1400 microscope.Courtesy of Dr.Varpu 
Marjomaki,University of Jyvaskyla, Finland. 
 
2.10 RNA analysis 
2.10.1 RNA purification 
Cells between 70-80% confluent were washed twice in PBS and RNA was 
extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany) as per the kits 
instructions. From this kit, RLT buffer was added to disrupt the cell plasma 
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membrane to release the RNA.  Ethanol was then added to promote selective 
binding of RNA to the spin column. RNA binding enables contaminants to be 
washed away efficiently in wash steps and also allows for high RNA quality. The 
binding, washing and elution steps were carried out in a centrifuge at 8000g. 
2.10.2 RNA or DNA estimation 
A Nanodrop 8000 spectrophotometer (Fisher Scientific) was used to quantify the 
amount of DNA or RNA and assess purity. The Nanodrop provides a 260/280nm 
ratio that allows the assessment of purity.  Values close to 1.8 are generally 
accepted for ‘pure’ DNA and 2.0 for ‘pure’ RNA. 
2.10.3cDNA (Complementary DNA) synthesis 
For reverse transcription, 500ng/ml of random hexamers was incubated with 1μg 
of purified RNA. The hexamers randomly bind to the RNA nucleotide sequence 
at 70oC for 10mins followed by rapid cooling on ice for 5mins. A reaction 
containing either reverse transcriptase (RT) or no reverse transcriptase (nRT) in 
separate tubes wasset up with the following components 940U/nl RNasin (to 
inhibit RNase degradation), (10mM) dNTPs and (5X) reverse transcriptase buffer. 
This mixture was incubated at 250C for 15mins, 420C for 50mins and 700C for 
15mins to generate cDNA from the RNA template in the RT tubes. The nRT 
mixtures acts as a negative control where no product will be amplified during 
PCR. 
2.10.4 Primer design 
Primers (Invitrogen) were designed using the Primer 3 software 
(http://primer3.ut.ee/). Specificity of primers was confirmed by performing a 
BLASTsearch (https://blast.ncbi.nlm.nih.gov/Blast.cgi).  
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2.11 Polymerase chain reaction (PCR) 
PCR reactions were set up in PCR tubes containing 1μg cDNA template, forward, 
and reverse primers (25µm) and DreamTaq Green PCR Master Mix (2X). PCR 
was performed in a three step process in a thermal cycler (Life Technologies, 
California, USA) where the DNA was amplified in repeated cycles. The initial step 
included denaturation 950C, 5min followed by 35cycles (or as required) consisting 
of 950C, 1min denaturation step, 520C 1min annealing (hybridisation) step and 
720C 1min elongation step). Finally, an extension time of 720C 10min. The 
annealing temperature for each PCR was determined by the melting temperature 
(TM) of each primer. 
PCR products were analysed qualitatively by agarose gel electrophoresis which 
separates DNA by size and charge. Samples were placed in 1% agarose gel 
(AGTC Biproducts Ltd, Hessle, UK) in TBE buffer containing GelRedTM (Biotium, 
California, USA).  GelRedTM  is a nucleic acid fluorescent dye (Huang et al., 
2010).  A DNA ladder with known sizes was used to determine the size of 
unknown bands.The gel was placed in a tank (Fisher scientific) filled with TBE 
and run at 120 V for 45mins or until the ladder had separated. After running, the 
gel was visualised and image was captured under a UV illumination (UVPGelMax 
Imager, Fisher scientific). 
2.12 DNA sequencing 
It is possible that during the PCR process, primers could anneal non-specifically 
to sequence of non-target DNA thereby giving misleading results. In order to 
avoid this, the amplicons were sent for sequencing to confirm the expected PCR 
product. Bands in agarose gels were excised with a scalpel blade already washed 
in 70% ethanol under a dark reader transilluminator (Labtech, East Sussex). DNA 
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fragments within the gel was extracted and purified using a QIA quick gel 
extraction Kit (Qiagen) according to the manufacture’s protocol. The purified DNA 
was sent to Source bioscience, Nottingham (http://www.sourcebioscience.com/) 
where Sanger sequencing was used. The sequenced results returned as a 
chromatogram and were compared with the expected sequence using BLAST 
search https://blast.ncbi.nlm.nih.gov/Blast.cgi to confirm the identity of the 
amplicon. 
2.13 RT-Real Time PCR 
Differential expression of alternatively spliced isoforms of the human CXADR 
gene was evaluated using custom designed TaqMan primers and probes 
(Thermofisher) (Chapter 3, Table 3.2).  For human isolated islets, 250ng of total 
RNA was retro-transcribed using Superscript III Reverse Transcriptase kit 
(Thermofisher) and 10ng of the resultant cDNA was loaded into (2X) TaqMan 
Universal Master Mix, (20X) TaqMan gene expression assay buffer and 
nuclease-free water in a final volume of 20µl. Data were normalised using the 
expression of β-Actin, GAPDH and β2-microglobulin. Reactions were performed 
on a verity Thermal Cycler and ViiA7 Real Time PCR instruments (Thermofisher). 
Data was analysed and exported using Expression Suite software 1.1 
(Thermofisher) and finally elaborated using the 2-ΔCt method. Courtesy of Prof. 
Francesco Dotta and Dr. Guido Sebastiani, University of Siena, Italy 
 
2.14 Laser capture microdissection of human islets 
Laser capture microdissection (LCM) of human islets was performed on OCT 
frozen sections from pancreas of non-diabetic nPOD donors (6017, 6096; Table 
3.4). Briefly, 5µm thick frozen sections were fixed in 70% (v/v) ethanol for 30 
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seconds and then dehydrated in 100% ethanol, xylene and then air dried for 5 
minutes. An Arcturus Xt microdissection instrument (Thermofisher, Waltham, MA, 
USA) was used to capture human islets based on beta-cell autofluorescence. Hs-
Caps (Thermofisher) were used to microdissect identified islets. Microdissected 
islets were then lysed in Arcturus Picopure kit Extraction Buffer for 30 minutes at 
42°C and subjected to total RNA extraction using Arcturus Picopure RNA 
extraction kit following the manufacturer’s instructions (Thermofisher). 
Total RNA from isolated human islets was extracted using miRNeasy mini kit 
(Qiagen,). Briefly, human isolated islets were lysed in Qiazol solution and 
chloroform was added to separate DNA, RNA and proteins. The aqueous phase 
was then loaded on to RNA binding columns and eluted in 30µl of nuclease-free 
water. RNA quality were evaluated using a 2100 Bioanalyzer RNA 6000 Pico kit 
(Agilent Technologies, Santa Clara, CA, USA) and only samples with RNA 
Integrity Number (RIN) >5.0 were used for further analyses. 
1ng of total RNA was retro-transcribed using Superscript III Reverse 
Transcriptase kit (Thermofisher). The resultant cDNA was pre-amplified using 
0.2x Tris-EDTA diluted TaqMan assays pool (designed to amplify CXADR 
isoforms plus 3 housekeeping genes (β-Actin, GAPDH, β2-microglobulin) and 2x 
Preamp Master Mix in a final volume of 50µl. The pre-amplification reaction was 
diluted in Tris-EDTA and 5µl of each pre-amplified cDNAs were used in a Real-
Time PCR reaction in a final volume of 20µl. Courtesy of Prof. Francesco Dotta 
and Dr. Guido Sebastiani, University of Siena, Italy 
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2.15 RNAseq 
RNA sequencing (RNAseq) was performed using islets obtained from 5 
normoglycemic human islet donors or EndoC-βH1 cells as described (Eizirik et 
al., 2012). Genes and transcripts were assigned a relative coverage rate as 
measured in RPKM units (“reads per kilobase of exon model per million mapped 
reads”) and compared with 15 other normal human tissues, analysed by RNA 
sequencing and deposited at the Illumina Body Map 2.0:GSE30611. 
RNAseq analysis was also examined from isolated human islets and EndoC-βH1 
which were exposed to the following cytokines; (50U/ml) recombinant human IL-
1β (R & D Systems, Abingdon, UK) and (1000U/ml) human IFN-(PeproTech, 
London,UK) for 48hrs. Courtesy of Prof. Decio L. Eizirik, Universite Libre de 
bruxelles, Belgium. 
 
2.16 Protein analysisby Western blotting 
2.16.1 Sample preparation 
Cell linescultured to 70% confluency were washed with ice-cold PBS and lysed 
with an amount of lysis buffer depending on the growth area of culture flasks for 
10mins on ice.10μl/ml of both protease and phosphatase inhibitors (Sigma) were 
added to the lysis buffer (Table 2.1) to inhibit the degradation of proteins. 
Adherent cells were removed from flasks using cell scrapers (Sarstedt, Nmbrecht, 
Germany) and transferred to microfuge tubes. Tubes with cell lysate were 
vortexed for 15secs with 5sec on ice between each vortexing. Protein lysate 
(supernatant) was separated from the insoluble fraction by centrifugation for 
10mins at 5000rpm at 40C. Lysates were either stored at -20oC or protein 
concentration was determined using the BCA protein detection assay. 
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2.16.2 Protein estimation 
The total protein concentration of unknown samples was quantified with the 
Pierce TM BCA Protein Assay (Thermofisher Scientific). Bicinchoninic acid (BCA) 
uses a colorimetric approach whereby Cu2+ is reduced to Cu1+ by the interaction 
of protein bonds in an alkaline solution. A colour change from green to purple is 
observed when bicinchoninic acid molecules chelate with Cu+ ion. The colour 
change is directly proportional to the amount of protein present in the sample. 
In a 96 well plate, a standard curve of BSA (0, 200, 400, 600, 800, 1000 and 1200 
μg/ml) was created with lysis buffer and protein samples mixed at a dilution of 1:5 
and 1:10 in lysis buffer in duplicates were added. BCA reagents A and B were 
mixed at a ratio of 1:50; 200µl of this solution was added to each well. The plate 
was left to incubate at room temperature for about 10-15mins while placed on a 
microplate shaker (Grant-bio, Cambridgeshire, UK) and absorbance was 
measured at 562nm with a PHERAstar (BMG Labtech Ltd, Aylesbury, England). 
The protein concentration was either estimated manually by comparing the 
absorbance of standards to those of the unknown samples with Microsoft excel 
or using the PHERAstar wizard software. 
2.16.3 Electrophoresis and protein transfer 
Initially proteins were denatured before subjected to electrophoresis, which 
involved protein separation based on their molecular size, shape and charge 
through the addition of an electric current. For protein denaturing, equal amount 
of protein (20-50µg) were used and lysates were treated with (4X) LDS sample 
buffer (25%) and 10% β-mercaptoethanol (reducing agent that cleaves protein 
disulphide bonds) and heated for 10min at 70oC. Samples were loaded along with 
the prestained protein ladder (Geneflow) onto pre cast Bis-Tris4-12% poly-
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acrylamide gels (Invitrogen) in a XCell Sure Lock system (Invitrogen, California, 
USA) set at 120volts in (20X) MOPS SDS running buffer) for 1hr.  Samples were 
ran until the dye reached the bottom of the gel. The gel was removed from the 
tank and placed on blotting paper soaked in transfer buffer. PVDF (polyvinylidene 
difluoride) membrane cut at the appropriate size was first permeabilised in 
methanol before being placed on top of the gel. Additional blotting paper was 
placed on top of the membrane (blotting paper-gel-membrane), finally padded 
foams were placed on either side to form a sandwich. The sandwich was then 
placed in a cassette and transferred into aXCell II Blot Module (Invitrogen) 
containing transfer buffer (Table 2.1). The transfer was run at 30v for 2hrs to allow 
for protein transfer from the gel to the PVDF membrane 
2.16.4 Antibody probing 
After transfer, membranes were blocked in 5%(w/v) skimmed milk protein 
(Sigma) made in Tris buffered saline with Tween 20 (TBST) buffer (Table 2.1) for 
1hr on a roller mixer (BioCote Ltd, Coventry, UK) to prevent non-specific binding 
of antibody to the membrane. After blocking, membranes were probed with 
primary antibody diluted in 5% (w/v) milk overnight at 40C. Primary antibody was 
removed by washing thrice in TBST for 5mins. Secondary antibody (of the 
appropriate species) conjugated to alkaline phosphatase (AP) at 1:10,000 or goat 
anti-rabbit IgG (H+L) AlexaFluor680 (Table 2.6) was made in 1% (v/v) milk with 
TBST and added to the membrane for 1hr at room temperature. Membrane was 
washed three times in TBST for 15mins before detection with a chemiluminescent 
detection agent. 
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Table 2.6 List of secondary antibodies for Western blotting 
 
2.16.5 Detection of proteins 
Proteins were detected using a CDP-star (Sigma) for AP conjugated antibodies 
and for streptavidin conjugated antibody, ECL substrate was utilised (Cell 
signalling, Massachusetts, United States). Membranes were incubated with 
chemiluminescent substrate for 5min after draining off the excess. Proteins were 
visualised using the C-Digit blot or Odyssey CLX scanner (Li-COR Biosciences, 
UK), to detect protein bands. Protein ladder was made visible by drawing lines 
on top of the membrane ladder and exposing to bright light for 30secs afterwhich 
membrane was placed with protein facing downwards on the surface for 
scanning. Bands were developed on the scanner after 12mins 
2.17 Flow cytometry 
Flow cytometry measures the chemical and physical characteristics of the single 
cells through a beam of light while flowing in suspension. Properties measured 
include cell number, size, granularity as well as fluorescence intensity of cells 
(McSharry, 1994). In this study, cellular antigens were detected both, 
extracellularly and/or intracellularly. 
Western blotting secondary antibodies Company Catalogue # 
Anti-Mouse alkaline phosphatase Sigma A3562 
Anti-Rabbit Alkaline phosphatase Sigma A3687 
Goat anti-rabbit IgG(H+L) highly 
crossed absorbed, AlexaFluor plus 680 
Thermofisher A327-34 
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2.17.1 Cell preparation 
Cells were collected in culture media and pelleted by centrifugation at 1500RPM 
for 5mins. Cells were then re-suspended at a concentration of 2 x 105 cells/ml in 
a fluorescence activated cell sorting (FACS) wash buffer (Table 2.1) in FACS 
tubes (Sarstedt). 
2.17.2 Extracellular staining of surface antigen 
For extracellular staining, the cell pellet was re-suspended in FACS tube at a 
suitable antibody concentration made in FACS buffer and incubated for 45mins 
at room temperature. Cells were then washed once in FACS buffer to remove 
any non–specific binding and centrifuged at 1500rpmfor 5mins. Secondary 
antibody was made up in FACS buffer and incubated with the cells for 30min at 
room temperature. Cells were washed in FACS buffer, then re-suspended in 
500μl FACS buffer and analysed immediately on a flow cytometer (BD AccuriTM 
C6 Plus). 
2.17.3 Intracellular staining of antigen 
For intracellular staining after the cell preparation step, cells were fixed with 500μl 
of 4% paraformaldehyde for 10minutes and washed twice with FACS buffer at 
1500rpm for 5mins. Primary antibody was made up in permeabilisation buffer 
(0.3% (v/w) saponin in FACS buffer). The fixation-permeabilisation step is 
necessary to retain the morphological structure of the cells while enabling 
antibody to gain access to the intracellular compartment. Cells were incubated in 
primary antibody on ice for 1hr, after this time point cells were washed twice with 
500μl of 0.03% (v/v) saponinin FACS buffer with centrifugation at 5000rpm for 
5minutes at 40C. Secondary antibody was prepared in 0.3% saponin in FACS 
buffer, ratchet and incubated for 30mins in ice. Cells were then washed in 0.03% 
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(v/v) saponin in FACS buffer twice for 5mins, 40C at 1500rpm and 3000rpm 
respectively. Finally cells were re-suspended in 500μl in FACS buffer and 
analysed on the BD AccuriTM C6 plus Flow cytometer. 
 
2.18 Proximity ligation assay (PLA) 
Proximity ligation assay was developed by the Fredriksson research group 
(Fredriksson et al., 2002) and can be used to visualise protein-protein interactions 
(provided that two proteins are within 30-40nm of one another) in fixed cells and 
tissue samples. DuoLink in situdetection reagent red (DUO92008) was 
purchased from Sigma-Aldrich, Dorset, United Kingdom. This experiment 
requires two primary CAR antibodies recognizing different epitopes, a pair of PLA 
probes (positive and negative) and a detection reagent.   
Initially, samples were blocked in blocking solution followed by two primary 
antibodies (raised in rabbit or mouse) incubation at a suitable concentration 
overnight in cells or depending on antibody incubation time on tissues. Samples 
were then washed  twice for 5mins in Wash buffer A (1X) and secondary antibody 
conjugated with a PLA oligonucleotides (5X) stock were added at 1:5 dilution in 
a pre-heated humidity chamber for 1hr at 37oC. Cells or tissues were washed in 
Buffer A twice for 5mins and ligationsolution (5X) was mixed in high purity water 
(1:5 dilution) with the addition of 1U /μl Ligase (1:40 dilution) to create a ligation-
ligase which was added to the sample and incubated in a pre-heated humidity 
chamber for 30mins at 370C.  Amplification (5X) solution was made in high purity 
water (1:5 dilution) with 10U/μl polymerase (1:80 dilution) which was incubated 
with samples in a pre-heated humidity chamber for 100mins at 370C. Slides were 
then washed in 1X washbuffer B twice for 10mins and in 0.01X wash buffer B for 
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1min. Slides were then mounted in Duolink insitu mounting medium with DAPI. 
After 15mins samples were visualised with a fluorescence microscope. 
 
2.19 Co-immunoprecipitation 
2.19.1 Cell lysate preparation 
Cells at 70% confluency were washed twice in ice cold PBS and lysed with co-
immunoprecipitation lysis buffer (Table 2.1) for 30mins with occasional rocking. 
Cells were then scraped and gently transferred to a microfuge tube. Cells were 
further disrupted by vortexing (3 times) for 5secs. Cell lysates were centrifuged 
at 12000rpm for 10mins at 40C and supernatant were transferred into fresh 
microfuge tubes. As an input control, 2%(v/v) of protein lysate was taken out of 
each sample, denatured at 700C for 10min and stored at 40C.Thereafter, protein 
lysates were incubated with (2-3μg) of antibodies or isotype control (mouse IgG 
and rabbit IgG antibodies) on a rotator (Bio-Cote, Staffordshire, UK) overnight at 
4oC.The following day, protein G sepharose bead slurry (50%;w/v) supplemented 
with protease and phosphatase inhibitors was added to the protein lysate-
antibody mix and incubated for 4hrs at 40C. 50% (w/v) bead slurry was prepared 
by washing protein G sepharose bead (three times) with lysis buffer followed by 
adding equal volumes of beads and lysis buffer. 
2.19.2 Precipitation of Immune complexes 
The protein-bead mixture was centrifuged at 12000rpm for 20sec at 4oC. 
Supernatant was discarded and the resultant pellet was washed three times; 1, 
in lysis buffer, 2, TBS with 10% lysis buffer and 3, TBS with centrifugation at 
12000rpm for 20sec in between. Protein was eluted from the beads by adding 
25%(v/v) LDS buffer and 10%(v/v) β-mercaptoethanol and heating at 70oC for 
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10min. Samples were vortexed briefly and the protein was loaded on an SDS-
PAGE gel and Western blotting was performed as  described in section 2.16 
 
2.20 DNA cloning 
This is a molecular technique in which fragments of DNA (gene of interest) are 
inserted into a plasmid to produce a recombinant DNA vector which is then 
transformed in vivo into competent bacteria to be replicated (Vosberg, 1977). I 
utilised this technique to generate vectors containing the specific isoform of CAR 
(CAR-SIV) and a truncated form of this which were transfected into the human 
beta cell line 1.1B4. 
2.20.1 Agar plates 
Culture growth medium for agar plates was prepared with 35g/l of LB broth with 
agar (Sigma). LB broth (liquid growth medium) was also prepared with 20g/l of 
LB broth. Both solutions were autoclaved at 1210C, 15psi for 15minand stored at 
40C until required. To make agar plates, culture growth medium was melted in a 
microwave and allowed to cool. Antibiotics (25mg/ml Kanamycin and 100μg/ml 
Ampicillin) (Sigma) were added (to enable selection of bacteria containing the 
plasmid) and dispensed into multiple sterile petri dishes. Agar plates were then 
wrapped in parafilm and stored at 40C for a maximum of 3 months. 
2.20.2 Bacterial transformation and plasmid purification 
The commercially available CAR plasmid (Origene, Rockville, USA) (Appendix, 
Figure 8.1) was used at low and high concentration (100ng or 1μg) with 
Competent E. coli (JM109 strain, Promega), which had a transformation 
efficiency of either >1 x107 or >1 x108cfu/μgpU CDNA. Initially, plasmid was 
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added to 100μl of competent E.coli and gently ‘flicked’ to mix, then left on ice for 
10mins, heat shocked at exactly 420C for 50secs and immediately returned toice 
for 2mins. Heat shocking is a critical step for optimal transformation because it 
makes the bacteria membrane more permeable for the plasmid to gain entry 
(Crameri et al., 1996). 900μl of liquid growth medium (LB broth) was added to 
each transformation reaction and incubated for 1hr at 370C on anorbital shaker 
incubator (Grant-bio). 50μl of culture was spread onto kanamycin or Ampicillin 
containing agar plates. Kanamycin and Ampicillin were used because all 
plasmids in this study had the resistance gene to both antibiotics. The plates were 
then left to grow overnight in an incubatorat 370C. Single colonies were picked up 
from plates with sterile loops and inoculated into 5ml Kanamycin/ Ampicillin LB 
broth for 8hrs at 370C on a shaker until turbid.  
Purified plasmid DNA was then extracted according to the manufacturer’s 
instruction by Mini-prep and Maxi-prep kit (Qiagen). 
2.20.3 Glycerol storage 
Transformed bacteria colonies not used regularly were stored for up to a year in 
glycerol. In a cryovial with 150μl of glycerol, 850μl of turbid bacteria suspension 
was added, vortexed and stored at -800C. These colonies could then be easily 
used again by scraping the top of the glycerol stock with sterile microbial loop 
and streaking onto an agar plate with either Kanamycin or Ampicillin. 
2.21 Transient transfection of purified plasmid 
1.1B4 cells (5 x 104cells/ml and 2 x 105 cells/ml) were seeded into a 24 well plate 
and 6 well plate respectively and left to adhere. Transfection mix was made by 
incubating DNA in Opti-MEM (Fisher Scientific) and transfection reagent 
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wasincubated for 15mins at room temperature. Thereafter, cells were incubated 
with this mix for 6-24hrs. 
2.21.1 Identification of a suitable transfection reagent for the 
human pancreatic beta cell line 1.1B4 
In order to utilise the human beta cell line 1.1B4 for overexpression studies, a 
suitable transfection reagent had to be selected and optimised. A control pMax-
GFP tag vector provided as a kind gift from Dr. John Chilton (Appendix, Figure 
8.2), which makes transfected cells fluoresce green, was transiently transfected 
into the 1.1B4 cells utilising a variety of different transfection reagents which 
include Lipofectamine (Fisher Scientific), Attractene (Qiagen), Fugene (Promega) 
and Avalanche-Omni (EZ Biosystems) 
To determine if the transfected pMax-GFP vector could be detected in the 1.1B4, 
cells in culture were transfected, PFA fixed and then visualised under an Upright 
fluorescence microscope. Representative images of pMax-GFP transfection in 
1.1B4 cells are presented demonstrating no green fluorescent protein (GFP) 
positive cells with the Lipofectamine reagent (Figure 2.3A). With the Attactene 
reagent, GFP+cells were observed but the staining pattern showed compromised 
nuclei either condensed or abnormal invaginations in some cells (white arrows), 
likely due to high toxicity. Only a few GFP+ cells were detected with the Fugene 
reagent. In contrast, many GFP+ cells were observed when the Avalanche-Omni 
reagent was utilised in1.1B4 cells. There was also minimal evidence of toxicity 
(Figure 2.3D) 
The Lipofectamine and Attractene reagent were discontinued from further 
experiments. This was due to the lack of GFP+ transfected cells by the 
103 | P a g e  
 
Lipofectamine reagent and the toxicity encountered in cells with Attractene.The 
transfection efficiency of Fugene and Avalanche-Omni transfection reagent were 
further optimised according to the manufacturers’ instruction and quantified by 
flow cytometry.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To further optimise the transfection efficiency, different DNA to transfection 
reagent ratios were chosen and the % of GFP+ cells was analysed by flow 
cytometry. The representative flow plots display the optimum DNA to transfection 
 
A B 
C D 
Figure 2.3 Immunocytochemical analysis showing pMax-GFP vector transfected 
into 1.1B4 cells utilising different transfection reagents  
1.1B4 cells were seeded at 5 x 104 cells/ml and transfected with the different 
transfection reagents (lipofectamine, attractene, fugene and avalanche-omni) for 
24hrs. The transfected pMax-GFP vector in 1.1B4 cells with the different transfection 
reagents are shown (green) in (A) lipofectamine (B) attractene with compromised 
nucleus due to toxicity (white arrows) (C) fugene and (D) avalanche-omni.Nucleic 
were stained using DAPI (blue). Data are representative of three independent 
replicates. Scale bar 25µm 
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reagent ratio selected for Fugene reagent yielding approximately 0.1%. 
Avalanche-Omni had a transfection efficiency of between 7-20%, dependent on 
the ratio of DNA to transfection reagent, the optimal ratio was 0.5µg DNA: 0.4µl 
Avalanche-Omni (Figure 2.4). Avalanche-Omni clearly had the best transfection 
efficiency (~20%) in 1.1B4 cells and was utilised in subsequent experiments. 
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Figure 2.4 Avalanche-Omni reagent has a 20% transfection efficiency when 
compared to Fugene transfection reagent in the 1.1B4 
1.1B4 cells were seeded at 5 x 104 cells/ml and pMax-GFP vector was transfected 
with either the avalanche-omni or fugene transfection reagents for 24hrs. Graph 
displays (A) DNA: Fugene reagent ratios and a flow plot with 0.1% transfection 
efficiency in quadrant 1, lower right (Q-1LR) (B) DNA: Avalanche ratios and a flow 
plot with 20% transfection efficiencyin quadrant 1, lower right (Q-1LR. In the 
graphs, data represent mean values from three independent experiments (mean± 
SEM).  
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2.21.2 Transient transfection of CAR-SIV Myc construct into the 
human pancreatic beta cell line 1.1B4. 
The presence of CAR-SIV in transiently transfected cells was initially analysed 
using RT-PCR and specific primers that selectively amplify either CAR-SIV or 
CAR-TVV. Only the CAR-SIV isoform was detected in transfected cells shown 
in Figure 2.5A. 
Additionally, CAR-SIV protein levels was also detected by immunocytochemistry 
using anti-CAR CT, anti-Myc and anti-insulin. Myc positive cells were detected, 
however only very low levels of overexpressed CAR-SIV were detected in those 
same 1.1B4 cells that should in theory have Myc-tagged CAR-SIV (Figure 2.6). 
The result suggested that the Myc-tag located at the end of CAR-SIV C’ terminus 
is interfering with anti-CAR CT binding. 
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Figure 2.5 RT-PCR confirms the overexpression of CAR-SIV and not CAR-TVV in 
1.1B4 cells transfected with CAR SIV-Myc. 
 1.1B4 cells were seeded at 5 x 104 cells/ml, CAR SIV-Myc and empty vector was 
transfected for 24hrs. Total RNA was isolated and normalised to contain 1µg of RNA 
before converting to cDNA. The cDNA was subsequently used in PCR reaction 
(35cycles) with specific primers designed to specifically amplify CAR-SIV and CAR-
TVV (Table 3.2). (A) Overexpressed CAR-SIV is visualised at an intense band size of 
approximately 253bp (black arrow) in the CAR-SIV Myc tag and bands confirming the 
expression of endogeneous CAR-SIV are also present in the control and empty 
vectors in the 1.1B4 cells (B) No detection of CAR-TVV in the CAR SIV-Myc tag vector, 
empty vector or control 1.1B4 cells. Data are representative of three independent 
experiments. 
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Figure 2.6 Immunocytochemical analysis demonstrates low expression of 
CAR-SIV in transfected CAR-SIV Myc 1.1B4 cells 
 
 
 
 
 
To assess if indeed the Myc-tag was preventing the visualisation of CAR-SIV 
overexpression in the cells, western blotting was utilised and blots were probed 
with the CAR CT or CAR ECD antisera. The results revealed that the CAR CT 
antibody (targeted towards the C-terminus epitope of CAR-SIV) did not obtain a 
band with increased intensity (estimated 40kDa) in CAR-SIV Myc-tag transfected 
1.1B4 cells were seeded at 5 x 104 cells/ml and transfected with CAR-SIV 
Myc vector in avalanche-omni transfection reagent for 24hrs. Cells were 
labelled with anti-Myc, anti-CAR CT and nuclei were stained with DAPI 
(dark blue). Immunocytochemical image confirms the expression of Myc-
tag (anti-Myc;green) but very low expression of CAR-SIV (anti-CAR CT; 
red) in transfected CAR-SIV Myc tag vector, insulin (anti-insulin; light blue) 
is also detected in the 1.1B4 cells. Scale bar 25µm Data are representative 
of three replicates. 
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cells. The (positive) control, HEK cells transfected with CAR-SIV Myc, also show 
no dramatic increase in the band intensity when compared to the empty vector 
transfected cells (Figure 2.7A). However, the CAR ECD antiserum (which 
recognises the extracellular domain; located away from the Myc-tag) did detect 
an intense band with slightly increased molecular weight at around 50kDa in the 
CAR-SIV Myc-tranfected cells when compared with the empty vector and control 
cells (Figure 2.7B). The increased molecular weight is likely due to the addition 
of the Myc-tag to CAR-SIV construct. HeLa cells which endogenously express 
high levels of CAR were utilised as a positive control (Polacek et al., 2005), where 
an intense band at the estimated size of 40kDa was observed. These results 
suggest that the Myc-tag could hinder the access of the CAR CT antiserum to the 
very C’ terminus of CAR. This could also have an impact on the localisation of 
CAR and the binding of other cellular CAR interacting proteins (Shevtsova et al., 
2006) 
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Figure 2.7 Western blot analysis confirms low expression of CAR-SIV in transfected 
CAR-SIV Myc-tag 1.1B4 cells 
 
 
 
  
1.1B4 and HEK 293T cells were seeded at 5 x 104 cells/ml, CAR-SIV Myc and empty 
vector were transfected for 24hrs. Cells were lysed and total protein was isolated for 
western blot analysis utilising antisera against CAR CT or CAR ECD. β-actin was 
used as a loading control. (A) low CAR-SIV (anti-CAR CT) is detected at 40kDa in 
the CAR-SIV Myc vector as well as the empty and control vector in both 1.1B4 and 
HEK 293T cells (B) In contrast, there is an intense band size at a higher molecular 
weight detecting CAR (anti-CAR ECD) in CAR-SIV Myc compared to empty and 
control vector in 1.1B4 cells and positive control HeLa cells. Blot images are 
representative of three independent experiments 
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2.22 Site directed mutagenesis 
To investigate whether the Myc-tag was interfering with CAR CT antiserum 
binding and potentially CAR-SIV localisation, we next employed a site-directed 
mutagenesis approach to remove the Myc-tag from the CAR-SIV Myc construct 
by introducing a mutation (a stop codon encoded in primers) at the end of the C’ 
terminus of CAR-SIV before the beginning of the Myc tag in the nucleotide 
sequence (Appendix, Figure 8.3). A truncated version of CAR-SIV isoform was 
also created from the CAR-SIV Myc-tag (Appendix, Figure 8.3). Site directed 
mutagenesis was carried out according to the manufacturer’s protocol (New 
England Biolabs) as shown in Figure 2.8. 
Initially, an exponential amplification (PCR) was carried out using a SimpliAmp 
thermal cycler (Life technologies, California, USA). In a PCR tube the following 
reagents were assembled for a 25μl reaction; Q5 Hot Start High-Fidelity 2X 
Master Mix, 10μMforward primer, 10μm reverse primer, 10ng/µl of template DNA 
and nuclease–free water. Annealing temperatures and time were set according 
to the mutagenic primers designed from the NEB primer design software and final 
extension time was set at 720C for 10 mins. 
Kinase, Ligase and DpnI (KLD) reaction was set by treating the PCR products 
with (2X) KLD Reaction buffer, (10X) KLD Enzyme Mix (kinase, ligase and Dpnl) 
to allow for proper ligation of the plasmid and nuclease free water. These 
components were mixed and then incubated at room temperature for 5mins. 
Components were then transformed into NEB 5-alpha competent E.coli in the 
ratio of 1:10. SOC medium was added to the mixture and incubated at 370C for 
60mins on a shaker. Cells were plated on the Kanamycin-agar plate and 
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incubated overnight at 370C. Colonies were grown further in culture tubes with 
SOC medium overnight, gently shaking at 370C.  . 
 
 
 
 
 
Figure 2.8 Pipeline of site directed mutagenesis  
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2.22.1 Restriction digest 
The identity of the plasmid can be verified using enzymes to cleave specific DNA 
sequences and this was first demonstrated in an oncogenic virus SV40 (Nathans 
and Danna, 1972). Prior to digest, the circular DNA sequence was inputted in 
Ap.E, A plasmid Editor, version 1.11.0.0 software to determine what enzymes 
would cleave the sequence. Enzymes for single (one enzyme) or double digest 
(two enzymes) as well as 100% activity digestion buffers were chosen from 
Promega websitehttp://www.promega.com/a/apps/retool/. For all digests, the 
following components were assembled together in a tube; 100μg/ml BSA, 5μl of 
(1X) digestion buffer, 2μg DNA, 1μl of 10U restriction enzyme, with reaction mix 
made up to 50μl with nuclease-free (nf)H2O.  Negative controls containing no 
enzymes will be ‘uncut’ providing a basis for comparison with cut DNA. The 
reaction mix was incubated in a water bath for 12hrs at 370C or in a thermocycler 
with 2 cycles (370C for12hrs and then transferred to 100C) to ensure complete 
digestion. The digested product was added to 10μl (1X) DNA loading dye and ran 
on an agarose gel electrophoresis with a 1kb DNA ladder on a separate lane. The 
restriction digest carried out on the wild-type CAR-SIV-Myc construct should 
cleave at particular sites by restriction endonucleases (EcoRI and MluI). It is 
important to note that due to the insertion of the stop codon to the nucleotide 
sequence the MluI site was destroyed, hence it is expected that only one cut with 
the EcoRI would be observed in constructs with the new stop codon. As expected, 
the DNA extracted from majority of the colonies were cleaved by EcoRI yielding 
an approximate band size fragment of 3858bp (Figure 2.9). This revealed the 
successful mutation of the CAR-SIV Myc-tag construct to remove the Myc tag 
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Figure 2.9 Restriction digest confirms the wild-type CAR-SIV vector. 
 
 
 
 
2.22.2 Direct sequencing confirming successful site directed 
mutagenesis 
Direct DNA sequencing confirmed the presence of the inserted mutation and 
truncation and the identity of the wild- type CAR-SIV and the truncated CAR-SIV 
mutant construct by alignment with sequences held in the NCBI database as 
shown in Figure 2.10. 
 
 
 
  
PCR image shows that the wild-type CAR-SIV vector was digested by EcoRI and 
MluI in only three colonies (green box) wild-type. Data are representative of three 
replicates. 
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Figure 2.10 Direct sequencing confirmation of the generation of CAR-SIV wild 
type and truncated CAR-SIV constructs by insertion of mutation 
The DNA from colonies were extracted, purified and sequenced. Purple 
squares indicate (A) SeqA (CAR-SIV sequence held in NCBI database) aligned 
to Seq B (wildtype CAR-SIV construct), generated mutant (B) SeqA (CAR-SIV 
sequence held in NCBI database) aligned to Seq B (truncated CAR-SIV mutant 
construct).Data is a representative image from three replicates 
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2.23 Human growth hormone assay (HGH) 
The cell lines 1.1B4 or INS-1E cells were transfected with Avalanche reagent with 
several constructs; human growth hormone (HGH), wild-type CAR-SIV, truncated 
CAR-SIV mutant and empty vector between (6-13hrs). Thereafter, fresh cell 
media was added to cells and left for a further 48hrs. Cells were then washed 
with 500μl of pre-warmed Krebs buffer and then incubated with pre-warmed 500μl 
Krebs buffer supplemented with 0.1%(w/v) BSA and 0mM glucose for 90mins at 
370C. To stimulate cells to secrete growth hormone which is a surrogate of insulin 
secretion, 300μl Krebs buffer with 0.1%(w/v) BSA supplemented with 20mM 
glucose, 200μm IBMX, 10μm forskolin and 25mM KCl were incubated in cells for 
1hour at 370C. 200μl cell supernatant was collected and used for human Growth 
Hormone assay below or stored at -200C for later use.  
Growth Hormone Assay (Sigma-aldrich) is a quantitative colorimetric 
immunoassay which detects secreted human Growth Hormone (hGH) released 
into cell culture supernatants from cells transfected with a construct encoding 
hGH (da Silva Xavier et al., 2003). Growth hormone has been previously reported 
to monitor secretory activity and it was shown to be co-sorted and secreted with 
insulin (Iezzi et al., 1999). Therefore, it was used in this study to monitor the 
functional impact of CAR on insulin secretion in the 1.1B4 cells. The growth 
hormone assay is based on a sandwich ELISA principle with a microplate module 
already coated with anti-hGH antibodies to capture secreted human Growth 
Hormone which is then labelled with detection antibodies. To perform this assay, 
100μg/ml of hGH stock (1:2 dilution) was used to prepare standard dilution series 
(0pg/ml, 400pg/ml, 200pg/ml, 100pg/ml, 50pg/ml, 25pg/ml and 12.5pg/ml). 
Standards and cell supernatants (200μl) were pipetted in each well, covered and 
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incubated for 1hr at 370C. Wells were rinsed (5 times) with wash buffer (1X) and 
incubated with 200μl of 1μg/ml of anti-hGH-DIG for 1hr at 370C. Following this, 
wells were washed (5 times) and incubated with 200μl of 200mU/ml anti-DIG-
POD for 1hr at 370C. For the substrate reaction, microplate modules were 
washed (5 times) and 200μl of POD substrate mixed with substrate enhancer 
(1ml of POD substrate per 1mg of substrate enhancer) was added to each well 
and incubated at room temperature between 10-30mins until colour developed. 
Absorbance of samples was then measured at 405nm with a reference 
wavelength at 490nm.The standard curve was then plotted with y-axis depicting 
the absorbance readings and the hGH concentration (pg/ml) on the x axis. 
Unknown samples were determined by inserting the absorbance reading into a 
linear equation. A pictorial diagram of the human Growth Hormone process is 
shown below in Figure 2.11 
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Figure 2.11 Pictorial diagram of human Growth Hormone secretion process.   
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Cells are transfected with either human growth hormone (hGH) vector only 
(upper panel), a combination of human growth hormone (hGH) vector and 
empty vector (EV; middle panel or a combination of human growth hormone 
(hGH) vector and CAR-SIV Myc vector (CAR; lower panel). Following 
starvation, the cells are stimulated with glucose, IBMX, forskolin and KCl, to 
induce growth hormone release.The growth hormone secreted by the 
transfected cells in the supernatant is then collected and assessed by the hGH 
ELISA.  
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2.24 Statistical analysis 
Immunofluorescence images of islets were selected randomly from stained 
pancreas sections. Pearson correlation coefficient (PCC) was used to estimate 
the colocalisation between proteins using the JACoP plugin from Image J. The 
PCC values range from 0 to no correlation to 1 for positive correlation. Graphpad 
PRISM 5.04 was employed for all statistical analysis and data were expressed 
as mean values ± SEM. Statistical significance was calculated using student t-
test and for multiple comparisons the Bonferroni multiple comparison test was 
used.  
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CHAPTER 3 
Characterisation of CAR isoforms 
in the human beta cell and 
pancreas 
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3.1 Introduction 
There is accumulating evidence that Coxsackie B viruses can trigger the 
development of autoimmunity and type 1 diabetes with the weight of evidence 
implying that such viruses may directly infect human pancreatic beta cells (Yeung 
et al., 2011, Morgan and Richardson, 2014). CAR is an important mediator of 
CVB infection (Bergelson et al., 1997) and there have been extensive studies 
documenting the importance of an interaction between Coxsackie B viruses or 
adenoviruses with CAR as a means to  generate a productive infection (Excoffon 
et al., 2014). However, there are very few studies addressing the relative 
contribution of the various isoforms of CAR in different cells and tissues.  
Most studies to date have assessed the effects of whole or partial CAR knockout 
in mice to confirm its importance in CVB infections. For example, a study in adult 
mice demonstrated that specific deletion of CAR in heart and pancreas prevented 
CVB3 infection in these tissues (Kallewaard et al., 2009, Shi et al., 2009). Shi et 
al (2009) demonstrated that deleting exon 1 of CAR in mice knocked-out both the 
transmembrane and soluble isoforms of CAR and that this prevented CVB3 entry 
and replication in the heart (Shi et al., 2009). Ylipaasto et al (2004) reported that 
a monoclonal antibody “CAR RmcB” raised against human CAR (HCAR) 
prevented infection of CVB4 in human beta cells (Ylipaasto et al., 2004). 
Together, these studies demonstrate the importance of CAR in mediating CVB 
infection in mice and humans, but they do not elucidate the relative contributions 
of the different CAR isoforms. 
 In addition, it is important to note that CVBs show differential tissue tropism in 
mice compared to humans, with the exocrine tissue being the major target in 
mice, whereas the endocrine tissue is targeted in humans (Stone et al., 2018). 
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To better understand the specific endocrine cell targeting of CVBs in human it is 
important to study and characterise the precise CAR isoform expression profile 
in both human pancreatic islets and human beta cell lines at the mRNA and 
protein levels. 
The objectives of this chapter are as follows; 
 To examine the transmembrane and soluble CAR isoform expression 
profile at the RNA and protein level in in situ human pancreatic tissue and 
in cultured pancreatic beta (EndoC-βH1 and 1.1B4) and ductal cell lines 
(PANC-1). 
 To examine the effect of cytokine treatment on the different CAR isoforms 
in isolated human islets and human pancreatic beta cell (EndoC-βH1) 
 To evaluate CAR expression in autoantibody positive patients, type 1 
diabetes and type 2 diabetes patients 
 To assess if there is differential CAR isoform expression in human and 
mouse pancreas 
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3.2 Results 
3.2.1 RT-PCR detection of mRNA encoding specific CAR 
isoforms in human pancreatic islets and human beta cell lines 
To assess if isoforms of CAR having the transmembrane domains could be 
detected at the mRNA level in human pancreatic islets and human beta cell lines, 
RNA was extracted (Section 2.10) from isolated human islets and from the human 
pancreatic beta cell line, 1.1B4. cDNA was synthesised and the expression of 
CAR isoforms was assessed by PCR using primers (Table 3.1) designed to 
hybridise with sequences in exon 5 and exon 7. These primers are capable of 
amplifying both the transmembrane isoforms, CAR-SIV and CAR-TVV but are not 
able to distinguish between them. An amplicon of approximately 345bp was 
detected in isolated human islets and 1.1B4 cells (Figure 3.1). 
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Table 3.1 Primer sequence to target both CAR-SIV and CAR-TVV 
Target Sequence Primers 
CAR-SIV/CAR-TVV (exon 5 Fd) CAGTGCCTGTTGCGTCTAAA 
CAR-SIV/CAR-TVV (exon 7 RV) CTTAGCAGGTGGGAGAGTCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 3.1 CAR-SIV or CAR-TVV transmembrane isoforms are amplified in isolated 
human islet and 1.1B4. 
 
2 3 4 5 6 7
Exon 5 Fd Exon 7 Rv
32 4 5 6 7a 8
CAR-SIV
CAR-TVV
(B)
1.1B4Human islet
345bp
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400bp
300bp
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Total RNA was isolated from cell lysates of isolated human islets and 1.1B4 cells. 
Following quantification, 1µg of RNA was converted to cDNA. The cDNA was 
subsequently used in a PCR reaction (35cycles) with primers designed to amplify 
the transmembrane isoforms of CAR (Table 3.1). PCR products were then 
separated by electrophoresis (A) RT-PCR analysis display approximately 345bp 
band(black arrow head) for both transmembrane isoforms which cannot be 
discriminated in both isolated human islet and 1.1B4 cells (n=3) (B) Schematic 
diagram of primers annealing to exon 5 and exon 7 of both CAR-SIV and CAR-TVV 
isoform  
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To identify which of the transmembrane isoforms was specifically amplified in the 
human islet preparations; isoform specific primers (Table 3.2) were designed to 
selectively amplify either CAR-SIV or CAR-TVV. These would produce products 
of 253bp for CAR-SIV and 233bp for CAR-TVV. As shown (Figure 3.2A) the 
primer pair designed to amplify CAR-SIV, yielded a band at approximately 250bp 
and those against CAR-TVV generated a (faint) band at approximately 230bp. 
The differences in intensity of the products suggest that the CAR-SIV isoform 
could be more abundant. In support of this, when the amplification protocol was 
reduced from 35 to 30 cycles (Figure 3.2B), the CAR-TVV band was lost but the 
band corresponding to the CAR-SIV isoform was retained. These results were 
confirmed in two different isolated human islet preparations (obtained from 
Oxford and Worcester respectively) (Figure 3.2C). Controls in which no template 
DNA was added, yielded no bands thereby confirming the specificity of the RT-
PCR analysis of human islet RNA. The amplified bands were excised and 
sequenced to confirm the successful amplification of sequences equivalent to 
those expected in CAR-SIV and CAR-TVV respectively. The amplified sequences 
were aligned with those held in the NCBI database (Figure 3.3) and it was 
confirmed that the two relevant isoforms of CAR are expressed at the RNA level 
in human beta cells and in human beta cell lines.  
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Table 3.2 Primer sequence specific for CAR-SIV and CAR-TVV isoform 
Target Sequence Primers 
CAR-SIV (exon 6 Fd) GGAAGTTCATCACGATATCAG 
CAR-SIV (exon 7 Rv) AATCATCACAGGAATCGCAC 
CAR-TVV (exon 6 Fd) GGAAGTTCATCACGATATCAG 
CAR-TVV (exon 8 Rv) TTCCATCAGTCTTGTAAGGG 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Isoform specific RT-PCR analysis revealed that CAR-SIV is more abundant 
than CAR-TVV from two independent isolated human islets. 
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H.Islet  
HP10-41 
No template 
control 
30 Cycles 
300bp 
200bp 
200bp 
300bp 
(A) (B) 
(C) 
2 3 4 5 6 7 
Exon 6 Fd Exon 7 Rv 
Exon 6 Fd Exon 8 Fd 
3 2 4 5 6 7a 8 
CAR-SIV 
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Total RNA was isolated from cell lysates of isolated human islets. Following 
quantification, 1µg of RNA was converted to cDNA. The cDNA was subsequently used 
in a PCR reaction (35 and 30 cycles) with specific primers designed to amplify CAR-
SIV and CAR-TVV isoforms of CAR (Table 3.2). PCR products were then separated 
by electrophoresis. RT-PCR at (A) 35 cycles revealed that a band at 253bp for CAR-
SIV (black arrow) and a band at 233bp (black arrow) for CAR-TVV (n=3)(B) 30 cycles 
demonstrated that CAR-SIV is still retained (250bp) but the CAR-TVV band is lost (n=3) 
(C) Schematic diagram of specific primers annealing to (exon 6 and exon 7) for CAR-
SIV and (exon 6 and exon 8) for CAR-TVV isoform. 
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Figure 3.3 CAR-SIV and CAR-TVV isoform is confirmed in isolated human islets. 
 
 
  
Differences between CAR-SIV and CAR-TVV 
sequence 
DNA was extracted, purified and sequenced. Alignment of (A) CAR-SIV (sivA) from 
NCBI Accession NM_001338 to sequenced CAR-SIV (sivB) and (B) CAR-TVV (tvvA) 
from NCBI Accession NM_001207066 to sequenced CAR-TVV (tvvB). Data are 
representative of images from three replicates 
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3.2.2 TaqMan qRT-PCR detection of mRNA encoding specific 
CAR isoforms in isolated and laser captured micro-dissected 
human pancreatic islets 
To enable the identification and quantification of all of the different CAR isoforms 
(including those with transmembrane domains, as well as the soluble forms) we 
next utilised an isoform specific qRT-PCR using the TaqMan platform. This was 
performed by our collaborators at the University of Siena, Italy (Dr Sebastiani and 
Prof. Dotta). Specific primers targeting the transmembrane isoforms CAR-SIV 
and CAR-TVV were designed in Exeter (Table 3.2) while the soluble isoforms 
CAR 4/7, CAR 3/7 and CAR 2/7 were designed by a commercial supplier 
(Thermofisher) to span the exon-exon boundaries allowing for the selective 
amplification of specific CAR isoforms. TaqMan probes (Table 3.3) were also 
designed for each CAR isoform by ThermoFisher (Figure 3.4). RNA was 
extracted from isolated human islets from 5 non-diabetic control cases (University 
of Siena, Italy; Table 3.4) and from laser captured micro-dissected (LCM) islets 
from 2 non-diabetic control cases (Table 3.4) 
 
Table 3.3 TaqMan probe sequence for the five CAR isoforms 
Target sequence Probe ID TaqMan Probe Sequence 
CAR 2/7 exon _2_7 AIKAMSZ GGTGGATCAAGTGGGAAGAT 
CAR 3/7 exon_3_7 AILIKY7 GTAGTTCTTGGGAAGATGTG 
CAR 4/7 exon_4_7 AIMSI5F CATGGTTAGCAGGGAAGATG 
CAR-TVV exon_6_7 AIPAFHN CCAACATGGAAGGATATTCC 
CAR-SIV exon_6_7 AIN1HBN CGATATCAGGGAAGATGTGC 
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Figure 3.4 Schematic diagram displaying the location of TaqMan probes 
and primers for each of the five CAR isoforms 
 
 
Table 3.4 Isolated human islet donors 
Sample ID Gender Age BMI (Kg/m2) 
Isolated islet donors    
1 M 52 34.2 
2 M 50 27.4 
3 M 55 28.0 
4 F 79 23.9 
5 M 59 26.7 
LCM nPOD donors    
6017 F 59 24.8 
6096 F 16 18.8 
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Results from the TaqMan qRT-PCR analysis clearly demonstrated differential 
CAR isoform expression in human islets (Figure 3.5A). The two transmembrane 
domain containing isoforms CAR-SIV and CAR-TVV were expressed at highest 
levels in both the isolated human islet extracts (Figure 3.5A) and in RNA obtained 
from LCM islets recovered from pancreas sections (Figure 3.5B). The soluble 
CAR 4/7 was also present in both isolated and LCM islets but at a lower 
abundance; while the smaller soluble, isoforms (CAR 3/7 and CAR 2/7) were 
present only minimally. Visualisation of islets by virtue of their intrinsic 
autofluorescence enabled the LCM analysis to be performed on frozen human 
pancreatic tissue (Figure 3.6). Attempts were also made to assess CAR isoform 
expression in LCM exocrine tissue however; the RNA integrity number (RIN) 
values were extremely low (2.8 and 2.6) and therefore the RNA was deemed to 
be of insufficient quality for use in qRT-PCR. In contrast, good quality RNA (RIN 
values of 5.1 and 7.2) was extracted from the islets (Table 3.5). Thus, we have 
been unable to assess the expression of the different CAR isoforms in human 
exocrine pancreas tissue.  
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Figure 3.5 CAR-SIV and CAR-TVV is expressed in both isolated and LCM human islets 
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Total RNA was isolated from cell lysates of isolated and LCM human islets cells. 
Following quantification, 250ng of RNA was converted to cDNA. The cDNA was 
subsequently used in a qRT-PCR reaction with TaqMan probes and primers (Fig 3.4) 
designed to amplify both the transmembrane and soluble CAR isoforms. 
Analysis by qRT-PCR from A. isolated human islets (n= 5 individuals) and B. LCM 
human islets (n= 2 individuals) show that CAR-SIV and CAR-TVV are highly 
expressed, CAR4/7 is at low levels while CAR 3/7 and CAR 2/7 are barely detectable. 
Data were normalised to the relative expression of three housekeeping genes β-actin, 
GAPDH and B2M and relative expression is presented as mean ± SEM. Courtesy of 
University of Siena  
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Figure 3.6 Visualisation of human islets for laser capture microdissection (LCM) 
 
 
 
 
 
                    Table 3.5 RIN values of LCM human islets (nPOD) donor 
 
 
 
 
 
 
 
 
  
Sample ID Number of LCM 
islets 
RIN value 
6017 52 5.1 
6096 39 7.2 
(A)Autofluoresecence images show intact human islets (white arrows) for LCM  
(B)Bright field images of human islets removed after laser capture 
microdissection, Scale bar 50µm, Courtesy of University of Siena 
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3.2.3 RNAseq and RT-PCR detection of mRNA encoding specific 
CAR isoforms and effect on cytokine treatment in human 
pancreatic islets and human beta cell lines 
Via further collaboration (with Prof. Decio Eizirik of the Universite Libre de 
Bruxelles, Belgium), we have also been able to quantify the alternatively spliced 
isoforms using RNAseq analysis in both isolated human islets and in the human 
pancreatic beta cell line, EndoC-βH1. The results confirmed that the various CAR 
isoforms were differentially expressed (Figure 3.7) in both islets and EndoC-βH1 
cells. RNAseq obtains RNA content information by utilising high-throughput 
sequencing technologies to sequence cDNA (Morin et al., 2008) and provides 
data in the form of the total number of reads per kilobase per million mapped 
reads (RPKM) and this demonstrated a predominant expression of CAR-SIV. 
This agreed with the earlier PCR data where CAR-SIV had a higher intense band 
than CAR-TVV. CAR-SIV expression was three-fold higher than that of CAR-TVV 
in EndoC-βH1 cells, and was two-fold higher in human islets. The soluble isoform 
CAR 4/7 was less abundant than the two transmembrane isoforms, while CAR 
3/7 and CAR 2/7 were barely detectable in either the human beta cell line or in 
human islet preparations. This again supported the earlier TaqMan PCR 
analyses (Figure 3.5) 
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Figure 3.7 RNAseq analysis demonstrates higher expression of CAR-SIV compared to 
CAR-TVV and low expression of CAR4/7 
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(A) Isolated human islet 
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(B) EndoC-βH1 
Total RNA was isolated from cell lysates of isolated human islets cells and EndoC-
βH1. Following quantification, 2µg of RNA was converted to cDNA. The cDNA was 
subsequently subjected to RNAseq analysis  
(A) Isolated human islets obtained from 5 normoglycaemic human islets expressing 
CAR-SIV, CAR-TVV and CAR 4/7 (mean ± SEM) (B) EndoC-βH1 cells expresses the 
CAR-SIV, CAR-TVV, CAR 4/7, CAR3/7 and CAR 2/7, (n=3). Courtesy of Prof. Decio.L. 
Eizirik 
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Finally to confirm the presence of CAR4/7 isoform, a CAR4/7 isoform specific 
PCR was performed using specific primers (Table 3.6) on RNA extracted from 
isolated human islets and from the human pancreatic beta cell line 1.1B4. This 
confirmed the expression of the soluble CAR4/7 isoform shown in  
Figure 3.8B. A lower band was also observed which may imply the presence of 
other soluble CAR isoforms. The identity of the transcript was subsequently 
verified by direct DNA sequencing of the relevant amplified product (Figure 3.8C). 
 
 
 
Table 3.6 Primer sequence targeting the CAR soluble isoforms  
Target Sequence Primers 
CAR4/7 (exon 4 Fd) TAAGCCTTCAGGTGCGAGAT 
CAR4/7 (exon 7 Rv) GCGCTAGAGCAAGCAAAGTT 
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Figure 3.8 RT-PCR confirms the soluble CAR4/7 isoform expression in isolated human 
islets and 1.1B4 cell line 
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3 2 4 7 CAR4/7 
(A) 
Human islet 
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Total RNA was isolated from cell lysates of isolated human islets and 1.1B4 cells. 
Following quantification, 1µg of RNA was converted to cDNA. The cDNA was 
subsequently used in a PCR reaction (35 cycles) with primers designed to soluble CAR4/7 
isoform (Table 3.6) (A) Diagram of primers annealing to exon 4 and exon 7 in CAR4/7 
isoform (B) Soluble CAR4/7 produces a band at approximately 338bp (black arrow head) 
in isolated human islets and 1.1B4 (n=3) (C) CAR4/7 (CAR4/7A) sequence held in NCBI 
accession number NM_001207063 aligns perfectly with sequenced data (CAR4/7B) from 
human islets and 1.1B4 
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Several studies have demonstrated that isolated human islets infected with CVB 
strains can induce cytokines and chemokines that have a potential to trigger 
inflammatory responses contributing to autoimmune type 1 diabetes (Olsson et 
al., 2005, Anagandula et al., 2014a). The impact of these inflammatory signals 
on the expression of CAR isoforms has not been assessed. Utilising the RNAseq 
analysis performed by Prof. Decio Eizirik, we examined the effect of cytokine 
(human IL-1β and human IFN-) treatment of isolated human islets and EndoC-βH1 
cells on the transmembrane domain and soluble CAR isoforms. The results 
demonstrate that the cytokines did not alter expression of any of the different 
CAR isoforms (Figure 3.9), as these data were comparable to the RNAseq data 
from non-infected isolated human islets and EndoC-βH1 (Figure 3.7). 
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Figure 3.9 RNAseq analysis confirms no effect of cytokines on levels of mRNA of CAR 
isoforms 
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(A) Human islet (+ cytokine) 
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(B) EndoC-βH1 (+ cytokine) 
 
Isolated human islets and EndoC-βH1 cells were exposed to the following cytokines 
human IL-1β (50U/ml) and human IFN- (1000U/ml) for 48hrs.  
Total RNA was then isolated from cell lysates of isolated human islets cells. Following 
quantification, 2µg of RNA was converted to cDNA. The cDNA was subsequently 
subjected to RNAseq analysis (A) Isolated human islets obtained from 
normoglycaemic human islets with no cytokine (plain bar) and cytokine treatment 
(shaded graph) (n=5 individuals)(mean ± SEM) (B) EndoC-βH1(n=3),(mean ± SEM). 
Courtesy of Prof. Decio. L. Eizirik 
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3.2.4 Detection of CAR isoform protein expression in human 
pancreatic tissue by immunohistochemistry 
To determine the CAR isoform protein expression profile in human pancreatic 
tissue, three commercially available antisera were employed in parallel. These 
were directed, respectively against the N terminus (designated “CAR NT”), an 
unspecified region within the extracellular domain (“CAR ECD”) or the C’ terminus 
(“CAR CT”) of CAR. As such, use of these antisera enabled the multiple isoforms 
of CAR to be distinguished according to their predicated differences in 
immunoreactivity when probed with the various antisera (Figure 3.10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 3.10 Schematic diagram of CAR antisera immunoreactivity against CAR 
protein 
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protein 
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An immunohistochemical approach was utilised to examine the protein 
expression profile in the human pancreas sections of non-diabetic adults 
(Appendix, Table 8.1) using the three different CAR antisera. The antiserum 
designated “CAR NT” was raised against the immediate N’ terminus of the CAR 
protein (Figure 3.10), therefore, this antiserum can be expected to detect the 
CAR-SIV, CAR-TVV, CAR 4/7, CAR 3/7 and CAR 2/7 isoforms. The image 
presented (Figure 3.11; upper panels) reveals that this antiserum diffusely 
labelled both the endocrine cells in the islets and the acinar cells within the 
exocrine tissue (as judged by the areas of brown immunostaining). The “CAR 
ECD” antiserum recognises epitopes present within a large region encompassing 
217 amino acids of the extracellular domain of CAR (Figure 3.10), implying that 
it should recognise isoforms CAR-SIV, CAR-TVV, CAR 4/7 and potentially, CAR 
3/7. In human pancreas sections, this antiserum stained the islets strongly (Figure 
3.11; lower panels), whereas the acinar cells of the exocrine tissue were stained 
only weakly. 
Finally, the CAR CT antiserum was tested. This was raised against an epitope 
within the C’ terminal 30 amino acids (335-365) of the CAR-SIV isoform; a region 
which harbours a unique PDZ binding domain. As such, this antiserum is highly 
specific for the CAR-SIV isoform. As shown in (Figure 3.12) CAR CT 
immunoreactivity was restricted only to the islets in human pancreas and no 
staining was detected in the exocrine tissue. Importantly, no staining was 
observed in either the islets or the exocrine tissue when a rabbit IgG isotype 
(negative) control was tested in the pancreatic tissue (Figure 3.12).  
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Figure 3.11 CAR isoforms are detected in the islet and exocrine pancreas utilising CAR 
(NT and ECD) antisera in NDA pancreas. 
 
 
 
  
CAR NT CAR NT 
CAR 
ECD 
CAR 
ECD 
Islet Exocrine 
Islet Exocrine 
Immunohistochemical images revealed brown immunostaining with CAR NT antiserum 
(upper panels) detected in both islets (left hand side) and exocrine tissue (right hand side) 
and CAR ECD (lower panels) antiserum detected in islets but faintly in exocrine. Data are 
representative of at least three donors, Scale bar 20µm  
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Figure 3.12 CAR isoform is detected in the islet and not in the exocrine tissue utilising 
CAR CT antiserum in NDA pancreas. 
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Islet Exocrine 
Islet Exocrine 
Immunohistochemical images revealed brown immunostaining with CAR CT antiserum 
(Upper panel) detected in only islets(left hand side) while rabbit IgG (Lower panel) 
negative control antiserum is negative in both the islet and exocrine pancreas. Data 
are representative of at least three donors, Scale bar 20µm 
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In order to begin to estimate the extent of expression of CAR isoforms in human 
pancreas, the chromogen detected under the bright field microscope was 
quantified using a method which measures the Reciprocal intensity (RI) of the 
brown stain (Nguyen et al., 2013). In this approach, standard colour images 
acquired by bright field microscopy are deemed to have a maximum intensity 
value of 250 (for white/unstained areas) as measured by a function in the Fiji 
software available within Image J. By contrast, the target chromogen and 
haematoxylin stained areas have lower intensity values which are inversely 
correlated with the amount of antigen present. RI is derived by subtracting the 
intensity of staining measured within a selected stained region of interest (ROI) 
from the maximum intensity (250). This then serves as a reference resulting in a 
value for RI that correlates with the amount of chromogen and/or haematoxylin 
present in that region of the sample (Nguyen et al., 2013), with the higher the 
value the more intense the stain. Using this method, it was revealed (Figure 
3.13A) that all three CAR antisera labelled the islets to an equivalent extent while 
the rabbit isotype control yielded a much lower value (as expected). By contrast 
with the data obtained from islets, differential staining intensities (indicative of 
differential CAR expression) were detected in the exocrine pancreas (Figure 
3.13B). Most significantly, the staining intensity measured after treatment with the 
CAR CT antiserum was equivalent to that measured with the isotype control, 
thereby implying that the epitope detected by this antiserum (i.e. the CAR-SIV 
isoform) is absent from the exocrine pancreas (Figure 3.12)  
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Figure 3.13 CAR isoform expression estimated by reciprocal intensity demonstrates that 
staining with CAR CT antisera detects high levels of CAR expression in the islets and 
not in the exocrine 
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The reciprocal intensity was utilised to quantify the extent of CAR isoform expression 
from the immunohistochemical images in (Fig.3.11 and Fig 3.12). The higher the 
values, the higher the staining with CAR antisera in the tissue. (A) Staining with CAR 
antisera (CAR CT, CAR ECD and CAR NT) detects high levels of CAR in the islets and 
no rabbit IgG staining in the islets while (B) staining with CAR antisera (CAR NT and 
CAR ECD) are present at high and moderate levels respectively in the exocrine tissue 
but staining with antisera (CAR CT and rabbit IgG) are negative. Each bar graph 
represents 6 images from tissue samples stained with the different CAR antisera and 
Rabbit IgG. Each dataset is represented as (mean ± SEM). Arbitrary unit (a.u) 
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3.2.5 Detection of CAR isoform protein expression by 
immunofluorescence analysis in human pancreatic tissue 
Immunohistochemical analysis of human pancreas sections has revealed that the 
islets express high levels of the CAR-SIV isoform of CAR and that this isoform is 
absent from the exocrine pancreas. However, examination of staining pattern 
suggests that, although a large number of hormone expressing cells are 
immunopositive, not all islet cells express this isoform. Examples of islets cells 
which are immunonegative for CAR-SIV are indicated by the yellow arrows 
(Figure 3.14) 
 
 
 
 
 
Figure 3.14 The CAR-SIV isoform is absent in some endocrine cells of the islets. 
 
 
 
 
 
The magnified image (red box) revealed that CAR-SIV (anti-CAR CT; brown stain) is 
not detected in some endocrine cells of the islets (yellow arrows), data are 
representative of three independent donors.Scale bar 20µm 
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Therefore, to determine which of the islet cell subtypes may preferentially express 
the different CAR isoforms, “combined immunofluorescence microscopy” was 
employed.  This method enables the direct visualisation and localisation of 
antigens within a given cell or tissue. By employing the CAR CT antiserum in 
combination with anti-insulin (to label beta cells) and anti-glucagon (alpha cells), 
this allowed the subsets of endocrine cells expressing this particular isoform to 
be determined. Intriguingly, the CAR CT staining was present only within the 
insulin producing beta cells (Figure 3.15A), suggesting that the CAR-SIV isoform 
was expressed solely in these cells. Non-beta cells in the islets were 
immunonegative for the CAR-SIV isoform.  Staining with anti-glucagon antibody 
to identify alpha cells confirmed these findings (Figure 3.15B). In summary, these 
results demonstrate that the CAR-SIV isoform is expressed exclusively in human 
beta cells in the pancreas tissue. 
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Figure 3.15 Immunofluorescence images demonstrate that CAR-SIV is present in the 
beta cells 
 
 
 
 
  
 (A)CAR-SIV (anti-CAR CT; green) is detected in insulin (anti-insulin; light blue) 
containing beta cells; magnified images (light blue) show insulin and CAR-SIV (B) CAR-
SIV is not detected in glucagon positive (anti-glucagon; red) alpha cells, magnified 
images of CAR-SIV (yellow arrows), glucagon (orange arrows). Nuclei was stained with 
DAPI (dark blue). Data are representative of three independent donors, Scale bar 25µm  
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3.2.6 Detection of other CAR isoforms by immunofluorescence 
analysis in human pancreatic tissue 
To ascertain if, in addition to CAR-SIV, other CAR isoforms are also expressed 
at the protein level in human pancreas, a comparison was made between the 
staining obtained with the CAR CT antiserum (detects CAR-SIV only) and that 
seen with antiserum that recognises the extracellular domain of CAR (CAR ECD) 
and can label multiple isoforms (CAR NT)  
 
            Table 3.7 CAR antisera and their predicted CAR isoforms 
Antisera Predicted isoforms based on epitope 
recognised 
CAR CT CAR-SIV 
CAR ECD CAR-SIV CAR-TVV CAR 4/7 & CAR 3/7 
CAR NT CAR-SIV CAR-TVV CAR4/7 CAR 3/7 & CAR 2/7 
 
 
It was revealed that positive immunostaining with CARNT was detectable (albeit 
weakly) in some endocrine and exocrine cells (Figure 3.16) compared to the 
immunohistochemistry analysis in (Figure 3.11). Based on the inconsistencies 
obtained in the IHC and IF staining with the CAR NT antiserum, it was deemed 
unsuitable and therefore discontinued in this study. CAR ECD staining was 
detected in the beta cells of most islets, where it co-localised with insulin. Positive 
staining was not observed in alpha cells as assessed by co-labelling with anti-
glucagon (Figure 3.16). Unlike the earlier immunohistochemistry experiments 
where the Envision HRP system was utilised to visualise the immunostaining of 
CAR by deposition of a precipitated chromogen (Figure 3.11), there was limited/ 
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no labelling in the exocrine regions when immunofluorescence methods were 
employed (Figure 3.16). One potential reason for this could be that the protein 
expression of the relevant CAR isoforms in the exocrine tissue is low and this 
leads to loss of sensitivity when employing immunofluorescence approaches. 
The IHC protocol utilises a secondary antiserum having a dextran backbone 
containing multiple HRP molecules and as such, it acts to amplify the HRP signal. 
In contrast, in immunofluorescence the primary antiserum is recognised by a 
fluorescently-conjugated secondary antibody, which contains a single 
fluorophore, so no signal amplification is achieved. This means that weakly 
expressed proteins may not be detected efficiently using these reagents.  
Summing up the data generated by the immunostaining patterns; the expression 
profiles of CAR isoforms using the semi-quantitative method could be deduced 
as follows; the CAR-SIV isoform of CAR is expressed strongly and exclusively in 
the beta cells of the islets. The CAR-TVV isoform may be present at moderate 
levels in the beta cells as well as in the exocrine tissue. The soluble CAR 4/7 
isoform may also be present in the beta cells and exocrine cells, but at relatively 
low levels (Table 3.8). 
To independently validate the CAR CT antiserum staining of the“ CAR-SIV” 
isoform, Laura Nigi from the University of Siena (Professor Dotta’s Lab), 
performed combined immunofluorescence staining of CAR CT, insulin and 
glucagon in selected nPOD cases (Figure 3.17). The staining achieved was 
directly comparable to our results using samples from the Exeter Archival 
Diabetes Biobank (Figure 3.16) 
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Figure 3.16 Representative immunofluorescence microscopy images of CAR isoforms in the islet 
 Endocrine cells and exocrine cells of a normal human pancreas detected by CAR antisera. CAR NT, CAR ECD and CAR CT 
antisera (green), insulin (anti-insulin; light blue) and glucagon (anti-glucagon; red), DAPI (nuclei stain, dark blue). Data are 
representative of three independent donors.Scale bar 25μm    
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Table 3.8 Summary of CAR antisera staining pattern using the semi-quantitative method 
Antisera Isoform recognised Endocrine (β cell) 
expression 
Exocrine 
expression 
CAR CT CAR-SIV +++ (Strong) - (Negative) 
CAR ECD CAR-SIV CAR-TVV CAR4/7 
CAR3/7 
+++ (Strong) + (Weak) 
CAR NT CAR-SIV CAR-TVV CAR4/7 
CAR3/7 CAR2/7 
++ (Moderate) ++(Moderate) 
 
 
 
Table 3.9 Autoantibody positive, type1 diabetes and normal cases 
 
 
 
 
 
Figure 3.17 Immunofluorescence images provide independent confirmation of CAR-SIV 
isoform in the beta cells from an autoantibody positive non-diabetic case 
  
Case ID Case Type Cohort Age Sex Duration 
of disease 
6098 Diabetes nPOD 17.8 M - 
6153 No diabetes nPOD 15.2 M - 
6027 AAb+ nPOD 18.8 M - 
6167 AAb+ nPOD 37 M - 
Representative images displaying CAR-SIV (anti-CAR CT ; green) in insulin containing beta 
cells (anti-insulin; red), DAPI (dark blue; nuclei) in the human pancreatic tissue. Data are 
representative of two independent donors. Scale bar 25μm. Courtesy of University of Siena. 
 
152 | P a g e  
 
3.2.7 CAR isoform expression by Western blotting 
In addition to the antisera utility for immunohistochemical studies, the CAR CT and 
CAR ECD antisera are also both approved for use in Western blotting. Therefore, to 
further confirm the presence of CAR isoforms in the human pancreas, proteins were 
extracted from isolated human islets, two human beta cell lines (EndoC-βH1, 1.1B4) 
and a human pancreatic ductal cell line (PANC-1). Cell lysates were electrophoresed 
on poly-acrylamide gels then transferred onto a PVDF membrane. Following a 
blocking step, the membranes were probed with either CAR ECD or CAR CT antisera. 
Probing with the CAR CT antiserum revealed a band running approximately 40kDa 
(equivalent to the calculated molecular weight) in isolated human islets. A similar (but 
less intense) band was also seen in the human beta (EndoC-βH1, 1.1B4) and ductal 
(PANC-1) cell line models (Figure 3.18A). A lower 20kDa band was also observed 
which has been demonstrated in previous study to be a cleavage product by γ-
secretase (Houri et al 2013).The CAR ECD antiserum labelled an appropriately 40kDa 
band (corresponding to the expected size) which was more intense in isolated human 
islets compared to EndoC-βH1, 1.1B4 and PANC-1 cells (Figure 3.18B). With the CAR 
ECD, the results also show an intense band at a lower molecular weight estimated to 
be ~32kDa in 1.1B4 cells which was present, but much weaker in extracts of EndoC-
βH1 cells. This observed lower fragment may be due to the shedding of CAR 
extracellular domain into the extracellular space by Metalloproteases such as A 
Disintegrin and metalloprotease (ADAM10) known to cleave cell surface protein 
receptors (Huovila et al., 2005).   
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Figure 3.18 Western blot analysis utilising the CAR CT and CAR ECD antisera detects CAR-
SIV in isolated human islets, 1.1B4, EndoC-βH1 and PANC-1 cell lines 
 
 
 
 
 
 
 
GAPDH 
40kDa CAR CT 
36kDa 
CAR ECD 
GAPDH 
40kDa 
36kDa 
(A) (B) 
32kDa 
20kDa 
H.islet EndoC-βH11.1B4 PANC-1 H.islet EndoC-βH1 1.1B4 PANC-1 
EndoC-βH1, 1.1B4, PANC-1 cells and isolated human islets were lysed and total protein 
was isolated for western blotting to detect CAR CT and CAR ECD. β-actin was used as a 
loading control. (A) Detection of band size estimated at (40kDa) for CAR-SIV isoform (anti-
CAR CT), lower 20kDa molecular weight bands are cleavage product by γ-secretase 
observed in isolated human islets, EndoC-βH1 and 1.1B4 cells. (B) CAR ECD antiserum 
detects a band at approximately (40kDa) implying detection of the CAR-SIV isoform and 
the lower fragments are cleavage products by ADAM10 present in EndoC-βH1 and 1.1B4 
cells. Loading control GAPDH at 36kDa. Blot images are representative of three 
independent experiments 
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Overexpression of ADAM10 in the human glioma U251N cell line stably expressing 
CAR and murine embryonic hippocampal neurons endogenously expressing CAR led 
to shedding and increased shedding of CAR respectively, as detected by a band on a 
Western blot of approximately 32kDa (Houri et al., 2013). Accordingly, ADAM10 
expression in the human pancreatic tissue and human pancreatic beta cell lines was 
assessed in the next section 3.2.8. With the CAR CT, there were smaller CAR 
fragments visualised by lower bands observed at an estimated size of 20kDa in 
isolated human islets, weaker in EndoC-βH1 and more intense in 1.1B4. It has been 
reported previously that cell surface protein such as CAR that can undergo 
extracellular domain shedding could also undergo regulated intramembrane 
proteolysis (RIP) cleavage by γ-secretase complex leading to the release of their 
intracellular domains into the cytosol. A study by Houri et al (2013) also demonstrated 
that apart from the full length CAR observed in U87 CAR cell lysates, two lower C 
terminal fragments of approximately 20kDa (CTF1) and 14kDa (CTF2) were also 
detected (Houri et al., 2013). It was further observed that inhibition of the γ-secretase 
led to a decrease in CTF2 and CTF1 levels. This could represent the lower molecular 
weight band detected by the CAR CT antisera, particularly in the 1.1B4 cells (Figure 
3.18A). Together, these data imply that the CAR-SIV isoform is highly expressed in 
isolated human islets and is also expressed in EndoC-βH1, 1.1B4 and PANC-1 cells. 
The data also show that CAR can be cleaved in both human islets and human 
pancreatic beta cell lines. The CAR ECD antiserum could potentially detect CAR 
extracellular domain shedding and the CAR CT antiserum could detect intramembrane 
proteolysis (RIP) cleavage of the C terminal in isolated human islets and the pancreatic 
beta cell line EndoC-βH1 and 1.1B4. 
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3.2.8 Detection of ADAM10 expression in isolated human islets, 
human pancreatic tissue and beta cell line EndoC-βH1 
To assess the expression of ADAM10, Prof. Decio Eizirik performed RNAseq analysis 
in isolated human islets and EndoC-βH1 cells. RNAseq data revealed that ADAM10 
was expressed at high levels in isolated human islets and EndoC-βH1 (Figure 3.19A) 
Immunohistochemistry data also revealed that ADAM10 was expressed at high levels 
in the islets compared to the exocrine tissue of the pancreas (Figure 3.19B). 
Immunofluorescence analysis revealed that ADAM10 was detected in both alpha cells 
(detected by anti-glucagon) and the insulin containing beta cells (detected by anti-
insulin) as shown in Figure 3.19C 
 
 
 
.  
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Figure 3.19 ADAM10 is expressed in isolated human islets and EndoC-βH1 
 
 
 
 
  
(A) (B) 
Total RNA was isolated from human islets and EndoC-βH1 cells. Following 
quantification, 2µg of RNA was converted to cDNA. The cDNA was subsequently 
subjected to RNAseq analysis. ADAM10 expression was examined by IHC and IF by 
staining human pancreas tissue. 
 (A) RNAseq indicate high levels of ADAM10 in EndoC-βH1 and isolated human islets 
from 5 normoglycaemic islets (mean ± SEM), courtesy of Prof. Decio Eizirik (B) 
ADAM10 (brown stain) is expressed in the endocrine cells of the islet and (C) ADAM10 
(anti-ADAM10; green) is expressed in alpha cells (anti-glucagon; red) and some beta 
cells (anti-insulin; light blue).Nuclei were stained using DAPI (blue) in human 
pancreatic tissue. Data are representative of three independent donors. Scale bar (B) 
20μm (C) 25μm 
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3.2.9 Comparison of CAR CT and CAR RmcB antisera in human 
pancreatic tissue and the human pancreatic beta cell line 1.1B4 
A study by Hodik et al (2016) demonstrated that by using an antiserum designated 
“CAR RmcB” that CAR was significantly higher in type 1 diabetes pancreas and 
autoantibody positive cases compared with normal diabetes control cases (Hodik et 
al., 2016a). The CAR RmcB antiserum will recognise an unspecified region within the 
extracellular domain of CAR (Figure 3.20). We decided to acquire this CAR RmcB 
antiserum to test sequentially with CAR CT in the human pancreatic tissue and human 
pancreatic beta cell line 1.1B4 by immunohistochemistry and Western blotting. The 
results revealed that CAR CT was detected in the islet as expected but CAR RmcB 
was not detected in the islet or exocrine tissue of the human pancreatic tissue (Figure 
3.21A). Also, by Western blotting CAR CT was detected but not the CAR RmcB in the 
human beta cell line 1.1B4 (Figure 3.21B) 
 
 
Figure 3.20 CAR RmcB antiserum epitope recognises the extracellular domain of CAR protein 
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Figure 3.21 Comparison of the CAR CT and CAR RmcB antisera in the human pancreatic 
tissue and in the human pancreatic beta cell line 1.1B4 
 
 
 
  
(A) Pancreatic tissue 
 
CAR RmcB CAR CT 
(B) 1.1B4 cells 
CAR RmcB  
40kDa 
FFPE human pancreas tissue were subjected to IHC to detect antisera against CAR RmcB 
or CAR CT. 1.1B4 cells were also lysed and total protein was isolated, for western blotting 
to detect antisera against CAR RmcB or CAR CT. β-actin was used as a loading control (A) 
Staining with CAR RmcB antiserum is not detected in human pancreas tissue but staining 
with CAR CT antiserum is detected by IHC. Scale bar 20μm (B) CAR RmcB antiserum is not 
detected by western blotting in each lane of 1.1B4 cells but CAR CT antiserum is detected 
in each lane of 1.1B4 cells at an approximate size of 40kDa (black arrow head). IHC data 
are representative of three independent donors and western blots are representative of three 
independent experiments. 
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3.2.10 CAR-SIV isoform expression in the human pancreas 
CAR expression has been reported in embryonic mice with high levels found in the 
brain (Honda et al., 2000b) and heart (Ito et al., 2000). Interestingly, immediately after 
birth CAR was shown to be rapidly downregulated at both the mRNA and protein level 
with no detection in adult brains (Honda et al., 2000b).To address whether CAR-SIV 
expression changes in the human pancreas at different times of life, we examined its 
expression in pancreases from non-diabetic control individuals collected across 
different age groups (22 cases; age range 4 weeks (neonate) to 59yrs). The pancreatic 
samples studied were from the Exeter Archival Diabetes Biobank (EADB) cohort. The 
samples were co-stained with CAR CT, anti-insulin and anti-glucagon. No differences 
in the CAR-SIV isoform protein expression were observed across the different 
spectrum of ages (Figure 3.22). In all of these cases, CAR-SIV was expressed 
exclusively in insulin positive beta cells (Figure 3.23) in agreement with the previous 
findings. 
As stated above the initial staining was performed on EADB samples, which are mainly 
samples collected from autopsies conducted as long as 50 years ago and in which the 
fixation types and times were variable. To confirm that the pattern of staining was the 
same in pancreas material collected more recently and under standardised conditions, 
the CAR-SIV isoform expression was also confirmed in two further cohorts; the DiViD 
and nPOD collections. In complete agreement with the findings from the EADB cohort, 
CAR-SIV was expressed exclusively in the beta cells.  
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Figure 3.22 Consistent expression of CAR-SIV isoform in the islets of non-diabetes cases 
from neonates to adulthood. 
 
 
 
 
 
 
  
Representative images examined by immunofluorescence analysis. This revealed that 
CAR-SIV (anti-CAR CT; green) expression is consistent in the islets from neonates 
(<4weeks) to adulthood (47years). Nuclei were stained using DAPI (blue). Data are 
representative of images from five donors. Scale bar 25μm 
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Figure 3.23 Consistent expression of CAR-SIV isoform and insulin in beta cells in non 
diabetic pancreas. 
 
 
 
 
 
Representative images examined by immunofluorescence analysis.This revealed that 
CAR-SIV (anti-CAR CT; green) is expressed exclusively in the insulin (anti-insulin; light 
blue) containing beta cells in normal non-diabetes cases from neonates (<4weeks) to 
adulthood (47years). Nuclei were stained using DAPI (blue). Data are representative of 
images from five donors. Scale bar 25μm 
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Careful analysis of the normal pancreas tissues in the EADB samples also revealed 
that CAR CT and CAR ECD immunostaining was faintly detected in the ductal cells of 
the normal pancreas which appeared to be expressed on the surface (Figure 3.24). 
This result suggests that CAR-SIV and other CAR isoforms (CAR-TVV, CAR4/7, or 
CAR3/7) recognised by CAR ECD antiserum may be expressed at low levels in the 
ductal cells of the pancreas. To confirm at the RNA level, if the transmembrane CAR 
isoforms are both expressed in the ductal cells, RT-PCR analysis on the ductal cell 
line, PANC1, with the isoform specific primers to specifically amplify CAR-SIV and 
CAR-TVV was employed. As shown in Figure 3.24, the primer pair designed to amplify 
CAR-SIV yielded an intense band size at approximately 250bp and those against 
CAR-TVV generated a smaller band at approximately 230bp. This implies that both 
the CAR-SIV and CAR-TVV are both expressed in the ductal cells 
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  Figure 3.24 CAR isoforms expression in the ductal cells of the human pancreas. 
 
 
 
  
CAR-SIV CAR-TVV No 
template 
ctrl 
No 
template 
ctrl 
300bp 
200bp 
CAR CT CAR ECD 
(A) PCR 
(B) IHC 
Total RNA was isolated from cell lysates of PANC-1 cells. Following quantification, 1µg 
of RNA was converted to cDNA. The cDNA was subsequently used in a PCR reaction 
with specific primers designed to amplify CAR-SIV and CAR-TVV isoforms of CAR 
(Table 3.2). FFPE human pancreas tissue were subjected to either anti-CAR CT or 
anti-CAR ECD for IHC analysis. (A) RT-PCR revealed bands at 250bp for CAR-SIV 
and a band at 230bp for CAR-TVV in the human ductal PANC-1 cell line (B) Left panel 
show magnified image of immunostaining with anti-CAR CT detecting faint CAR-SIV 
(black arrow) on the surface of ductal cells and right panel show CAR ECD (black 
arrow) which detects CAR-SIV, CAR-TVV, CAR 4/7 and CAR3/7 on the surface of 
ductal cells. RT-PCR data are representative of three independent experiments while 
IHC data are representative images from at least three donors. Scale bar 20μm 
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3.2.11 CAR-SIV isoform expression in the pancreas of Type 1 
diabetes patients 
As previously noted, there is circumstantial evidence for a role of enteroviruses in the 
development of type 1 diabetes and a viral capsid protein (VP1) can be found in the 
beta cells of patients with this disease (Richardson et al., 2014). The two 
transmembrane isoforms, CAR-SIV and CAR-TVV are known to be capable of 
propagating a productive infection and we decided to investigate whether the 
expression of these proteins changes in the pancreases of people with type 1 diabetes 
(Appendix, Table 8.1). Strikingly, it was observed that the CAR-SIV isoform was 
labelled only in residual insulin-containing islets (ICI). In these islets CAR-SIV 
expression was similar to healthy controls. In contrast, CAR-SIV was not expressed 
in insulin deficient islet (IDI) where the beta cells have been destroyed (Figure 3.25 & 
Figure 3.26) 
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  Figure 3.25 CAR-SIV is expressed in only the insulin containing islets of Type 1 diabetes cases and not in insulin deficient islets. 
 
 
 
Representative immunofluorescence images of the CAR-SIV isoform (anti-CAR CT; green), insulin (anti-insulin; light blue), glucagon (anti-
glucagon; red) and DAPI (nuclei; dark blue) in an insulin containing islet (ICI; upper panel) and insulin deficient islet (IDI); lower panel) of a type 
1 diabetes case. Data are representative of images from ten independent donors, Scale bar 25μm 
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Figure 3.26 CAR-SIV is present only in insulin containing islets (ICI) and absent in insulin deficient islets (IDI) 
 
Immunofluorescence image shows CAR-SIV (anti-CAR CT; green) in insulin containing islets (ICI) of beta cells (anti-insulin; light blue, black 
arrow head) and not in alpha cells (anti-glucagon; red). In contrast, the neighbouring insulin deficient islet (IDI), is negative for CAR-SIV but 
positive for glucagon.Nuclei were stained using DAPI (blue). Data are representative of images from ten independent donors, Scale bar 50μm   
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3.2.12 CAR-SIV isoform expression in the pancreas of Type 2 
diabetes patients 
Type 1 and Type 2 diabetes are clearly different diseases although they share 
certain similarities and both are defined according to the inability of affected 
people to regulate blood glucose levels effectively. Type 1 diabetes is 
characterised by the increasing loss of beta cells while in Type 2 diabetes, the 
pancreas tissue retains beta cells but these become progressively more 
dysfunctional (Lillioja et al., 1993). The aim here, was to monitor the expression 
of the CAR-SIV isoform in the pancreases of people with type 2 diabetes (T2D, 3 
cases; 46-56years). The presence of CAR-SIV in pancreatic beta cells within the 
islets was confirmed and its expression did not appear to be altered when 
compared with normal pancreas (Figure 3.27) 
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Figure 3.27 Expression of CAR-SIV is not altered in a pancreas from a Type 2 diabetes 
case 
 
 
 
3.2.13 Differential staining of CAR-SIV isoform in mouse and 
human pancreas tissue 
In acute enteroviral infection of the human pancreas, only the beta cells are 
infected (Berinstein et al., 1995, Roivainen et al., 2000). By contrast, when mice 
are inoculated with CVB viruses, the exocrine tissue is heavily infected while the 
islets are largely spared (Arola et al., 1995, Klingel et al., 1996, Szopa et al., 
1989). Immunostaining of CVB-infected human neonatal pancreas tissue and 
Representative immunofluorescence images of consistent expression of CAR-SIV (anti-
CAR CT; green) in insulin containing islets (anti-insulin; light blue) and DAPI (nucleic; 
blue). Data are representative of images from three donors, Scale bar 25μm. 
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CVB-infected mouse pancreas tissue with an antiserum that recognises the 
enteroviral VP1 protein confirmed these previous observations shown in Figure 
3.28,in that, VP1 expression is observed only in the islets of the human tissue 
(upper panel) and in the exocrine tissue of the mouse pancreas (lower panel). 
 
Figure 3.28 Differential enteroviral VP1 protein expression in CVB infected human and 
mouse pancreatic tissue 
 
  
VP1 
Immunohistochemical images displaying expression of enteroviral protein VP1 (black 
arrow) specifically in the islets of human pancreas, however, the exocrine tissue is 
negative (upper panel). In contrast, the exocrine tissue of the mouse pancreas is 
strongly VP1 positive (black arrow) whereas the islets are negative, lower panel. Data 
are representative of images from three donors and from three independent mice.Scale 
bar 50μm  
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To examine whether this reflects a difference in the expression of CAR in mouse 
and human pancreas, we utilised the CAR CT and CAR ECD antisera, both of 
which are capable of recognising murine CAR. Intriguingly, the CAR CT 
antiserum failed to label CAR-SIV in either the islets or exocrine tissue of mouse 
and rat pancreas (Figure 3.29). However, the CAR ECD antiserum, which 
purportedly reacts with both mouse and human CAR (according to the 
manufacturer) detected CAR protein in the exocrine tissue. In contrast to the 
cytoplasmic localisation seen in human islets, the CAR ECD staining was 
distributed on the surface of the exocrine cells (Figure 3.29). This antiserum 
cannot differentiate between the CAR-SIV and CAR-TVV isoforms and is capable 
of recognising both. Alignment of the human and mouse CAR show 93% similarity 
in the protein sequence for the epitope recognised by CAR CT (Figure 3.30) and 
given that specific binding epitope of the CAR CT (detects CAR-SIV isoform) was 
not detected in the mouse pancreas, the combined results suggest that the CAR-
TVV isoform is expressed on the surface of the pancreatic exocrine cells in 
mouse. In stark contrast to humans, very little CAR isoform staining is observed 
in the islet cells. Importantly though, this distribution of expression fits with the 
tropism of the CVB virus in human and mouse pancreas tissue. 
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                   Figure 3.29 Differential immunostaining with CAR CT and CAR ECD antisera in mouse pancreas tissue. 
 
 
 
 
 
 
Upper panel show that staining with anti-CAR CT (CAR-SIV) is not detected in the islet or exocrine of mouse pancreas. 
Lower panel revealed that staining with CAR ECD is detected in the exocrine but negative in the islet (anti-insulin; light 
blue andanti-glucagon; red) in mouse pancreas. Nuclei were stained using DAPI (dark blue). Data are representative of 
images from three independent mice, Scale bar 25μm. 
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   Figure 3.30 Alignment of the human and mouse CAR-SIV isoform 
 
 
 
 
 
 
 
 
 
CAR-SIV isoform show 93% similarity in the sequence for the epitope recognised 
by CAR CT antiserum 
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3.3 Discussion 
3.3.1 Expression of transmembrane CAR isoform in isolated 
human islets and beta cell lines 
This current study used a range of RNA detection techniques, including RT-PCR, 
TaqMan qRT-PCR and RNASeq to demonstrate collectively that three CAR 
isoforms, which include the two transmembrane domain containing isoforms 
CAR-SIV and CAR-TVV, and the soluble CAR4/7 isoform are expressed in 
isolated human islets, laser capture microdissected (LCM) human islets and in 
the human pancreatic beta cell lines EndoC-βH1 and 1.1B4. The RT-PCR and 
RNAseq data imply that CAR-SIV is predominant. The other transmembrane 
domain isoform, CAR-TVV, is more moderately expressed and CAR 4/7 is 
expressed at only a low level in isolated human islets and in the human pancreatic 
beta cell line EndoC-βH1. Conversely, qRT-PCR analysis showed that in both 
isolated and LCM islets the two transmembrane isoforms CAR-SIV and CAR-
TVV maybe expressed in equivalent amounts. It is important to note that this 
technique utilises high specificity TaqMan qRT-PCR with fluorescently labelled 
probes that will only hybridize to specific sequences (Tajadini et al., 
2014).Therefore, the discrepancy in the data obtained from the qRT-PCR may be 
attributed to the contamination of isolated human islet cells with exocrine cells 
during islet isolation thereby enriching CAR-TVV expression. Unfortunately, we 
could not assess CAR isoform expression in the exocrine tissue, despite efforts 
to do so via LCM of exocrine material, due to low RNA integrity. This would have 
enabled further discrimination of CAR isoforms in the exocrine compartment. 
Hence, one limitation of this study was the inability to assess the isoforms present 
at the RNA level in the exocrine pancreas. A recent in vitro study by Hodik et al 
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(2016) utilised SYBR green based Real time PCR to demonstrate that CAR 
mRNA expression levels decreased linearly over a period of 12 days in isolated 
cultured human islets and that CAR mRNA levels were significantly reduced in 
isolated human islets infected with three different strains of CVB-1, compared to 
uninfected control islets (Hodik et al., 2016a). The relative CAR mRNA 
expression levels measured in that study utilised SYBR green based Real time 
PCR while in this thesis we employed the TaqMan qRTPCR  making it difficult to 
compare CAR mRNA expression in both studies. A drawback of the Hodik (2016) 
study is that the alternatively spliced CAR isoforms were indistinguishable 
because the sequences of the primers were not designed to identify the different 
isoforms. In conclusion, these findings are in agreement with our data in that they 
identify robust CAR expression in isolated human islets. Their finding that CAR 
levels reduce following infection is also interesting and implies that the direct 
infection and destruction of beta cells, could consequentially then result in a 
reduction of CAR expression over time.  
3.3.2 Expression of soluble CAR isoform in isolated human islets 
and pancreatic beta cell lines 
This present study also demonstrated at the RNA level that soluble CAR4/7 was 
expressed in modest amounts, while the other soluble isoforms, CAR 3/7 and 
CAR 2/7, were barely detectable in isolated human islets or in the human 
pancreatic beta cell lines, EndoC-βH1 and 1.1B4.Taken together, the different 
RNA approaches concur that the soluble CAR4/7 isoform is expressed in isolated 
human islets, EndoC-βH1 and 1.1B4 cells. The CAR4/7 isoform may also be 
expressed in the acinar cells of the exocrine tissue and /or at low levels in the 
beta cell although, there was no antisera available in this present study to 
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specifically recognize the CAR4/7. The structure of the CAR 4/7 isoform contains 
a complete extracellular D1 domain and a partial D2 domain that are known to be 
important for CVB binding, since mutations leading to deletion of the  extracellular 
domain in Chinese hamster ovary (CHO) cells resulted in lack of virus binding 
(Excoffon et al., 2005). As CAR 4/7 lacks the transmembrane domain (Figure 3.8) 
the protein is soluble and secreted from the cell and is unable to mediate infection 
(Dörner et al., 2004) unless, perhaps, it is internalized by an endocytic 
mechanism. Studies by Yanagawa et al (2004) and Dorner et al (2006) show that 
if mice are infected with CVB3 strains in the presence of CAR4/7 that the level of 
infection in myocardium and pancreas are reduced when compared to mice 
infected with CVB3 strains alone (Yanagawa et al., 2004, Dörner et al., 2006). 
The same was also seen in an in vitro model where HeLa cells were less 
susceptible to infection with CVB in the presence of CAR4/7  (Goodfellow et al., 
2005). In addition, Excoffon et al (2014) have highlighted the possibility that CAR 
soluble isoforms secreted from the cells could directly interact with both 
Coxsackieviruses and Adenoviruses thereby acting as a decoy viral receptor  
reducing viral infectivity (Excoffon et al., 2014). 
3.3.3 Cytokine treatment has no effect in CAR isoform 
expression in the isolated human islets and EndoC-βH1 cells 
Study by Eizirik et al (2012) showed that pro-inflammatory cytokines could alter 
the splicing and expression of about 20% of genes present in the human islet 
(Eizirik et al., 2012). In the present study, RNAseq analysis of cytokine treated 
isolated human islets and EndoC-βH1 showed no significant changes in the 
various CAR mRNA isoforms (Figure 3.9), suggesting that there is no alteration 
in splicing of CAR under these conditions. qPCR analysis of isolated human islets 
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that had been incubated with the chemokine CXCL10 also failed to show a 
change in CAR  expression (Hodik et al., 2016a). It is possible though that there 
may be other factors regulating CAR expression during a viral infection that have 
not been identified as Hodik et al (2016) also demonstrated that UV-treated 
culture supernatants of CVB infected human islets increased CAR mRNA 
expression even after 4 days of culture compared to control culture medium 
(Hodik et al., 2016a).  
3.3.4 CAR isoform expression in the human pancreatic tissue 
CAR isoform expression at the protein level was assessed using a range of 
different technologies (immunohistochemistry, immunofluorescence microscopy 
and Western blotting) with these antisera (CAR CT, CAR ECD and CAR NT).  
The antibody epitopes were carefully assessed to map the different CAR antisera 
to the different CAR isoforms. The results demonstrate that CAR CT would 
recognise only the CAR-SIV isoform. In contrast, the CAR ECD could recognise 
CAR-SIV, CAR-TVV, CAR 4/7 and potentially also the CAR3/7 isoforms. Finally, 
CAR NT should recognise all of the CAR isoforms. The CAR CT antisera proved 
to be specific in recognising the CAR-SIV isoform in the human beta cells utilising 
the different approaches immunohistochemistry, immunofluorescence 
microscopy and Western blotting (the specificity of this antisera is investigated 
further in Chapter 6). However, when utilising the CAR ECD and CAR NT 
antisera, other CAR isoforms such as the CAR-TVV and CAR4/7, seen at the 
RNA level, are likely to be detected.  The data presented here suggest that these 
isoforms could be present in the pancreatic beta cell or in the exocrine 
compartment as additional staining, on top of that observed with the CAR CT 
antisera was seen in these compartments.  
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The pancreatic ductal cells have also been shown to be infected by enterovirus 
(Ylipaasto et al., 2004, Alidjinou et al., 2017), interestingly, both staining with CAR 
CT and CAR ECD antisera were detected on the surface of the ductal cells in the 
pancreas implying the presence of CAR isoforms in these cells (Alidjinou et al., 
2017).The CAR-TVV isoform may also be expressed in the other endocrine cells 
as well as in the beta cells, acinar and ductal cells of the exocrine pancreas but 
there was no specific CAR-TVV antiserum commercially available to directly test 
its expression in the human pancreatic tissue. Hence, another limitation in this 
present study was the lack of a CAR-TVV antiserum. In conclusion, the results of 
the antisera staining (Table 3.8) in combination with the RNA expression data, 
imply that CAR-SIV is the predominant isoform present in the human pancreas 
and that it is specifically expressed within human pancreatic beta cells.   
3.3.5 CAR isoform protein expression in the isolated human 
islets and pancreatic beta cell lines 
The Western blot analysis in this study revealed that labelling with the CAR ECD 
antisera recognised a molecular weight band at approximately 40kDa in isolated 
human islets, EndoC-βH1, 1.1B4 and PANC-1 cells. Interestingly, there were 
some lower band fragments in the EndoC-βH1 and 1.1B4 which have been 
reported in previous studies to be the cleavage products of metalloproteases 
such as ADAM10 (Houri et al., 2013). Indeed, our results (Figure 3.19) by 
RNAseq and immunohistochemistry revealed that ADAM10 is highly expressed 
in isolated human islets, EndoC-βH1, and also in the beta and alpha cells of the 
human pancreatic tissue. It is possible that since ADAM10 is present in the islet 
cells that it can access CAR-SIV and cleave the extracellular domain. One could 
also speculate that the lower fragments detected by the CAR antisera could be 
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other isoforms of CAR because the CAR ECD antiserum will be able to detect 
CAR-TVV and CAR 4/7. However, this is unlikely because the molecular weight 
of CAR-SIV and CAR-TVV cannot be distinguishable (40kDa and 39kDa 
respectively) and the soluble CAR4/7 has a predicted molecular weight of 28kDa 
which is much lower than the 32kDa band observed. Importantly, the CAR CT 
antiserum which only recognises the CAR-SIV isoform, produced a band of 
~40kDa in isolated human islets, the human pancreatic beta and ductal cell lines. 
The size of the band seen with the CAR CT antiserum is comparable to that 
observed with the CAR ECD antiserum. If the cells were expressing high levels 
of the CAR-TVV isoforms, one would expect the band to be bigger in the CAR 
ECD probed samples, as it can recognise both CAR-SIV and CAR-TVV. This 
suggests that although CAR-TVV may be expressed it is unlikely to be at very 
high levels. The lower fragments (approx. 20kDa) detected were also seen in 
previous work by Houri et al (2013) demonstrating that after cleavage by 
ADAM10, CAR could undergo regulated intramembrane proteolysis (RIP) 
cleavage by a γ-secretase complex leading to the release of the intracellular 
domains into the cytosol (Houri et al., 2013). The CAR CT antiserum will be able 
to detect these intracellular fragments and the smaller fragment sizes observed 
in this present study would fit with this hypothesis. Houri et al (2013) posited that 
the extracellular domain shedding and regulated intramembrane proteolysis 
(RIP) may be a mechanism for CAR degradation and protein turnover. The 
Western blotting results confirm the microscopy findings and suggest that CAR-
SIV is the predominant CAR isoform in human islets.  
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3.3.6 CAR isoform expression in autoantibody positive 
individuals without diabetes and individuals with Type 2 
Diabetes 
Whilst investigating CAR in the human pancreas tissue Hodik et al (2016) 
suggested that CAR expression was increased in the endocrine cells of 
autoantibody-positive non-diabetic donors and type 1 diabetes patients when 
compared to non-diabetic controls (Hodik et al., 2016a).Their study utilised the 
CAR RmcB antiserum which is predicted to recognise an unspecified region in 
CAR extracellular domain and as such these isoforms; CAR-SIV, CAR-TVV, CAR 
4/7 and CAR 3/7. The data presented in this thesis (Figure 3.21) were not able to 
reproduce their findings with this particular antiserum. The CAR CT and CAR 
RmcB antisera were used simultaneously in several different techniques, but the 
anti-CAR RmcB was negative in the pancreatic tissue, as opposed to the positive 
staining observed with CAR CT antiserum. The CAR RmcB antiserum was also 
shown to not be appropriate for use in Western blotting. In Chapter 4 of this thesis, 
this antiserum is shown to be suitable in flow cytometry and 
immunocytochemistry, but not for Western blotting and IHC-paraffin protocol 
(IHC-P). This suggests that this antibody recognises the native form of CAR, 
which is further, supported by its ability to act as a blocking antibody (binds CAR 
in live cells) and as such can prevent CVB-infection (Ylipaasto et al., 2004). An 
additional limitation of the Hodik study was that they did not address which 
endocrine cells are expressing CAR. Having shown that the CAR RmcB 
antiserum was not suitable for IHC-P sections, we utilised the CAR CT antiserum 
in combination with anti-insulin and anti-glucagon antisera in the human 
pancreatic tissue from normal pancreas donors, autoantibody positive non-
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diabetic donor and type 1 diabetes patients. Contrary to the data by Hodik et al 
(2016) there were no observed changes in CAR-SIV expression pattern in the 
human pancreatic beta cells in any of the type 1 diabetes pancreas cases (Figure 
3.25) and there was no age related changes in the normal diabetes cases (Figure 
3.22). Our collaborator, Dr Laura Nigi (University of Sienna) provided an 
independent confirmation of a similar CAR-SIV expression pattern in the human 
pancreatic tissues which were in agreement with what we observed (Figure 3.23). 
However, one interesting finding emerged from the study of the type 1 diabetes 
pancreas cases was that when the beta cells had been destroyed (insulin-
deficient islets); CAR-SIV expression was completely lost. Importantly, this 
supports our observation that the CAR-SIV isoform is selectively expressed in the 
beta cells. 
3.3.7 Differential CAR isoform expression in mouse and human 
pancreatic tissue 
Experimental studies in mice have reported that Coxsackie B viruses 
preferentially infect the pancreatic acinar cells and not the islets (Ross et al., 
1974, Szopa et al., 1989, Arola et al., 1995, Bopegamage et al., 2005a). In 
support of this, our findings, demonstrate that we fail to detect CAR-SIV in mouse 
islets at the protein level. In agreement, studies utilizing in situ hybridization assay 
in pancreatic tissue from mice failed to show any expression of CAR mRNA in 
the islets (Mena et al., 2000, Bopegamage et al., 2005b), together this may 
explain why mouse islets are normally spared during CBV infection.  Another 
study using purified CAR-TVV antiserum indicated via Western blotting that 
mCAR1 (CAR-TVV) is highly expressed in whole mice pancreases when 
compared to mCAR2 (CAR-SIV) (Raschperger et al., 2006). As described above, 
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CAR mRNA levels in mice have been observed at much higher levels in acinar 
cells of the exocrine tissue than in islets (Mena et al., 2000). The study by Mena 
et al (2000) did not discriminate between the different CAR isoforms present, but 
one could speculate that it is the CAR-TVV that is present in the exocrine cells. 
This is in accord with our results where staining within the pancreas was only 
observed with the CAR ECD antisera (detects both CAR-SIV and CAR-TVV) in 
the acinar cells and not with the CAR CT antisera (detects only CAR-SIV).  
3.3.8 Summary: 
Our data provides compelling evidence that CAR-SIV is the predominant 
transmembrane domain CAR isoform confined to the human beta cell and that 
CAR-TVV and CAR 4/7 may also be present at lower amounts in the human beta 
cell and/or acinar cells of the exocrine pancreas. Importantly, CAR-SIV presence 
in the pancreatic beta cells supports the susceptibility of these cells towards CVB 
replication and infection. In contrast, failure to observe the CAR-SIV expression 
in the islets of mice may explain why their islets are normally spared during 
infection. 
This chapter has been able to identify a specific isoform of CAR (CAR-SIV) that 
is distributed in the human beta cell and also acknowledges that other CAR 
isoforms (CAR-TVV and CAR 4/7) may also be present in the beta and acinar 
cells of the human pancreas. 
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CHAPTER 4 
Characterisation of CAR antisera 
using human pancreas tissue, beta 
and ductal cell lines 
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4.1 Introduction 
In Chapter 3, it was demonstrated that the CAR antisera (CAR CT and CAR ECD) 
were both suitable for immunohistochemistry, immunofluorescence microscopy 
and Western blotting while the CAR RmcB antiserum was not suitable for any of 
these assays (Table 4.1). 
 
Table 4.1 Summary of the utility of CAR antisera in different assays (+ suitable, -not 
suitable) 
Antisera CAR isoforms recognised  IHC-P/IF  
(FFPE) 
Western 
blotting 
CAR CT CAR-SIV + + 
CAR ECD CAR-SIV CAR-TVV CAR4/7 
CAR3/7 
+ + 
CAR RmcB CAR-SIV CAR-TVV CAR4/7 
CAR3/7 
_ _ 
 
To characterise the CAR antisera (CAR CT, CAR ECD and CAR RmcB) further 
in this study, human pancreatic beta and ductal cell lines were employed. The 
“CAR RmcB” antiserum was also chosen because it had previously been utilised 
in immunocytochemistry (ICC) and flow cytometry to demonstrate CAR surface 
expression on a range of different cell lines; for example HeLa, A549, HCT, 
HRT18 (McDonald et al., 1999). The CAR RmcB antiserum is also predicted to 
be directed against an unspecified region within the extracellular domain (Figure 
4.1) and therefore might be expected to detect CAR-SIV, CAR-TVV, CAR4/7 and 
CAR3/7. 
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The objectives of this chapter are therefore as follows; 
 To characterise CAR isoform antisera specificity and evaluate their utility 
in different assays utilising human pancreatic beta and ductal cell lines 
(EndoC-βH1, 1.1B4 and PANC-1) 
 To determine CAR-SIV orientation in the human beta cell line utilising the 
different CAR antisera 
 To explore CAR-SIV differential expression further in a variety of normal 
and cancerous tissues 
 
 
 
 
 
 
 
 
Figure 4.1 Schematic diagram of CAR antisera (CAR NT, CAR ECD, CAR RmcB and 
CAR CT) immunoreactivity against CAR protein 
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4.2 Results 
4.2.1 Trial of CAR antisera in human pancreatic ductal cell line 
In order to further characterise the three CAR antisera (CAR CT, CAR ECD and 
CAR RmcB), PANC-1 cells (which have been shown to express CAR in Chapter 
3, section 3.2.10 and in a recent study (Alidjinou et al., 2017) were employed to 
determine their suitability for ICC and flow cytometry.  
In this analysis, the three CAR antisera (CAR CT, CAR ECD and CAR RmcB) 
were delivered to permeabilised PANC-1 cells and unbound antiserum was 
removed by washing. This was followed by staining with goat anti-rabbit or anti-
mouse AlexaFluor555 secondary antisera; cells were mounted with Dako 
mounting medium and viewed under a fluorescence microscope. Trial of these 
antisera on PANC-1 cells revealed that anti-CAR CT and anti-CAR RmcB could 
be detected by ICC, as indicated by the yellow arrows, while the CAR ECD 
antiserum could not be detected (Figure 4.2A) 
To assess the three CAR antisera by flow cytometry, surface analysis was 
performed with the CAR ECD and CAR RmcB antisera, both of which recognise 
the extracellular domain of CAR on the outer surface of the cells, while an 
intracellular approach was undertaken for CAR CT antiserum because of its 
ability to recognise CAR’s cytoplasmic tail  (Wang and Bergelson, 1999).  Intact, 
PANC-1 cells were incubated with CAR antisera (CAR ECD and CAR RmcB) to 
detect CAR on the cell surface, while in the case of anti-CAR CT, immunolabelling 
was carried out on permeabilised cells where the antiserum could gain access to 
intracellular epitopes. A rabbit/mouse IgG isotype control (negative) was also 
included. Unbound antisera were removed by washing and a secondary goat anti-
rabbit or anti-mouse AlexaFluor488 detection antiserum was used to visualise 
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staining. This was then analysed on a flow cytometer. In accord with the ICC 
results, the CAR CT and CAR RmcB antisera were both detected as clearly seen 
by the displacement of the peak (in red) to the right compared with isotype 
controls (black)(Figure 4.2B). In contrast, CAR ECD antiserum was not detected 
as clearly seen by the lack of peak shift when compared to the isotype control 
(Figure 4.2B). This is despite the fact that CAR protein of the appropriate 
molecular weight was observed in PANC1 cells by Western blotting with this 
antiserum (Chapter 3, section 3.2.7). 
The above results imply that anti-CAR CT and anti-CAR RmcB are both suitable 
for use in ICC and flow cytometry, while anti-CAR ECD is not appropriate for 
utilisation in these assays.  
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Figure 4.2 Staining with CAR RmcB and CAR CT antisera, but not CAR ECD, in PANC-1 cell line 
 
 
 
 
 
 
 
 
 
A 
B 
(A) Immunocytochemical analysis detected staining with anti-CAR CT, anti-CAR RmcB as shown by the pale white signal (yellow arrows), 
Nuclei were stained with DAPI (white spherical shape), anti-CAR ECD was not detected. Scale Bar 25μm (B) Representative flow 
cytometry plots showing positive staining with anti-CAR CT and anti-CAR RmcB immunolabelling compared to negative controls (Rabbit 
IgG (RbIgG) and Mouse IgG (MsIgG) while anti-CAR ECD staining was not detected as observed by the lack of shift from the negative 
control (Rabbit IgG) (n=3).  
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4.2.2 Detection of CAR surface expression in the human 
pancreatic beta and ductal cell line model 
Having confirmed that the CAR RmcB antiserum is suitable for flow cytometry, it 
was utilised to determine if CAR is expressed on the surface of the human 
pancreatic beta cell lines, EndoC-βH1 and 1.1B4. The PANC-1 cell was utilised 
as a positive control. Cells in routine culture were harvested and incubated with 
either anti-CAR RmcB directly conjugated to a phycoerythrin (PE) or mouse IgG 
PE isotype (negative) control. The representative histogram plot of the surface 
expression demonstrates that CAR is expressed on the surface of both EndoC-
βH1 and PANC-1 cells (Figure 4.3A). The flow cytometric analysis clearly shows 
a displacement of the peak (in red) to the right with anti-CAR RmcB labelled cells, 
compared with mouse IgG isotype control (black). Importantly, this also confirms 
that the extracellular domain of CAR is presented on the outer surface of the cells. 
In contrast, 1.1B4 cells exhibited only very weak expression of CAR on the cell 
surface when compared to the isotype control (Figure 4.3A) 
To support these data, cells grown on coverslips were PFA fixed, followed by 
immunolabelling with CAR RmcB antiserum. The staining was detected with a 
goat anti-mouse AlexaFluor555 secondary antiserum; cells were mounted with 
Dako mounting medium and viewed under a high resolution confocal microscope. 
The results demonstrate anti-CAR RmcB labelling on the surface ofEndoC-βH1 
and PANC-1 cells (Figure 4.3B). Punctate CAR surface expression was observed 
in both cell lines with occasional areas of enriched CAR localised to junctions 
between neighbouring cells (yellow arrow heads). This is indicative of cell surface 
tight junction formation between cells (Cohen et al., 2001b). The 1.1B4 cells 
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revealed very low expression of anti-CAR RmcB on the surface of 1.1B4 cells 
which correlates with the flow cytometry data (Figure 4.3A). 
The flow cytometry and confocal immunocytochemistry analysis revealed that 
anti-CAR RmcB (which is expected to recognise the three known CAR isoforms 
present in the human pancreas CAR-SIV, CAR-TVV and CAR4/7 (as 
demonstrated in Chapter 3 RNA and proteomics analysis) can recognise CAR 
expressed on the surface of EndoC-βH1 and PANC-1 cells. CAR was found to 
be only weakly expressed on the surface of 1.1B4 cells. 
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EndoCβH1 1.1B4 PANC-1
PANC-11.1B4EndoCβH1 
 
Figure 4.3 CAR expression is detected on the surface of cells by staining with CAR RmcB antisera 
 
A 
B 
CAR RmcB antisera labelling demonstrates that CAR is strongly expressed on the surface of EndoC-βH1, PANC-1 but weakly on 1.1B4 cells. 
(A) Representative flow cytometry plots showing staining with anti-CAR RmcB revealed surface expression (red) in EndoC-βH1, 1.1B4 and 
PANC-1 cells, Isotype control (black) (B) Immunocytochemical images of anti-CAR RmcB (red) and nuclei (blue) in EndoC-βH1 (yellow 
arrows), PANC-1(yellow arrows) and no labelling in 1.1B4. Scale bar 7.5μm (n=3) 
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4.2.3 Detection of intracellular CAR expression in the human 
pancreatic beta and ductal cell line models 
In order to detect intracellular CAR expression in the human pancreatic beta and 
ductal cell line models, EndoC-βH1, 1.1B4 and PANC-1 cells were collected and 
subjected to PFA fixation. Cells were then incubated with anti-CAR CT or rabbit 
IgG isotype control (negative) diluted in a permeabilisation buffer containing 0.3% 
saponin, to allow each antiserum to gain access to the intracellular cell 
compartment. Unbound antiserum was removed by washing and a secondary 
goat anti-rabbit AlexaFluor488 detection antiserum was used to visualise 
staining. This was then analysed on a flow cytometer. Intracellular CAR-SIV 
expression (red) was detected in all three cell lines (Figure 4.4A) when compared 
to the rabbit IgG isotype control (black).  
To further confirm the flow analysis, ICC staining of each of the cell lines was 
performed. PFA fixed cells were permeabilised with 0.5% Triton X-100 and 
labelled with anti-CAR CT followed by a goat anti-rabbit AlexaFluor488 
secondary antiserum. Comparison of the staining pattern of anti-CAR CT in the 
cell lines confirmed that intracellular CAR is clearly visible in the EndoC-βH1 and 
PANC-1 cells but that it is only weakly expressed in 1.1B4 cells (Figure 4.4). 
Interestingly, there tended to be differential pattern of localisation between the 
cell lines. Although, the staining pattern was predominantly cytoplasmic in all 
three cell lines, the expression appeared more punctate in the EndoC-βH1 and 
PANC-1 cell lines. The ICC analysis therefore concurs with the flow cytometry 
data and suggests that the C terminus of CAR-SIV can be detected in the 
intracellular compartment of all the three cell models, albeit at higher levels in the 
EndoC-βH1 and PANC-1 cells compared to the 1.1B4 cells.  
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1.1B4  
EndoC-βH1 
1.1B4 PANC-1 
1.1B4 PANC-1 EndoC-βH1 
Figure 4.4 CAR-SIV isoform is detected intracellularly by staining with the CAR CT antisera in EndoC-βH1, 1.1B4 and PANC-1 cells. 
A 
B 
(A) Representative flow cytometric plot detecting intracellular CAR-SIV isoform (red) in EndoC-βH1, 1.1B4 and PANC-1. (B) Clear 
cytoplasmic and punctate localisation of anti-CAR CT (green) in EndoC-βH1 and PANC-1 and nuclei were stained with DAPI (blue). 
Cytoplasmic CAR-SIV expression is lower in 1.1B4 cells. Scale Bar 2.5μm (n=3) 
 
 
193 | P a g e  
 
4.2.4 Bioinformatics prediction of CAR-SIV isoform structural 
orientation within a cell 
Taking into account the flow cytometry and ICC data in section 4.2.2 and 4.2.3 
one would predict that CAR-SIV is orientated with the extracellular domain (ECD) 
exposed on the outside surface of the cell whereas the C terminus (CT) faces the 
cytoplasm. By inserting the protein sequence (FASTA format) from UniProt 
database into a proteomic bioinformatic tool “Protter” 
(http://wlab.ethz.ch/protter/start/)(Omasits et al., 2014), one can bioinformatically 
predict the orientation of the CAR-SIV isoform. The proposed orientation of CAR-
SIV is illustrated (Figure 4.5) such that the region corresponding to the sequence 
beyond the signal peptide to the end of the extracellular domain is in the 
extracellular space/on the surface of cells and region beneath the 
transmembrane domain harbouring the C terminus (CT) is intracellular. The 
orientation of CAR-SIV was examined in more detail in the subsequent 
experiments detailed below. 
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Signal peptide 
 
 
Figure 4.5 Bioinformatics prediction of the orientation of the CAR-SIV isoform 
with bioinformatic tool (Protter). 
 The region initiating from the signal peptide (red) to the end of the extracellular 
domain (1) is in the extracellular space or on the surface of the cell while the 
region beyond the transmembrane domain harbouring the C’terminus is 
intracellular 
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4.2.5. Flow cytometry detection of CAR orientation in the human 
pancreatic beta cell model (EndoC-βH1) 
In order to confirm the orientation of CAR across the plasma membrane in human 
beta cells, the human pancreatic beta cell line EndoC-βH1 (shown to express 
high levels of the CAR-SIV isoform (Figure 4.4) was selected. The two CAR 
antisera that had previously been shown to be suitable for flow cytometry were 
utilised. The CAR RmcB antiserum, which binds to the ECD, and the CAR CT 
antiserum which binds to the CT of CAR-SIV were both tested in EndoC-βH1 
cells. Cells were stained with both antisera immediately (without 
permeabilisation) to assess which epitope was expressed on the outer surface of 
the cell.  Alternatively, the cells were fixed and permeabilised and then stained, 
to assess the intracellular epitopes. Isotype (controls) mouse IgG-PE or rabbit 
IgG were also included. In keeping with the previous results, the surface analysis 
demonstrates that anti-CAR RmcB was detectable on the extracellular surface of 
EndoC-βH1 cells (Figure 4.6A).There is a clear shift to the right in the histogram 
plot (red) labelled with anti-CAR RmcB compared to the mouse IgG-PE isotype 
(black) control. In contrast, no surface expression was observed with the anti-
CAR CT on the EndoC-βH1 cells, as evidenced by the lack of a shift on the 
histogram plot when compared to the rabbit IgG (negative) control (Figure 4.6A).  
Assessment of permeabilised cells with the anti-CAR RmcB revealed weak 
intracellular expression when compared to the mouseisotype control antiserum 
(Figure 4.6B). With anti-CAR CT there was a significant shift in expression 
observed when compared with its appropriate isotype control (Figure 4.6B). 
However, the punctate granular staining observed with the CAR RmcB antiserum 
(detecting majorly CAR-SIV and CAR-TVV)  in permeabilised cells suggests that 
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a proportion of CAR expressed in these cells resides on/in a cytoplasmic 
organelle (Figure 4.7; lower panel)  
These results confirmed that in the human pancreatic beta cell EndoC-βH1, the 
orientation of CAR-SIV is such that the extracellular domain is located on the 
surface/outside of the cell, while the C terminus harbouring the PDZ binding 
domain is located inside the cytoplasm. This fits nicely with the bioinformatics 
predicted orientation (Figure 4.5) and several other studies (Matthäus et al., 2017, 
Raschperger et al., 2006, Excoffon et al., 2014). The three CAR antisera (CAR 
CT, CAR ECD and CAR RmcB) have been successfully tested and characterised 
in the human pancreatic beta and ductal cell lines and this is summarised in Table 
4.2. 
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A. Surface Expression 
CAR RmcB 
IgGPE 
IgGPE 
CAR RmcB 
RbIgG 
CAR CT 
CAR CT 
RbIgG 
B. Intracellular Expression 
Extracellular Extracellular 
Intracellular Intracellular 
Figure 4.6 CAR orientation is detected utilising staining with anti-CAR RmcB and anti-CAR CT in the human pancreatic beta cell EndoC-
βH1. 
 
(A) Surface epitope labelling of anti-CAR RmcB (red) left plot and no surface labelling of anti-CAR CT (red) right plot in comparison to the 
negative controls (Rabbit IgG (RbIgG) and IgGPE (Black) (B) Intracellular epitope labelling of anti-CAR CT (red) right plot and no 
intracellular labelling of anti-CAR RmcB (red) left plot in comparison to the negative control Rabbit IgG (RbIgG) and IgGPE (black)(n=3)   
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Figure 4.7 Staining with CAR RmcB suggests that the CAR-SIV isoform is present 
both on the surface of the cells and in an intracellular compartment 
  EndoC-βH1 permeabilised cells 
EndoC-βH1 non-permeabilised cells  
Immunocytochemical analysis (upper panel) show that staining with CAR RmcB (red) 
(A) revealed surface staining in non-permeabilised cells, (lower panel) but (B) in 
permeabilised cells there is some intracellular staining with CAR RmcB (red). Nuclei 
were stained in blue (DAPI). Data are representative of images from three replicates, 
Scale 7.5μm  
 
B 
A 
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Table 4.2 Validation of CAR antisera with different assays  
Antisera CAR 
isoforms 
recognised 
IHC/IF 
FFPE 
ICC 
Coverslips 
Western 
blotting 
Flow  
cytometry 
CAR-form 
recognised 
CAR CT CAR-SIV + + + + Native & 
denatured 
CAR 
ECD 
CAR-SIV 
CAR-TVV 
CAR4/7 
CAR3/7 
+ _ + _ Non-native 
CAR 
RmcB 
CAR-SIV 
CAR-TVV 
CAR4/7 
CAR3/7 
_ + _ + Native 
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4.2.6 CAR-SIV isoform immunolabelling in normal and 
cancerous human tissues 
The differential anti-CAR CT staining pattern in the human pancreatic beta and 
ductal cells shown in (Figure 4.4) prompted an investigation of CAR-SIV 
expression in a variety of tissues to assess its distribution and subcellular 
localisation profile. 
Standard immunohistochemical staining was employed on a normal and 
cancerous human tissue microarray (TMA; Kind gift from Prof. Alan Foulis, 
Glasgow). The TMA was labelled with CAR CT antiserum using the conditions 
optimised in Chapter 3, section 3.2.4. The staining of the TMA demonstrates that 
CAR-SIV is highly expressed in the brain, pancreatic islets, testis, kidney 
(transitional cell carcinoma), bladder small cell carcinoma, stomach, heart and 
liver parenchyma (Figure 4.8). Expression was also observed in other normal and 
cancerous tissues, but not in normal nerve, normal vasculature, normal omentum 
and smooth muscle (Figure 4.9) 
Careful examination of the TMA revealed that the pattern of CAR-SIV staining 
was not uniform in all cell types. Certain tissues/cancers exhibited clear surface 
expression (e.g. bladder, testis, kidney (transitional cell carcinoma); (Figure 4.8) 
In contrast, other tissues/cancers exhibited a more granular cytoplasmic 
expression of CAR-SIV (e.g. the stomach, brain, heart, pancreatic islet, liver 
parenchyma; Figure 4.8). Interestingly, many of the normal and cancerous 
tissues/cell types in which this granular expression was observed have secretory 
functions. 
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                     Figure 4.8 CAR-SIV isoform distribution and cellular localisation in normal and cancerous human tissues. 
 
 
Kidney (transitional cell carcinoma)Brain Testis
HeartBladder Small cell carcinoma Stomach
Pancreas
Liver parenchyma
Staining with CAR CT antisera showed more cytoplasmic, granular expression in brain, islets, stomach, heart and liver (yellow 
arrow). In contrast, surface expression was observed in testis, kidney (transitional cell carcinoma), and bladder parenchyma (purple 
arrow). Scale bar 20μm 
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Normal alveoli  
Merkel cell tumor Melanoma Endometrium 
adenocarcinoma 
Ectocervix 
Normal 
nipple 
Liver portal tract Normal prostatic 
acini 
Normal salivary 
acini 
 
Basal cell carcinoma 
Normal ometum Normal nerve Normal vasculature Thyroid 
 
Figure 4.9 CAR-SIV isoform expression in normal and cancerous human tissues. 
 
Staining with CAR CT antisera demonstrates that CAR-SIV is positive in merkel cell tumor, melanoma, endometrium adenocarcinoma, basal cell 
carcinoma, normal nipple, normal alveoli, squamous cell carcinoma, ectocervix, liver portal tract, normal prostatic acini, normal salivary acini and 
negative in normal nerve, vasculature, ometum and smooth muscle. Scale bar 20μm  
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An independent confirmation of these results was achieved by utilising RNAseq 
data kindly provided by Prof. Decio Eizirik (Brussels). Quantitative RNAseq 
measurements of the three CAR isoforms (CAR-SIV, CAR-TVV and CAR4/7) 
were performed in a variety of normal human tissues (Figure 4.10).CAR-SIV and 
CAR-TVV were both detected in 13 of 16 (81%) of normal tissues but were both 
negative in adipose, skeletal muscle and white blood cells. The soluble CAR 4/7 
isoform was detectable at very low levels in 5 of 13 (38%) of the tissues. CAR-
SIV was expressed at a higher level than CAR-TVV in 12 of 16 (75%) tissues 
including the brain, breast, lymph node, ovary, prostrate, heart, kidney, testes, 
thyroid, liver, lungs and in isolated dispersed islets. CAR-SIV expression was 
highest in dispersed islet, brain, kidney, prostrate, testis, and thyroid all of which 
contain secretory cells. Encouragingly, the CAR-SIV RNAseq data aligned 
closely with the protein expression data previously presented (Figure 4.8 & Figure 
4.9). Furthermore, this RNAseq analysis supports the hypothesis that CAR-SIV 
is highly expressed in cells with secretory functions. 
Together, the immunohistochemical and RNAseq results demonstrate that the 
CAR-SIV isoform is differentially localised depending on the cell type and that 
CAR-SIV is highly expressed at both the RNA and protein level in many cell types 
with a biological secretory function. 
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Figure 4.10 RNAseq analysis confirming the expression profile of CAR-SIV, CAR-
TVV and CAR4/7. 
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Total RNA was isolated from cell lysates in different cells and tissues. Following 
quantification, 2µg of RNA was converted to cDNA. The cDNA was subsequently 
subjected to RNAseq analysis  
CAR-SIV is expressed at higher levels than CAR-TVV and CAR 4/7 in most tissues. 
In particular, CAR-SIV is highly expressed compared to CAR-TVV in dispersed 
islets, brain, kidney, prostrate, testes and thyroid, while CAR4/7 is least expressed 
in all tissues (mean RPKM). Courtesy of Prof. Decio. L. Eizirik   
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4.3 Discussion 
4.3.1 CAR CT, CAR ECD and CAR RmcB antisera differentially 
label the human pancreatic ductal cell (PANC-1) 
In characterising the three different CAR antisera (CARCT, CAR ECD and CAR 
RmcB) on the PANC-1 cells, it was resolved that the CAR CT antiserum 
recognises both the native and denatured form of CAR, while CAR RmcB 
recognises only the native form. This fits well with studies that have utilised CAR 
RmcB as a blocking antibody (Ylipaasto et al., 2004).In contrast, the CAR ECD 
antiserum only recognises CAR in a non-native form, produced following heating 
(IHC – Chapter 3, section 3.2.4) or upon treatment with reducing agents (Western 
blotting – Chapter 3, section 3.2.7) and is unable to recognise the native form (in 
flow cytometry and ICC). The utilisation of flow cytometry and ICC in the PANC-
1 cells demonstrated that the anti-CAR CT detects intracellular CAR and the anti-
CAR RmcB could detect CAR on the surface of the PANC-1 cells (see Figure4.2). 
4.3.2 The extracellular domain of CAR is present on the surface 
of human pancreatic beta and ductal cell lines 
This present study revealed high levels of CAR surface expression on EndoC-
βH1 and PANC-1 cells with a distinct pattern of localisation that was concentrated 
at points between adjacent cells. This pattern of localisation is a feature of cell-
cell junctions and has been previously reported by a group utilising the CAR 
RmcB antiserum, which recognises the ECD (Excoffon et al., 2005).The 
significance of the CAR ECD for the cell-cell interactionwas demonstrated 
through the generation of deletion mutants of the CAR ECD expressed in Chinese 
hamster ovary (CHO) cells. These mutants showed diffuse staining and 
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completely lacked any junctional surface localisation between the cells (Excoffon 
et al., 2005). 
The importance of the ECD of CAR to drive CAR localisation to these cell-cell 
junctions was further demonstrated in CHO cells in which a 
glycophosphatidylinositol linked CAR ECD, which lacked the cytoplasmic and 
transmembrane domain, was shown to still accumulate at the cell-cell junction 
(Cohen et al., 2001b). Finally, mutations of the D2 domain (see Chapter 3 Figure 
3.8) within the ECD also led to a lack of junctional localisation (Excoffon et al., 
2005). Since CAR4/7 lacks the complete D2 domain and the transmembrane 
domain, this suggests that the distinct surface cell-cell staining observed in the 
EndoC-βH1 and PANC-1 cells is mediated by CAR-SIV and/or CAR-TVV isoform 
expression. This fits with the CAR-SIV and CAR-TVV isoform specific RNA 
expression in EndoC-βH1 and PANC-1 cells previously shown (Chapter 3, Figure 
3.7B, & 3.25A). 
One unanticipated finding was the very low/weak surface expression of anti-CAR 
RmcB on 1.1B4 cells, which was supported byflow cytometry and ICC data. An 
explanation for this could be that 1.1B4 cells have very low levels of CAR protein 
and/or could have high levels of ADAM10, which has been demonstrated to 
cleave the CAR extracellular domain (Houri et al., 2013).The ADAM10 mediated 
cleavage products of CAR are approximately 32kDa (contains ECD) and 20kDa 
(contains the CT of CAR). A further cleavage of the 20kDa fragment by a γ-
secretase, releases a 14kDa fragment of the CT CAR lacking any 
transmembrane sequence (Figure 4.11). Importantly, intense lower ~35kDa and 
14kDa bands, which maybe these cleavage products (Chapter3, Figure 3.19) 
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were detected in 1.1B4 cells, when probed with CAR ECD and CAR CT antisera 
respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Together these result suggest that CAR is expressed in 1.1B4 cells, but that the 
levels of CAR on the surface may be lower (as suggested by the CAR RmcB 
results) than the other cell lines tested, potentially due to cleavage by ADAM10. 
In the future, it would be interesting to confirm this by using a specific inhibitor of 
ADAM10, such as G1254023X (Li et al., 2017) 
In summary, these data suggest that both the CAR-SIV and CAR-TVV isoform 
(recognisable by CAR RmcB) can be localised to the surface of the pancreatic 
beta and ductal cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 A model of CAR proteolysis, with molecular weights of the resulting 
fragments indicated. 
 
 
CAR ECD (32kDa)  
D1 
D2 
CAR CT 
(14kDa) 
CAR CT (20kDa) 
Cleavage of CAR by ADAM10 (represented by the top pair of scissors) releases a 
32 kDa fragment (CAR ECD) into the extracellular environment. The remaining 20 
kDa fragment (CTF1) is processed by the γ-secretase complex (represented by the 
lower pair of scissors), generating a 14 kDa fragment (CTF2), adapted from (Houri 
et al., 2013) 
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4.3.3 CAR CT antiserum staining suggests that CAR-SIV is 
present in intracellular compartments in human pancreatic beta 
and ductal cells 
The CAR CT antiserum will detect the C terminus of only the CAR-SIV isoform 
and intracellular CAR-SIV expression was found in EndoC-βH1, 1.1B4 and 
PANC-1 cell lines.  
Interestingly, with anti-CAR CT a predominantly cytoplasmic pattern was 
observed which was more punctate in EndoC-βH1 and PANC-1 than in 1.1B4. 
The result suggests that the CAR-SIV isoform may reside in a distinct intracellular 
membrane-bound compartment within the cytoplasm in the EndoC-βH1, PANC-
1 and 1.1B4 cells (Figure 4.4). The 20kDa cleavage product observed in the 
1.1B4 cells when probed with anti-CAR CT in Chapter 3, Figure 3.19 and the low 
level of expression observed in 1.1B4 cells imply that the EndoC-βH1 cells model 
would be more appropriate for further study. 
4.3.4 CAR orientation in EndoC-βH1cell line 
In this thesis, the orientation of CAR was confirmed in the human beta cell 
EndoC-βH1. The extracellular domain of CAR was demonstrated to face the 
outside of the cell, while the C terminus was present solely inside the cell. This is 
consistent with the predicted CAR orientation (Excoffon et al., 2010, Matthäus et 
al., 2017, Raschperger et al., 2006) and studies that have utilised mammalian 
cell expression systemto show that CAR’s N terminus (He et al., 2001) and 
extracellular domains interact with Coxsackie B viruses when presented outside 
the cell (Wang and Bergelson, 1999, Pinkert et al., 2016).Significantly, the level 
of the CAR-SIV isoform expression is high in these cells, as assessed by RNAseq 
(Chapter 3, Figure 3.7), Western blotting (Chapter 3, Figure 3.19) and intracellular 
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flow cytometry (Figure 4.4A) with the CAR CT antiserum and is likely to represent 
the major isoform in these cells. This is also supported by the observation that 
Western blotting with the CAR ECD antiserum (which recognises both CAR-SIV 
and CAR-TVV) did not reveal a larger or differently sized band when compared 
to the CAR CT antiserum (Chapter 3, Figure 3.19B). Importantly though, distinct 
intracellular membrane-bound compartments were also positive for CAR-SIV (as 
assessed by CAR CT staining), suggesting that this isoform can localise both at 
the surface and within distinct organelles within the EndoC-βH1 cells. 
 
 
 
 
 
 
 
  
C
A
R
 C
T
Beta cell
CAR-SIV
ECD
CT
GLUT 1/3
Figure 4.12 CAR-SIV orientation in the beta cell. 
 
 
The C terminus (CT) harbouring the PDZ domain is located inside the cell (detected by 
anti-CAR CT) while the extracellular domain (ECD) is located on the surface of the cell 
(detected by anti-CAR RmcB). Could CAR CT be in an intracellular compartment such as 
the insulin granule? 
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4.3.5 CAR-SIV is differentially expressed in normal and 
cancerous human tissues 
Interestingly, IHC analysis with anti-CAR CT in normal and cancerous tissues 
demonstrated that CAR-SIV was expressed in a large number of the tested 
tissues. The staining pattern, however, revealed differential localisation with the 
exhibition of surface staining in some tissues (for example bladder and kidney) 
which is consistent with its role in cell adhesion and tight junctions. In contrast, 
other cells (for example the stomach, islets and the brain) had a more granular 
cytoplasmic pattern.Interestingly, when assessing the functions of many of these 
tissues with this distinct CAR-SIV localisation, they were found to be involved in 
the secretion of various factors such as hormones, neurotransmitters and 
enzymes. The cytoplasmic granular or surface staining pattern in these tissues 
suggests that CAR-SIV may have distinct functions in these cell types. 
Although, this present study was not focused on cancer progression, differential 
expression was observed in cancerous tissues.It has been proposed by many 
that CAR may act as a tumour-suppressor because several studies have shown 
that loss of CAR impacts on proliferation, migration, invasion and the metastatic 
potential of several cancer types and also leads to a decline in cell adhesion 
(Okegawa et al., 2001, Okegawa et al., 2000, Huang et al., 2005, Anders et al., 
2009, Stecker et al., 2011, Matsumoto et al., 2005).  
4.3.6 Differential CAR-SIV and CAR-TVV expression in normal 
and cancerous human tissues by RNAseq 
The RNAseq analysis provided good confirmation of the IHC data by 
demonstrating that CAR-SIV RNA expression was detected in many of the 
cells/tissues shown to be positive for the CAR-SIV protein. Importantly, it 
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demonstrated that expression levels were high in many of the tissues involved in 
secretion. This provides further support for the hypothesis that CAR-SIV may 
have a distinct biological role in secretory cells. Importantly, CAR-SIV tended to 
be expressed at higher levels compared to CAR-TVV in these tissues. So 
although CAR-SIV and CAR-TVV may be present in similar tissues, their 
differential localisation suggests that they have different roles within these cells. 
Unfortunately, as mentioned previously, I have been unable to source CAR-TVV 
antiserum commercially or via authors of publications describing such an 
antiserum, which has made studying the localisation of this isoform in detail 
impossible within these studies. However, the localisation of the two 
transmembrane domain isoforms, CAR-SIV and CAR-TVV, in primary human 
epithelial cells has been assessed by Excoffon et al (2010). Initially, they 
generated adenovirus vectors expressing both of these two distinct forms. These 
were then utilised to generate isoform specific antisera from rabbits immunised 
with peptides directed against the last 13 C terminal amino acid of each, which 
differ between the two as described previously in (Chapter 1, Figure 1.9). Utilising 
these antisera in polarised human epithelial cells, which have distinct apical and 
basolateral membrane domains separated by tight and adherens junctions, the 
authors were able to demonstrate that CAR-SIV specifically localised to the 
basolateral membrane in these cells, mediating tight junction integrity via its  
colocalisation with ZO-1, a tight junction protein. In contrast, CAR-TVV was 
present at the apical membrane and did not colocalise with ZO-1 (Excoffon et al., 
2010). In a different study on murine tissue, utilising mCAR-2(CAR-SIV) and 
mCAR-1(CAR-TVV) specific antisera with immunofluorescence and Western 
blotting approaches, CAR-SIV was shown to be expressed at high levels at cell-
cell contacts in hepatocytes in the liver and kidney. In contrast, only very 
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low/weak expression of CAR-TVV was observed (Raschperger et al., 2006). This 
is in accord with the RNAseq data presented in this thesis. 
These differences in abundance and localisation have also been studied in 
human lung tissue and polarised airway epithelial cells (Excoffon et al., 2010). In 
terms of abundance, quantitative RT-PCR analysis revealed that CAR-SIV was 
expressed at higher levels than CAR-TVV in both human lung tissue and 
polarised airway epithelial cells (Excoffon et al., 2010) indicating that the CAR-
SIV isoform is predominant. This finding agrees with the RNAseq data in the lung, 
presented in this study. In that same study, Excoffon et al (2010), confirmed the 
importance of CAR subcellular localisation for infection by utilising dissociated 
human polarised airway epithelial cells, that were transduced with adenovirus 
vectors expressing either CAR-SIV (which will localise to the basolateral face) or 
CAR-TVV (which will localise to the apical face). After culturing these cells for 1 
week, to allow the cells to polarise and form a continuous epithelium, the cells 
were then infected with an adenovirus containing the LacZ gene. This 
demonstrated that cells transduced with the CAR-TVV (localised to the apical 
face) had a 5-fold increase in LacZ gene transfer compared to cells transduced 
with a GFP control and double the level compared to the CAR-SIV transduced 
cells. Therefore both CAR-TVV and CAR-SIV can mediate infection, but the 
localisation of the proteins could determine the initial entry route (Excoffon et al., 
2010). In another study, the human colonic cell line (T-84) was allowed to form 
polarised monolayers by culturing cells to confluency in transwells for 1 week. 
Analysis of CAR localisation, assessed by CAR antisera that recognise both 
CAR-SIV and CAR-TVV, confirmed that CAR was localised to tight junctions 
between cells (Cohen et al., 2001b). These cells were then infected with CVB3 
or adenovirus GFP (AdGFP) from either the apical region or the basolateral 
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region (performed by inverting the transwell insert and applying the virus). 
Immunocytochemical staining revealed little or no infection with CVB3 or AdGFP 
in cells exposed to virus on either the apical or basolateral surfaces. However, 
when the tight junctions were disrupted by EDTA before infection in these cells, 
there was a significant increase in infection by CVB3 and AdGFP in the cells 
(Cohen et al., 2001b). Moreover, to determine if this infection was mediated by 
CAR, EDTA treatment was followed by incubation with pre-immune serum or 
CAR antiserum raised against the extracellular domain (capable of recognising 
both CAR-SIV and CAR-TVV isoforms) before infection with CVB3 and AdGFP 
(Cohen et al., 2001b). The results demonstrate that both CVB3 and AdGFP 
infection were inhibited by CAR antiserum, but not by the pre-immune serum, 
signifying that disrupting the tight junctions makes CAR localisation accessible 
for virus attachment and infection. Thus, this implies that the localisation of both 
CAR-SIV and CAR-TVV in cells is critical for viral entry and successful virus 
production. All of these studies suggest that CAR expression at the cell surface 
is required to mediate entry of viruses. Our present study demonstrates that CAR-
SIV is expressed in beta cells, with at least a proportion of it on the cell surface, 
and concurs with the sensitivity of beta cells to infection by enteroviral serotypes 
that utilise this receptor for entry. 
In summary this chapter has characterised the use of CAR antisera in human 
pancreatic beta and ductal cell lines, revealing the orientation of CAR on the beta 
cell. It has also provided important evidence that the CAR-SIV isoform is enriched 
in several human cell type/ tissues that have a secretory function. 
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                  CHAPTER 5 
Subcellular localisation of CAR-SIV 
in the human beta cell of the 
pancreas 
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5.1 Introduction 
Several studies have investigated the subcellular localisation of CAR-SIV in 
various tissues, cells and cell lines and as such have provided some insights into 
CAR’s biological role which include; 
 Role in structural integrity in human and mouse cardiac muscle (Shaw et 
al., 2004) 
 Role in cell-cell adhesion (Cohen et al., 2001b) 
 A role in regulating paracellular transport of ions and molecules (Cohen et 
al., 2001b) 
 Mediates the retention and trafficking of innate immune cells between 
different body compartments (Kotha et al., 2015) 
As a result of the unexpected cytosolic localisation of CAR-SIV isoform in the 
human beta cells (revealed in chapter 3), it was important to further investigate 
its subcellular localisation which could provide moreinsights into its physiological 
role in human beta cell. 
The objectives of this chapter are as follows; 
 To examine the subcellular localisation of CAR-SIV in insitu human 
pancreatic tissue, isolated human islets and human pancreatic beta cell 
(EndoC-βH1, & 1.1B4). 
 To examine CAR-SIV colocalisation with other insulin secretory granule 
proteins  
 To explore CAR-SIV interaction with other protein partners in the human 
beta cell 
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5.2 Results 
5.2.1 Cellular localisation of CAR-SIV in the human pancreatic 
beta cell 
To determine where CAR-SIV is localised in the beta cells, formalin fixed paraffin 
embedded (FFPE) isolated human islets and in situ pancreas tissue, were 
subjected to co-immunofluorescence staining with anti-CAR CT and anti-insulin. 
This revealed that CAR-SIV was expressed in the insulin positive beta cells (as 
observed in Chapter 3, section 3.2.10) in both isolated human islets and in in situ 
pancreas sections. In isolated human islets all other cell types (DAPI positive, 
insulin negative) were negative for CAR-SIV expression (Figure 5.1). Strikingly, 
high resolution confocal microscopy revealed a punctate localisation of CAR-SIV 
within the beta cells and the apparent co-localisation with insulin (Figure 5.2). 
This implies a possible association between CAR-SIV and insulin secretory 
granule in beta cells in the human pancreas 
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   Figure 5.1 CAR-SIV colocalises with insulin in FFPE isolated human islets 
 
A 
CAR CT Insulin Overlay 
B 
(A) Representative immunofluorescence staining with CAR CT antisera revealed that CAR-SIV isoform (anti-CAR CT; green) 
and insulin (anti-insulin; red) colocalises (yellow) in isolated human islets. (B) Magnified images from (white broken box) 
demonstrates that CAR-SIV (anti-CAR CT; green) and insulin (anti-insulin; red) colocalises (yellow) in the human beta cell.Nuclei 
were stained with DAPI (blue). Data are representative of images from three donors. Scale bar 10μm 
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Figure 5.2 CAR-SIV colocalises with insulin in insitu human pancreas 
 
 
Insulin CAR CT Overlay 
A 
B 
(A) Confocal immunofluorescence staining with anti-CAR CT (green) show that CAR-SIV isoform colocalises (yellow, punctuate distribution) with 
insulin (anti-insulin; red) in the islet of normal control pancreas. Nuclei were stained with DAPI (blue). (B) Magnified images (white broken box) 
demonstrating immunofluorescence staining showing CAR-SIV (anti-CAR CT; green) colocalisation with insulin. Data are representative of images 
from three donors, Scale bar 5μm 
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5.2.2 Co-localisation of CAR-SIV with insulin secretory granule 
(ISG) proteins in the beta cell 
Based on the interesting result that CAR-SIV co-localises with insulin in the beta 
cells, it was important to confirm whether CAR-SIV also co-localises with other 
insulin secretory granule proteins expressed in beta cells (Table 5.1). Initially, two 
ISG (insulin secretory granule) proteins were selected; the Zinc Transporter 
protein 8 (ZnT8), a granule membrane marker which mediates Zn ion transport, 
essential for the crystallisation of insulin, and prohormone convertase 1/3 
(PC1/3), necessary for the conversion of proinsulin to insulin. The staining 
confirmed that both ZnT8 and PC1/3 were expressed (as expected) within the 
islets and that they were localised to the beta cells. Importantly, these two granule 
protein markers co-localised with the CAR-SIV isoform in the beta cells 
(Figure5.3) 
 
Table 5.1 Secretory granule proteins and their localisation in endocrine cells 
Secretory granule protein Endocrine cell localisation 
ZnT8 Beta cells (Mature granule) 
PC1/3 (Prohormone convertase) Beta cells (Mature granule) 
Proinsulin Beta cell (immature granule/Golgi) 
Glucagon Alpha cells (granules; utilised as a 
negative control) 
 
220 | P a g e  
 
 
        
      Figure 5.3 CAR-SIV colocalises with insulin secretory granule proteins in the beta cell. 
 
 
Insulin CAR CT
ZnT8
PC1/3
CAR CTInsulin ZnT8 & CAR CT
PC1/3 & CAR CT
A
B
Representative confocal immunofluorescence images shows the colocalisation (yellow) of CAR-SIV (anti-CAR CT; green) and insulin (anti-
insulin; light blue) in relation to insulin secretory granule proteins (red) (A) ZnT8 (anti-ZnT8; red); (B) PC1/3(anti-PC1/3; red) in the islet of 
normal pancreas. Data are representative of images from at least three donors, Scale bar 10μm 
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Another beta cell marker, proinsulin, a precursor of mature insulin, is known to be 
localised mainly within the trans-Golgi and the immature insulin secretory 
granules (Liu et al., 2014). Co-staining of proinsulin and CAR-SIV revealed only 
partial colocalisation of these proteins in the beta cell (Figure 5.4A). An alpha cell 
granule marker “glucagon” was employed as a control (negative) to verify CAR-
SIV colocalisation within the beta cell. The results demonstrate that anti-glucagon 
staining was detected in alpha cells (as expected) and that CAR-SIV did not 
colocalise with glucagon (Figure 5.4B). Indeed, these results suggest that CAR-
SIV isoform is preferentially concentrated in the human beta cell mainly within the 
mature insulin secretory granules. 
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    Figure 5.4 CAR-SIV shows a partial colocalisation with proinsulin and no colocalisation with glucagon secretory granule proteins in the human islet. 
 
 
 
 
 
 
 
CAR CTProinsulin
Insulin Glucagon
Insulin
CAR CT
Proinsulin & CAR CT
Glucagon & CAR CT
A
B
Representative confocal immunofluorescence images of CAR-SIV isoform (anti CAR CT; green) and insulin (anti-insulin; light blue) in relation to 
secretory granule proteins (red). Staining with CAR CT antisera reveals CAR-SIV partial colocalisation with (A) Pro-insulin (anti-proinsulin; red); 
and no colocalisation with (B) Glucagon (anti-glucagon; red) in the islet of normal pancreas. Data are representative of images from at least three 
donors. Scale bar 10μm 
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5.2.3 Pearson’s correlation coefficient (PCC) quantifies the 
colocalisation between CAR-SIV and the secretory granule 
proteins 
To quantitatively evaluate the colocalisation of CAR-SIV with secretory granule 
markers, labelled co-immunofluorescence images obtained from the confocal 
microscope were assessed using colocalisation software JACoP plugin from 
Image J version 1.48 Java 1.6.0 _20; (https://imagej.nih.gov/ij/plugins/track/jacop2.html). 
This allowed the generation of a Pearson’s correlation coefficient (PCC) which 
estimates the degree of colocalisation/ association between any two labelled 
proteins in human pancreas tissue. The PCC values range from (0 – which 
indicates no colocalisation, to 1 for complete colocalisation). 
The PCC provided a confirmation that insulin strongly colocalises with ZnT8 
(0.94±0.01) as would be expected from their well-known distribution in beta cells. 
Importantly, CAR-SIV strongly colocalises with insulin (0.95±0.02), ZnT8 (0.84 
±0.01) and PC1/3(0.81± 0.02) (Figure 5.5B&C, Table 5.2).  
In contrast, CAR-SIV weakly associates with proinsulin (0.55± 0.04) and does not 
associate with glucagon (0.05± 0.02) (Figure 5.5, Table 5.2) which is consistent 
with the representative high resolution images (Figure 5.4D&E and Figure 5.5B). 
These data provide further evidence that CAR-SIV is concentrated more within 
the mature insulin granule in comparison to the immature granule and that it is 
unique to the beta cell granules in the islet.  
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Figure 5.5 Pearson’s correlation coefficient (PCC) demonstrating an association 
between CAR-SIV and insulin secretory granule protein 
 
 
CAR CT ZnT8 
CAR CT Pro-insulin CAR CT glucagon 
CAR CT PC1/3 
B C 
D E 
A 
In the PCC graph (A) each data point represents an islet and from the combination of 
insulin secretory granule proteins assessed, 2 islets were examined from 3 independent 
cases. Zoomed in, higher magnification images of CAR-SIV isoform (anti-CAR CT; 
green) co-localises with secretory granule protein (red) (B)ZnT8; (C) PC1/3; partial co-
localisation with (D)proinsulin and no co-localisation was observed with (E) glucagon, 
(DAPI) is shown in dark blue. Nuclei were stained with DAPI (blue). 
Immunofluorescence image are representative of images from three donors. Scale bar 
10μm 
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                Table 5.2 PCC analysis of CAR-SIV and secretory granule proteins 
 
 
 
 
 
 
5.2.4 Manders correlation coefficient (MCC) quantifies the 
colocalisation between CAR-SIV and the secretory granule 
proteins 
By means of an extension of the PCC analysis, the Manders correlation 
coefficient (MCC) was utilised to quantify the extent/proportion of one protein that 
overlaps/co-localises with a second protein and vice versa in the human 
pancreas. For example, it can be used to ask what proportion of the total CAR-
SIV protein overlaps with proinsulin and in reverse, what proportion of proinsulin 
overlaps with CAR-SIV. 
The MCC estimate of the co-localisation between CAR-SIV and other secretory 
granule proteins demonstrates that the majority of ZnT8 co-localises with insulin 
(0.93 ± 0.02) and the same was true in the reverse for insulin (insulin co-localises 
with ZnT8;0.88 ± 0.02). Importantly, a high proportion of CAR-SIV co-localises 
with insulin (0.91 ±0.02), ZnT8 (0.87± 0.01) and PC1/3 (0.87 ± 0.02). This was 
also similar in reverse where the majority of ZnT8, insulin and PC1/3 also co-
localise with CAR-SIV (0.73 ± 0.04), (0.91 ± 0.02) and (0.70±0.02) respectively 
Granule Markers PCC (Mean ± 
SEM) 
ZnT8 & insulin 0.94 ± 0.01 
CAR CT & insulin 0.95 ± 0.02 
CAR CT & ZnT8 0.84 ± 0.01 
CAR CT & PC1/3 0.81 ± 0.02  
CAR CT & proinsulin 0.55 ± 0.04 
CAR CT & glucagon 0.05 ± 0.02 
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(Figure 5.6).This is consistent with these granule proteins all being present in 
mature insulin secretory granules. 
In contrast, no co-localisation of CAR-SIV was found in either direction between 
CAR-SIV (0.03 ±0.01) and glucagon (0.03 ±0.01), (Figure 5.6). Importantly, there 
was a weak overlap between proinsulin and CAR-SIV (Figure 5.6). 
 
 
 
Figure 5.6 Mander’s correlation coefficient (MCC) demonstrating the proportion of CAR-
SIV that associates with insulin secretory granule proteins 
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Careful examination of the MCC analysis for CAR-SIV and proinsulin revealed 
that a large proportion of total proinsulin colocalises with CAR-SIV (0.71±0.082), 
this is likely to represent both CAR-SIV and proinsulin in the immature granules, 
as these emerge from the trans-Golgi.In contrast, CAR-SIV does not co-localise 
to the same extent with proinsulin (MCC: 0.21±0.042), presumably because the 
majority of CAR-SIV is in the mature granules (shown below in Figure 5.7, Table 
5.3). 
Together, the Pearson’s and Manders correlation coefficient reiterate the 
previous findings and provide supporting evidence that the majority of CAR-SIV 
is localised to the mature insulin secretory granule. A smaller fraction of CAR-SIV 
is also observed in the immature insulin granule. The proinsulin that colocalises 
with CAR-SIV may represent CAR-SIV and proinsulin present in the immature 
granule soon after emergence from trans-Golgi network 
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      Table 5.3 MCC analysis of CAR-SIV, insulin and proinsulin proteins 
M1 ± SEM M2 ± SEM 
Insulin        0.912 ± 0.028 CAR CT     0.914 ±  0.016 
Proinsulin  0.708 ± 0.082 CAR CT      0.211 ±  0.042 
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Figure 5.7 Mander’s correlation coefficient (MCC) demonstrates that CAR-SIV 
associates more with insulin but less with proinsulin 
 
 
M1 (red) is the proportion of insulin or proinsulin granule proteins that 
overlaps with CAR-SIV while M2 (green) is the proportion of CAR-SIV that 
overlaps with insulin or proinsulin proteins. In the MCC graph each data point 
represents an islet and from the combination of (CAR CT & insulin) and CAR 
CT & proinsulin) granule proteins assessed, 2 islets were examined from 3 
independent cases 
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5.2.5 Cryo-immunogold electron microscopy (Cryo-EM) of CAR-
SIV and ZnT8 in the insulin granule 
To directly examine the subcellular localisation of CAR-SIV in the beta cells and 
confirm whether or not it is located within the insulin secretory granule, Dr Varpu 
Marjomaki (University of Jyväskylä, Finland), performed cryo-immunogold 
electron microscopy with the CAR CT and ZnT8 antisera. 
Immunogold labelling was performed on thin frozen non-diabetic human 
pancreas (nPOD) sections using the post-embedding Tokuyasu method (Slot and 
Geuze, 2007) with the antisera CAR CT (labelled with 10nm gold particles) and 
ZnT8 (labelled with 5nm gold particles). The micrograph images revealed no 
labelling in the exocrine granules (Figure 5.8A&B). Importantly, both the anti-CAR 
CT and anti-ZnT8 were localised to the dense core insulin secretory granules in 
human pancreas sections (Figure 5.8C). Higher magnification images confirmed 
the different sizes of gold labelling for anti-CAR CT (10nm) and anti-ZnT8 (5nm) 
(indicated by black arrows and arrowheads respectively) preferentially at the 
periphery of the insulin granule (Figure 5.9). The characteristic electron dense 
core structure of the secretory granule observed implies that they contain insulin 
(Hou et al., 2009). Immunostaining of the pancreas section with anti-insulin 
antiserum also verified that these were insulin granules (data not shown). It is 
important to note that the Cryo-EM technique used in this study employs uranyl 
acetate which yields “negative contrast" for organelle membranes in the staining 
method employed and as a consequence the appearance of the secretory 
granules differs from that seen using more conventional osmium labelled cells.  
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Figure 5.8 Cryo-immunogold electron microscopy revealed that CAR-SIV and ZnT8 is localised to the insulin granule 
 (A) Low magnification image demonstrates the presence of granules in both the acinar cells and islet cells (Black, broken lines)  (B) Higher 
magnification image revealed lack of CAR-SIV labelling in acinar cell granules (C) Higher magnification image confirms immunogold labelling 
of CAR-SIV (anti-CAR CT; 10nm) and ZnT8 (ant-ZnT8; 5nm) in thin frozen sections of human pancreas tissue, Scale Bar: 2μm(A), 1μm( B,C). 
Courtesy of Dr. Varpu Marjomaki  
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Figure 5.9 Cryo-immunogold electron microscopy. 
 Higher magnification image showing immunogold labelling of CAR-SIV (anti-CAR CT; 10nm; black arrows) and ZnT8 (anti-ZnT8; 5nm; black arrow 
heads) in thin frozen sections of human pancreas tissue. Scale bar 500nm. Courtesy of Dr. Varpu Marjomaki 
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5.2.6 Morphometric quantification of CAR-SIV labelling density 
A morphometric analysis of CAR-SIV labelling density was quantified on non-
diabetic (nPOD) control pancreas. CAR CT antiserum gold particle labelling in 
the different compartments of the beta cells, were calculated from 21 different 
micrographs across 1291 different membrane intersections utilising 841 CAR-SIV 
immunogold particles. This revealed that 79% of CAR-SIV gold particles were 
localised to the mature insulin secretory granule and only 14.4% in the immature 
insulin granule (Figure 5.10). Very minimal labelling of CAR-SIV gold particles 
were found in other intracellular vesicles (1%), endoplasmic reticulum (1.1%), 
mitochondria (1%), nucleus (1%) and the plasma membrane (2.5%) (Figure 
5.10). These data provide firm confirmation that CAR-SIV is mainly found in the 
insulin secretory granule in comparison to other internal subcellular 
compartments. 
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5.2.7CAR-SIV immunogold labelling at different stages of insulin 
granule maturation 
Further confirmation of CAR-SIV localisation at different stages of insulin granule 
maturation was also provided by performing immunogold labelling on normal 
human pancreatic tissue with the following antisera: proinsulin (labelled with 
 
Figure 5.10Cryo-immunogold electron microscopy quantification. 
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20nm gold particles), CAR-SIV (10nm gold particles) and insulin (5nm gold 
particles).The data demonstrate that CAR-SIV was localised to granules in the 
beta cell (Figure 5.11A&B) which included; immature granules shown by the 
presence of proinsulin and CAR-SIV (Figure 5.11C); CAR-SIV was also localised 
to the maturing granules shown by the simultaneous presence of proinsulin, 
insulin and CAR-SIV (Figure 5.11D); and finally CAR-SIV was localised to the 
mature granule shown by the presence of insulin and CAR-SIV (Figure 
5.11E).Assessment of 122 granules containing CAR-SIV revealed that 6 (4.9%) 
were positive for proinsulin (immature granules); 30 (24.6%) were positive for 
proinsulin and insulin (maturing granules) while the majority of CAR-SIV(86 
(70.5%)) immunogold labelled granules were positive for insulin (mature 
granules).In addition, we show that unconjugated gold particles not bound to 
serum did not label the pancreatic tissue (Figure 5.12) 
Collectively, these results suggest that CAR-SIV is present at all stages of 
granule maturation.  
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          Figure 5.11 Cryo-immune EM analysis of insulin granules at different stages of maturation. 
 
 
Low magnification image (a-b) demonstrates immunogold labelling of insulin (5nm gold; black triangle); CAR-SIV (10nm gold; 
black arrow) and proinsulin (20nm gold; white triangle) in thin frozen sections of human pancreas tissue. High magnification 
image reveal (c) immature granules positive for proinsulin and CAR-SIV (d) maturing granules positive for proinsulin, insulin 
and CAR-SIV and mature granules positive for insulin and CAR-SIV, Scale bar 500nm. Courtesy of Dr. Varpu Marjomaki 
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5.2.8 Detection of PICK1 protein expression in human pancreatic 
tissue by immunohistochemistry 
There is cumulative evidence that a peripheral membrane protein PICK1 (Protein 
interacting with Ckinase 1), plays a crucial role in vesicle trafficking and is highly 
expressed in tissues characterised by secretory vesicles such as the brain, testis, 
kidney, stomach, and pancreas where extensive vesicle secretion occurs (Dev et 
al., 1999, Cao et al., 2007, Xia et al., 1999). Importantly, it has recently been 
shown that PICK1 plays a crucial role in insulin granule budding and maturation  
(Cao et al., 2013). PICK1 is a unique protein that contains both a PDZ domain 
 
Figure 5.12 Cryo-EM analysis of pancreatic tissue with unconjugated gold particles 
Pancreatic tissue when exposed to unconjugated gold particles display no labelling 
in the granules in the beta cell, Scale bar 500nm. Courtesy of Dr. Varpu Marjomaki 
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and a BAR domain (Xu and Xia, 2006). The BAR domain mediates its interaction 
with ICA69 and is important in sensing membrane curvature and facilitating 
vesicle formation (Jin et al., 2006, Madsen et al., 2008). Strikingly, the PDZ 
domain of PICK1 specifically interacts with the PDZ binding domain of CAR-SIV 
(Excoffon et al., 2004), but not the PDZ binding domain of CAR-TVV. Due to the 
localisation of CAR-SIV to the insulin secretory granule it is possible that the 
CAR-SIV PDZ binding domain may interact with PICK1 and play a fundamental 
role in the beta cell.  
To assess if PICK1 is expressed in the human pancreas, a commercially 
available antiserum designated “PICK1 SC” with the capability of recognising the 
epitope belonging to the PDZ binding and BAR domain (22-105aa) was 
employed. Immunohistochemical studies revealed that PICK1 was detected in 
the islet cells and not in the exocrine compartment of insituhuman pancreas 
(Figure 5.13) 
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          Figure 5.13 PICK 1 is expressed in the islet of normal human pancreatic tissue. 
 
Immunohistochemical analysis detecting PICK1 (anti-PICK1 SC; brown stain) in 
the endocrine cells of the islets and negative (no brown stain) in the exocrine 
tissue. Data are representative of images from three donors, Scale bar 20µm      
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5.2.9 PICK1 detection by immunofluorescence and confocal 
immunofluorescence microscopy 
In order to determine if PICK1 is present in the beta cells, combined 
immunofluorescence staining was utilised with anti-PICK1 SC in combination with 
anti-CAR CT and anti-insulin in normal pancreatic tissue. PICK1 was present in 
the beta cells as detected by the colocalisation with anti-insulin and anti-CAR CT 
(Figure 5.14A) PICK1 was not however limited to the beta cells because non-beta 
cells were also PICK1 positive indicated by yellow arrows (Figure 5.14B). 
To assess the extent of colocalisation of PICK1, CAR-SIV and insulin in the beta 
cell, confocal microscopy coupled with a hyvolution software which provides 
improved resolution upon deconvolution was utilised. The result demonstrates 
that both PICK1 and CAR-SIV were colocalised with insulin as indicated by the 
brown arrows in Figure 5.15. 
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           Figure 5.14 CAR-SIV colocalises with PICK1 and insulin in the beta cell in normal pancreas tissues. 
 
 
InsulinPICK 1 CAR CT
PICK1 CAR CT Insulin
A
B
Merge
(A) Representative confocal immunofluorescence images of CAR-SIV (anti-CAR CT; green) and PICK1 (anti-PICK1; red) colocalising 
(light blue) with insulin (anti-insulin; blue). (B) Magnified images of PICK1 (red; yellow arrows) show positivity in non-beta cells that are 
insulin and CAR-SIV negative. Nuclei were stained with DAPI (blue). Data are representative of images from three donors, Scale bar 
(A) 5µm (B) 25µm    
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Figure 5.15 Confocal microscopy coupled with hyvolution imaging demonstrates a close association of CAR-SIV and PICK1 in insulin 
granule of normal human pancreas. 
 
CAR CTInsulin PICK1
CAR CT PICK1 insulin
CAR CT PICK1 CAR CT PICK1 insulin
CAR CT PICK1
Magnified images with brown arrows indicate granules positive for CAR-SIV (anti-CAR CT; green), PICK1 (anti-PICK1 SC; red) and 
insulin (anti-insulin; light blue) in the beta cell, Nuclei were stained with DAPI (blue). Data are representative of images from three 
donors, Scale bar 5μm 
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5.2.10 Pearson’s correlation coefficient and Mander's correlation 
coefficient quantifies the colocalisation of PICK1, CAR-SIV and 
Insulin 
To quantify the extent of colocalisation between PICK1, CAR-SIV and insulin, the 
Pearson’s correlation coefficient and Manders correlation coefficient were 
employed. PCC exhibited a strong association between CAR-SIV and insulin as 
expected (0.95±0.02), CAR-SIV showed a strong association with PICK1 
(0.73±0.02) while PICK1 also strongly associated with insulin (0.84±0.04) (Figure 
5.16A, Table 5.4) 
For MCC analysis, there was a strong overlap (as expected) between insulin and 
CAR-SIV (0.91± 0.03) and CAR-SIV and insulin (0.91± 0.02). The majority of 
CAR-SIV (0.84± 0.03) colocalises with PICK1, but not all PICK1 (0.55± 0.05) 
colocalises with CAR-SIV. A strong overlap was also observed with PICK1 and 
insulin (0.80± 0.06) and, insulin and PICK1 (0.85± 0.02) (Figure 5.16B, Table 
5.4).One explanation for the lower MCC value of the PICK1 (0.55± 0.05) 
colocalisation with CAR-SIV could be due to the fact that PICK1 is expressed 
innon-beta cells (as shown previously in Figure 5.14) as well as beta cells. 
Collectively, these data imply that PICK1 associates with CAR-SIV and insulin in 
the beta cell and based on PICK1’s role we can postulate that CAR-SIV 
association with PICK1 may synergistically play a role in insulin granule 
maturation and trafficking of insulin vesicle granules 
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Figure 5.16 Pearson correlation coefficient and Manders correlation coefficient 
demonstrating the extent of CAR-SIV colocalisation with PICK1 and insulin. 
 
 
 
 
A 
B 
(A) PCC and (B) MCC shows where M1 (red) is the proportion of insulin or 
PICK1 granule proteins that overlaps with CAR-SIV while M2 (green) is the 
proportion of CAR-SIV or insulin that overlaps with PICK1. In the graph, each 
data point represents an islet and from the combination of (CAR CT & 
insulin), (CAR CT & PICK1) and (insulin & PICK1) granule proteins 
assessed, 2 islets were examined from 3 independent cases 
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Table 5.4 Pearson and Manders correlation coefficient of CAR-SIV association with 
PICK1 and insulin. M1 – the proportion of the first protein that colocalises with the 
second; M2 – the proportion of the second protein that colocalises with the first. 
Granule Markers PCC (Mean ± 
SEM) 
M1 M2 
Insulin (M1) & CAR 
CT (M2) 
0.95 ± 0.02 0.91 ± 0.03 0.91 ± 0.02 
PICK1 (M1) & CAR CT 
(M2) 
0.73 ± 0.02 0.55 ± 0.05 0.84 ± 0.03 
PICK1 (M1) & Insulin 
(M2) 
0.84 ± 0.04 0.80 ± 0.06 0.85 ± 0.02 
 
5.2.11 PICK1 expression by Western blotting analysis 
To validate PICK1 expression shown previously by immunohistochemical and 
immunofluorescence approach, three further commercially available antisera 
(suitable for Western blotting) designated “PICK1 ab133773”, “PICK1 ab3420” 
and “PICK1 L20/8” whose epitope recognition sites are displayed inFigure 5.17 
were purchased.  
Protein lysates extracted from human islets and pancreatic beta cell lines EndoC-
βH1 and 1.1B4 were electrophoresed on poly-acrylamide gels and then 
transferred onto a PVDF membrane. Following a blocking step, membranes were 
probed with either “PICK1 ab133773” or “PICK1 L20/8”. Probing with PICK1 
ab133773 antiserum revealed an estimated band at around 50kDa (equivalent to 
the estimated molecular weight) in isolated human islets. A similar sized but less 
intense band was also observed in EndoC-βH1 cells (Figure 5.18A).The PICK1 
L20/8 antiserum also revealed a band estimated at 50kDa in the isolated human 
islets, again at a higher intensity when compared to EndoC-βH1 and 1.1B4 cells 
(Figure 5.18B). Together these results demonstrate that PICK1 is highly 
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expressed in isolated human islets and is also present in EndoC-βH1 and 1.1B4 
cells albeit at lower levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 5.17 Schematic diagram of PICK1 antisera with epitope recognition sites 
against the PICK1 protein. Adapted from (Xu and Xia, 2006) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PICK SC (1-300aa) PICK1 (Ab133773) recognition site not known 
but it is a Synthetic peptide corresponding to human residues
PICK1 L20/8 ( 10-130aa)
PICK1 ab3420 (1-18aa)
PDZ domain
19-103aa
Linker
BAR domain
147-356aa
N-terminus 
1-18aa  
C-terminus 
357-415
104-146aa
 
Figure 5.18 Confirmation of PICK1 expression in isolated human islets and pancreatic 
beta cell lines EndoC-βH1 and 1.1B4. 
 
 
 
 
 
 
 
 
H.islet EndoCβH1
36kDa
PICK1
GAPDH
PICK1
GADPH
H.islet EndoCβH1 1.1B4
36kDa
A. PICK1 ab133773 B. PICK1  L20/8 
53kDa
41kDa
53kDa
41kDa
EndoC-βH1, 1.1B4 cells and isolated human islets were lysed and total protein was 
isolated for western blotting to detect PICK1 with both antisera; PICK1 ab133773 and 
PICK1 L20/8 .Western blotting analysis detecting an approximate band size of 50kDa 
with two different PICK1 antisera (A) PICK1 ab133773 (B) PICK1 L20/8 and loading 
control GAPDH. Data are representative of 3 independent experiments. 
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5.2.12 Do PICK1 and CAR-SIV interact in the human pancreatic 
beta cell? 
The study by Excoffon et al (2004) utilised co-immunoprecipitation experiments 
in overexpression studies to demonstrate that CAR-SIV and PICK1 interact with 
one another via the PDZ domain in human airway epithelial cells (Excoffon et al., 
2004) 
To investigate if PICK1 could interact with CAR-SIV endogenously in the human 
pancreatic beta cells, we initially examined if these proteins could be individually 
immunoprecipitated from EndoC-βH1 cells. Protein lysates under non-denaturing 
conditions (Chapter 2, section 2.19) were collected from EndoC-βH1 cells and 
incubated with either CAR RmcB or PICK1 L20/8 antisera. Beads were added to 
bind to the antibody-lysate complex; unbound antibody/proteins were then 
removed by washing. Protein was then extracted from the beads using standard 
denaturing lysis buffer and examined by Western blotting.  
PICK1 was successfully pulled down from using the PICK1 L20/8 antiserum, with 
an approximate band size of 50kDa which was also present in the total lysates 
input (positive) control (Figure 5.19A). Utilising other antisera, PICK1 pull down 
was also confirmed by precipitating lysates incubated with PICK1 ab3420 
antiserum (Figure 5.19B). CAR-SIV was also successfully pulled down with the 
CAR RmcB antiserum, with a band size of 40kDa which was present in the total 
lysates input (positive) control (Figure 5.19C). CAR ECD antiserum was also 
capable of immunoprecipitating CAR (Figure 5.19D). 
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To directly confirm if PICK1 and CAR-SIV do interact, a co-immunoprecipitation 
(Co-IP) assay was utilised in lysates extracted from isolated human islets and 
EndoC-βH1 cells. The result shows that PICK1 was successfully pulled down 
along with CAR when immunoprecipitated with the CAR RmcB antiserum.  A 
band for PICK1 (50kDa) was clearly observed in the CAR Co-IP lane, when 
 
 
 
Figure 5.19 Immunoprecipitation of PICK1 and CAR-SIV independently from EndoC-
βH1 with different antisera. 
 
PICK1
L20/8
Input Mouse
IgG1
IP
PICK1 
ab133774
IP
CAR CT
A.
B.
Input CAR 
RmcB
Input
CAR ECD
PICK1 
L20/8
Input Input Rabbit
IgG
PICK1
ab3420
IP Input CAR 
RmcB
Input
53kDa
41kDa
53kDa
41kDa
53kDa
41kDa
53kDa
41kDa
IP
C.
D.
EndoC-βH1 cells were lysed and total protein was isolated for immunoprecipitation 
followed by western blotting.  Immunoprecipitation of PICK1 with (A) PICK1 L20/8 
antiserum pulls down PICK1 (anti-PICK1 ab133774) (B) PICK1 ab3420 antiserum 
pulls down PICK1 (anti-PICK1 IL/20). Immunoprecipitation of CAR-SIV with (C) CAR 
RmcB antiserum pulls down CAR-SIV   (anti-CAR CT) (D) CAR RmcB antiserum pulls 
down CAR (anti-CAR ECD). Anti-mouse IgG and Rabbit IgG (controls) were all 
negative and all input (positive controls) were 2%. Data are representative of 3 
independent experiments. 
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probed with the PICK1 SC antiserum. A PICK1 band was also present in total 
lysates input (positive) control lane (Figure 5.20A). These results were further 
confirmed in the EndoC-βH1 cells (Figure 5.20B) and when probed with the CAR 
CT antiserum a band for CAR-SIV at the appropriate molecular weight (40kDa) 
was observed confirming that the CAR-SIV isoform was part of this complex 
(Figure 5.20C). 
In the other direction, utilising the PICK1 SC antiserum to Co-IP the complex in 
isolated human islets, CAR was pulled down, albeit weakly, from precipitated 
PICK1, revealed by a band of approximately 46kDa (Figure 5.21A). Similarly, in 
EndoC-βH1, utilising the PICK1 ab3420 to Co-IP, CAR was also pulled down. 
This band was however marginally higher in molecular weight when compared to 
the total lysates input (positive) controls (Figure 5.21B). 
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        Figure 5.20 Co-immunoprecipitation of CAR pulls down PICK1. 
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41kDa 
C. EndoC-H1 
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IgG1 
Human islets and EndoC-βH1 cells were lysed and total protein was isolated for 
immunoprecipitation followed by western blotting. Co-Immunoprecipitation with CAR 
(anti- CAR RmcB) and PICK1(anti-PICK1 SC) pulls down PICK1(anti-PICK1 
ab133774) from (A)  isolated human islets and (B) EndoC-βH1 (C) CAR-SIV isoform 
complex is confirmed after probing with CAR CT antiserum, anti-mouse IgG and anti-
Rabbit IgG were all negative and all input (positive) controls were 2%. Data are 
representative of 3 independent experiments. 
 
 
 
 
250 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53kDa 
41kDa 
CAR ECD 
PICK1   
ab3420 IP 
Input Input 
IP CAR 
RmcB 
Mouse 
IgG 
PICK1  
SC 
CAR ECD 
53kDa 
41kDa 
A. Human islets 
  B. EndoC-H1 
 
 
 
 
Figure 5.21 Co-immunoprecipitation of PICK1 weakly pulls down CAR. 
 Human islets and EndoC-βH1 cells were lysed and total protein was isolated for 
immunoprecipitation followed by western blotting. Co-immunoprecipitation with 
PICK1 (anti-PICK1 SC/anti-PICK1 ab3420) pulls down CAR (anti-CAR ECD) (A) 
from isolated human islets and (B) EndoC-βH1. Anti-mouse IgG was used as 
negative control and all input (positive control) were 2%. Data are representative 
of 3 independent experiments. 
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5.3 Discussion 
The data obtained from examining the subcellular localisation of CAR-SIV 
isoform in the human pancreatic beta cell has provoked some fundamental 
findings which are discussed in this section below. 
5.3.1 CAR-SIV colocalises with insulin in human pancreatic beta 
cells 
In this study, high resolution confocal microscopy analysis observed a punctate 
cytoplasmic granular localisation of CAR-SIV in the beta cells of isolated human 
islets and human pancreatic tissue. This is consistent with CAR-SIV being 
distributed in a distinct intracellular organelle compartment. Analysis of the 
colocalisation of CAR-SIV and insulin demonstrated a strong association, 
suggesting that CAR-SIV is localised to the insulin granule within beta cells in 
vivo. Similarly, as shown previously in chapter 3 (Figure 3.17) two different CAR 
antisera, “CAR CT” antiserum which recognises the C terminus (CT) of CAR and 
the less selective “CAR ECD” antiserum which recognises the extracellular 
domain of CAR were shown to colocalise with insulin in isolated human islets and 
human pancreatic sections. These two independent CAR antisera directed 
against different regions of CAR protein provides strong supporting evidence of 
CAR-SIV localisation in the insulin granule. 
5.3.2 CAR-SIV is present in both immature and mature insulin 
secretory granule proteins 
This intriguing discovery that CAR-SIV was predominantly localised within the 
cytoplasm and that it closely associates with insulin in the beta cells, 
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encouragedadditional study of four secretory granule proteins PC1/3, ZnT8, 
proinsulin and glucagon to investigate this further. 
As described in Chapter 1 (section 1.3.3), during the biogenesis of insulin, the 
initial immature proinsulin secretory granules bud from the trans-Golgi network to 
undergo further processing. Acidification of the granule lumen then facilitates the 
cleavage activity of endoproteases PC1/3 (which cleaves the B-C junction of the 
proinsulin peptide sequence) and PC2 (which cleaves the A-C junction of the 
proinsulin peptide sequence) (Goodge and Hutton, 2000). Subsequently, 
carboxypeptidase (CPE) trims the C terminal two-basic amino acids yielding 
mature insulin and C peptide (Hutton, 1994, Tokarz et al., 2018) 
Labelling of normal pancreatic tissue with PC1/3 antiserum, revealed its expected 
localisation within the insulin granule. Importantly, PC1/3 expression was shown 
to be strongly associated with CAR-SIV in the beta cells, providing yet further 
evidence of the localisation of CAR-SIV to the insulin granules.  
The insulin secretory granule marker, ZnT8 may enable further maturation by 
facilitating the transport of two Zinc ions for insulin granule crystallisation to form 
dense core insulin structures (Dunn, 2005) 
We show with Manders correlation coefficient (MCC) colocalisation analysis, the 
extent of association between CAR-SIV, ZnT8 and PC1/3. This revealed that a 
high proportion of CAR-SIV colocalised with ZnT8 (0.87 ±0.01) and PC1/3 (0.87 
± 0.02). This was very similar in the reverse with ZnT8 colocalising with CAR-SIV 
(0.73 ±0.04) and PC1/3 colocalising with CAR-SIV (0.70 ±0.02) confirming strong 
association with CAR-SIV and ZnT8/PC1/3 in the human pancreatic beta cell.  
The finding that CAR-SIV colocalises with multiple proteins within the insulin 
secretory granule such as insulin, ZnT8 and PC1/3 (Arias et al., 2000, Chimienti 
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et al., 2006) provides strong supporting evidence that CAR-SIV is located on the 
membrane of the insulin granule. 
We also show no association between CAR-SIV and glucagon which further 
emphasises the fact that CAR-SIV is not present in alpha cells and is restricted 
to the insulin producing beta cells. 
Importantly, assessment of the colocalisation of CAR-SIV and proinsulin using 
the Pearson’s correlation coefficient (PCC) which estimates the degree of 
colocalisation between two proteins, demonstrates that CAR-SIV associates to a 
lesser extent with proinsulin. To understand this in more detail, we utilised an 
additional analysis to generate the MCC, which defines the extent of 
colocalisation between CAR-SIV and proinsulin. This revealed that the majority 
of proinsulin colocalised with CAR-SIV implying that both are contained in the 
trans-Golgi and in the immature granules as they bud from the trans-Golgi 
network. In reverse, however, the MCC analysis show that a lower proportion of 
CAR-SIV colocalised with proinsulin suggesting that the majority of CAR-SIV is 
in the mature granules. 
Together these findings imply that CAR-SIV associates more with the mature 
insulin secretory granule than with the immature granule.  
Additional strong confirmation of CAR-SIV localisation in the dense core mature 
insulin granules in the beta cell was made with Cryo-immuno EM studies, where 
the CAR-SIV was clearly shown to localise to the edge of the dense granule cores 
in beta cells.  Morphometric quantitative analysis, demonstrated that 79% of the 
CAR-SIV bound 10nm gold particles were localised to the mature insulin granule. 
The insulin granule was distinguished based on the characteristic electron dense 
appearance of the granule cores. A further 14.4% of the labelled gold particles 
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were observed on immature secretory insulin granules. These results are in full 
accord with the MCC colocalisation analysis of CAR-SIV associating more with 
insulin than with proinsulin. There was also minimal evidence of CAR-SIV in the 
nucleus (2.5%), plasma membrane (1.2%), endoplasmic reticulum (1.1%) and 
mitochondria (1%).  
To confirm further CAR-SIV localisation at different stages of insulin granule 
maturation, immunogold labelling of proinsulin, CAR-SIV and insulin was 
examined. This revealed that CAR-SIV was present in the immature granules, 
observed by the presence of proinsulin and CAR-SIV (Figure 5.11C); in the 
maturing granule observed by the presence of proinsulin, insulin and CAR-SIV 
(Figure 5.11D); and mature granules observed by the presence of insulin and 
CAR-SIV (Figure 5.11E). The assessment of 122 granules containing CAR-SIV 
also demonstrates that 4.9% were positive for proinsulin (immature granules); 
24.6% were positive for proinsulin and insulin (maturing granules) and 70.5% 
were positive for insulin (mature granules). Together these results suggest that 
CAR-SIV is present within the granule membrane at all stages of granule 
maturation.  
Importantly, in the pancreatic tissue no labelling was found when exposed to 
unconjugated gold particles and CAR-SIV was not labelled on adjacent acinar 
cells secretory granules, implying that CAR-SIV is not required for secretory 
granule biogenesis in all cell types.   
Both the colocalisation analysis and the Cryo-EM studies are in concordance with 
the confinement of CAR-SIV to the insulin secretory granule.  
 
255 | P a g e  
 
5.3.3 CAR-SIV colocalises and interacts with PICK1 in the insulin 
secretory granule 
In the previous sections multiple lines of evidence demonstrated that CAR-SIV is 
present in the insulin granule but the role of CAR-SIV in the insulin granule 
remains unclear. To address this, I examined which proteins can specifically 
interact with CAR-SIV, their roles in cells and identified the following proteins; ZO-
1, Ligand of Numb-X2, MAGI-1b, PSD-95 and PICK1 summarised in Table 5.5 
 
Table 5.5 Proteins interacting with CAR-SIV 
Proteins interacting with CAR-SIV and possible roles 
Interacts and associates with tight junction protein ZO-1 at tight 
junctions where it assists in the transport of ions and molecules (Cohen 
et al., 2001b, Excoffon et al., 2010) 
Interacts with Ligand of Numb protein X2 which plays a role in Notch 
signalling in human embryonic kidney cells (Mirza et al., 2005) 
Interacts with and permits the trafficking of MAGI-1b to cell-cell junction 
in human airway epithelial cells (Excoffon et al., 2010). MAGI-1b has 
been shown to interact with adenovirus viral proteins (Glaunsinger et 
al., 2000) 
Interacts with PSD-95 through the PDZ binding domain and immunocyto 
chemistry revealed that CAR-SIV can pull the protein from the 
cytoplasm to cell-cell junction in human airway epithelial cells (Excoffon 
et al., 2010, Excoffon et al., 2004) 
PICK1 Interacts with CAR-SIV through the PDZ binding domain 
(Excoffon et al., 2004)and PICK1 was previously shown to play a role in 
the maturation and trafficking of insulin granules (Cao et al., 2013) 
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It is possible that knowledge of CAR-SIV association and interaction with other 
cellular proteins may give insights into its biological role in the beta cell. 
Interestingly, from published studies, a candidate protein PICK1 with a unique 
PDZ domain and BAR domain was shown to interact specifically with the PDZ 
binding domain of CAR-SIV and not CAR-TVV. This was demonstrated by co-
immunoprecipitation (Co-IP) assay when co-transfected CAR-SIV and PICK1 
COS-7 cells, pulled down PICK1 (Excoffon et al., 2004). In contrast, co-
transfected CAR-TVV and PICK1 did not pull down PICK1 (Excoffon et al., 
2010).Moreover, immunocytochemical (ICC) analysis of co-transfected CAR-SIV 
and PICK1 in COS-7 cells resulted in the colocalisation of CAR-SIV and PICK1 
at the perinuclear region and cell-cell junction (Excoffon et al., 2004). In contrast, 
there was no colocalisation between CAR-TVV and PICK1 at cell-cell junction 
and limited perinuclear colocalisation was observed (Excoffon et al., 2010). 
These studies therefore affirm that CAR-SIV is a selective binding partner of 
PICK1 in polarised epithelial cells.   
In mouse pancreas, Cao et al (2013) found via immunocytochemical (ICC) and 
Cryo-EM studies that PICK1 is localised to insulin granules (Cao et al., 2013). 
PICK1 has also been found to play a fundamental role in insulin secretory granule 
trafficking and maturation for example, very recently a study with beta cell specific 
PICK1 knockout mice revealed that plasma insulin levels were significantly 
reduced when compared to age-matched WT mice  (Li et al., 2018). Also, in 
vitrotests in isolated islets from these knock-out micedemonstrated a reduction in 
glucose stimulated insulin secretion (Li et al., 2018). Additionally, it was revealed 
that PICK1 knockout mice had elevated circulating proinsulin levels. In addition, 
Cryo-EM analysisconfirmed the presence of more immature proinsulin granules 
than mature insulin granules when compared to the wildtype-mice (Cao et al., 
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2013), implying that PICK1 is not only involved in insulin secretory granule 
trafficking but also in the maturation of these insulin granules.  
Since, PICK1 is localised to the insulin granule and plays a role in maturation and 
trafficking of insulin secretory granule, it may therefore be a potential cytosolic 
protein which binds to the PDZ binding domain of CAR-SIV in the insulin granule. 
As such, we propose that the orientation of CAR-SIV in the insulin secretory 
granule is such that the “extracellular domain” would face the lumen of the insulin 
granule, with the transmembrane domain region securing the protein in the 
membrane surrounding the granule while the C terminus of CAR with the PDZ 
binding domain faces towards the cytoplasm area for possible interaction with 
other cytoplasmic PDZ domain proteins such as PICK1 (Figure 5.22). 
 
 
 
  
258 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We found via immunolabelling analysis that PICK1 is expressed in the human 
beta cell and western blotting analysis detected PICK1 in isolated human islets, 
EndoC-βH1 and 1.1B4 cells. Additionally, we show with hyvolution confocal 
microscopy that CAR-SIV colocalises with PICK1 in the human beta cells and 
that they both strongly associate with insulin.   
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Figure 5.22 Proposed CAR-SIV orientation in the insulin secretory granule. 
 
 
The “extracellular domain” faces the lumen of the insulin granule with the 
transmembrane domain anchoring the protein in the membrane surrounding the 
granule while the C terminus faces the extra-granular environment for possible 
interaction with other PDZ proteins such as PICK1    
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Furthermore, we tested to observe if there was any interaction between 
endogenous CAR-SIV and PICK1 in isolated human islets and EndoC-βH1. 
Indeed, PICK1 was robustly pulled down along with CAR immunoprecipitate. This 
indicates that CAR-SIV and PICK1 do interact endogenously in the human beta 
cell. We observed in the other direction that CAR was pulled down alongside 
immunoprecipitated PICK1 in EndoC-βH1 but at a marginally higher molecular 
weight when compared to the total lysates input (positive) controls (Figure 5.21B). 
A possible reason for this could be that PICK1 may preferentially bind to CAR 
that has undergone post-translational modification (phosphorylation or 
glycosylation), thereby impacting on its size.   
In isolated human islets there was a lower efficiency of CAR pull down with the 
PICK1 antisera. One potential reason for this could be that the PICK1 antisera 
utilised is targeted to the region of PICK1 that includes the PDZ domain. As such, 
if CAR is strongly interacting with PICK1, access to this epitope might be 
restricted. The PICK1 antisera, under these circumstances will preferentially 
recognise unbound PICK1 and not the PICK1 bound to CAR (pictorial diagram is 
displayed in Figure 5.23). Nevertheless, in all of the above experiments neither 
CAR, CAR-SIV nor PICK1 was pulled down in both directions by the control 
antisera (rabbit IgG or mouse IgG) confirming the specificity of the co-
immunoprecipitation assay. 
Collectively, these findings provide compelling evidence that CAR-SIV 
colocalises, interacts and associates with PICK1 in the human pancreatic beta 
cell. 
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Importantly, the role of PICK1 in insulin granule budding, maturation and 
trafficking had been investigated in several studies. As previously mentioned 
PICK1 also has a BAR domain, which has been shown to form tight heteromeric 
BAR domain complex with the BAR domain of an islet autoantigen ICA69 in the 
brain and in rodent beta cells (Cao et al., 2007, Cao et al., 2013). PICK1 and 
ICA69 interaction functions in sensing membrane curvature and facilitating 
vesicle formation (Jin et al., 2006, Madsen et al., 2008). It was further 
demonstrated that PICK 1 knockout mice lacked ICA69 and that ICA69 knockout 
 
Figure 5.23 Pictorial diagram of CAR-SIV and PICK1 binding 
 
 
KEY: CAR-SIV PICK1 PDZ 
domain
PICK1 
ab3420
PICK1 
L20/8
PICK1 
SC
A. B.
(A) CAR and PICK1 interaction via the PDZ binding domain (B) low efficiency of CAR 
pull down may be due to the inability of the available PICK1 antisera to successfully 
gain access to the epitopes of the PDZ binding domain interaction of CAR-SIV and 
PICK1 complex or that PICK1 may only bind to unbound PICK1. 
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mice exhibited lower insulin and high proinsulin levels,the same phenotype 
observed in the PICK1 knockout mice (Cao et al., 2013) supporting the evidence 
that both proteins are involved in the maturation and trafficking of insulin granules.  
I therefore propose the following model (see Figure 5.24). PICK1 associates 
through its BAR domain with ICA69 to form a heteromeric complex (PICK1-
ICA69) to induce the curvature of the membrane of an immature granule vesicle 
(containing proinsulin) and encourages the budding of the vesicle from the trans-
Golgi network. CAR-SIV is also localised to the immature granule vesicle and 
could interact with PICK1 via its PDZ binding domain. As the granule begins to 
mature, ICA69 is lost and it is thought that this enables PICK1 to form homomeric 
complexes (PICK1-PICK1) and also increases the PDZ domain binding slots 
(Cao et al., 2013) possibly for the enrichment of CAR-SIV to continue the process 
of maturation and trafficking of the insulin secretory granule. This therefore 
suggests a possibility that PICK1 and CAR-SIV interaction in the beta cell may 
play a role in the maturation and trafficking of the insulin secretory granules.  
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Figure 5.24 Model for CAR-SIV, PICK1 and ICA69 insulin granule maturation and 
trafficking. 
 PICK1 and ICA69 form a heteromeric BAR complex structure that assists in 
imposing curvature on membranes, to facilitate the budding of the immature 
granule from the trans-Golgi network. CAR-SIV also localises to the immature 
granule vesicle and interacts with PICK1 via its PDZ binding domain. As the 
granule begin to mature, ICA69 is lost from the maturing granule enabling CAR-
SIV and PICK1 interaction to continue the process of maturation and trafficking 
of the insulin granules. Adapted from (Holst et al., 2013) 
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Possibilities for CAR-SIV involvement in trafficking of insulin granules is further 
strengthened through its interaction with other proteins that have been revealed 
to be expressed in the beta cell. Recently, Gan et al (2017) utilising imaging 
analysis (3D confocal and electron microscopy) showed that human and mice 
beta cells can be polarised. It was further revealed that in situ pancreatic beta 
cells had 3 distinct domains consisting of an apical domain identified by the 
enrichment with PAR-3 and ZO-1 proteins, a lateral region enriched by E-
cadherin and GLUT-2 proteins and a distinct basal domain enriched with synaptic 
scaffold protein Liprin oriented towards the vasculature (Gan et al., 2017).  One 
hypothesis that would require more research is that CAR-SIV may be able to 
direct insulin granules to distinct membrane localisations within beta cells, 
depending on which protein it interacts with. At the apical domain CAR-SIV can 
interact with ZO-1(Excoffon et al., 2010); the lateral region where CAR interacts 
with E-cadherin (Morton et al., 2013) or the basal domain where it was shown 
that high K+ stimulated insulin exocytosis from the basal region into the 
bloodstream detected by two photon live cell imaging in stimulated isolated mice 
islets (Low et al., 2014). 
This chapter has therefore revealed a punctate localisation of CAR-SIV within the 
beta cells and further demonstrated that it was specifically localised to the insulin 
secretory granule. I also found that CAR-SIV colocalises and interacts with the 
cytosolic protein PICK1 in the beta cell. The CAR-SIV and PICK1 interaction may 
be important for the maturation and trafficking of insulin secretory granules. 
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CHAPTER 6 
Investigation of the role of CAR-SIV 
in the human pancreatic beta cell 
line 
 
 
 
 
 
 
 
  
265 | P a g e  
 
6.1 Introduction 
The novel findings presented in chapter 5 that the CAR-SIV isoform is localised 
to insulin secretory granules and that it co-localises and interacts with PICK1 
imply a synergistic role for CAR-SIV in the trafficking and maturation of the insulin 
secretory granules. On this basis, it was appropriate to undertake functional 
studies in a human pancreatic beta cell model to investigate the role of CAR-SIV 
in insulin secretion.  
The objectives of this chapter are as follows; 
 To confirm the generation of wildtype and truncated CAR-SIV vectors 
 To develop a human growth hormone model to explore CAR-SIV 
physiological role in the human pancreatic beta cell  
 
 
6.2 Results 
6.2.1 Confirming the generated wildtype CAR-SIV and truncated 
CAR-SIV mutant constructs 
To understand the functional role of CAR-SIV in human pancreatic beta cells, 
overexpression studies were employed in the 1.1B4 cell line. Two CAR-SIV 
constructs; one encoding the wild-type (full length) protein and a second encoding 
a truncated mutant (in which the three C-terminal amino acids “SIV”were deleted) 
were generated by site-directed mutagenesis (Chapter 2, section 2.22). Each 
was transiently transfected into 1.1B4 cells which were then immunolabelled with 
anti-CAR CT and anti-CAR RmcB. The results revealed that CAR-SIV was 
overexpressed successfully in the transfected cells and a similar staining pattern 
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was observed with CAR CT and CAR RmcB antisera (Figure 6.1A). In contrast, 
no immunolabelling was achieved with the CAR CT antiserum when the truncated 
CAR-SIV mutant was transfected into the cells which is consistent with the 
absolute requirement for the terminal three amino acid motif “SIV” for CAR CT 
antiserum binding. However, as expected, the CAR RmcB antiserum still 
detected the truncated CAR-SIV mutant (Figure 6.1B). 
 
 
Figure 6.1 Full length CAR-SIV isoform is overexpressed in wild-type CAR-SIV and 
not in truncated CAR-SIV mutant constructs in 1.1B4 cell line 
 
To further validate that CAR-SIV overexpression had been achieved, western 
blotting was employed. 1.1B4 cells were transfected with the following plasmids; 
(A). CAR-SIV (anti-CAR CT; green) and staining with anti-CAR RmcB (anti-CAR 
RmcB; red) is detected in wild-type CAR-SIV constructs (B) CAR-SIV (anti-CAR CT; 
green) is not detected but staining with CAR RmcB antiserum (anti-CAR RmcB ;red) 
is detected in truncated CAR-SIV mutant construct. Nuclei were stained with DAPI 
(blue). Data are representative of three replicates. Scale bar 2.5μm 
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empty vector, truncated CAR-SIV mutant, CAR-SIV Myc tag (where a Myc-tag 
was placed at the C’ terminal end of CAR-SIV) and wild-type CAR-SIV construct. 
The western blot analysis confirmed that wild type CAR-SIV isoform is detectable 
by the CAR CT antiserum in the 1.1B4 cells; as indicated by a single band 
(expected molecular weight of 40kDa) in the relevant lane (Figure 6.2).In contrast, 
this antiserum did not detect the truncated CAR-SIV mutant and it also failed to 
label the Myc-tagged variant, presumably because the Myc-tag physically 
hindered the antibody access. The anti-CAR ECD detected all variants of CAR 
as shown in Figure 6.2.  
 
 
 
 
 
 
 
 
 
 
 
To support these data, flow cytometry analysis (previously optimised as 
described in Chapter 4, section 4.5) was performed, utilising the CAR RmcB and 
CAR CT antisera. These were used to label both surface and intracellular  
 
 
Figure 6.2 Confirmation of the CAR CT antiserum detecting only the full length CAR-
SIV isoform. 
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1.1B4 cells were seeded at 5 x 104 cells/ml and transfected with empty vector, 
truncated CAR-SIV mutant, CAR-SIV Myc tag and Wild-type CAR-SIV in avalanche-
omni transfection reagent for 24hrs. 1.1B4 cells were then lysed and total protein 
was isolated for western blotting. Western blot analysis detects an estimated 
(40kDa) of CAR-SIV (anti-CAR CT) in only the wild-type CAR-SIV construct. In 
contrast, CAR ECD antiserum detects a band at approximately (40kDa) in control, 
empty vector, truncated CAR-SIV mutant, CAR-SIV Myc tag and in wild-type CAR-
SIV construct. Loading control β-actin (42kDa), Data are representative of three 
independent experiments. 
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To support these data, flow cytometry analysis (previously optimised as 
described in Chapter 4, section 4.2.2 and 4.2.3) was performed, utilising the CAR 
RmcB and CAR CT antisera. These were used to label both surface and 
intracellular CAR in non-permeabilised and permeabilised 1.1B4 cells transfected 
with the empty vector, wild-type CAR-SIV or truncated CAR-SIV mutant 
constructs, respectively.  
The results revealed that CAR RmcB antiserum labelled the surface of cells 
transfected with either wild-type or truncated CAR-SIV constructs (as expected) 
indicated by the orange arrows in the scatter plot (Figure 6.3A). However, little or 
no labelling was achieved in the cells transfected with empty vector. This is in 
agreement with the data obtained in Chapter 4 where 1.1B4 cells were shown to 
have very weak surface expression of endogenous CAR. As shown previously 
(Chapter 4) the CAR CT antiserum can label intracellular CAR-SIV in 
permeabilised pancreatic beta cells. As expected, CAR CT didnot label the 
surface of cells transfected with any of the constructs tested (Figure 6.3A).  
When assessing the patterns of intracellular staining in permeabilised 1.1B4 
cells, using anti-CAR CT, it was evident that intracellular CAR-SIV was present 
endogenously and that it was expressed at higher levels (indicated by purple 
arrows) in cells transfected with the wild-type CAR-SIV construct (Figure 6.3B). 
In contrast, no labelling was seen in cells expressing the truncated CAR-SIV 
mutant construct (Figure 6.3B) supporting previous conclusions about the 
antibody specificity. 
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Figure 6.3 Representative flow scatter plot confirming labelling with CAR RmcB and CAR CT antisera in CAR-SIV transfected 1.1B4 cells. 
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(A) Surface CAR (anti-CAR RmcB; orange arrow) is expressed in wild-type CAR-SIV, truncated CAR-SIV mutant but not in empty 
construct 1.1B4 cells. (B) Intracellular CAR-SIV (anti-CAR CT; purple arrows) is expressed in the empty and in the wild-type CAR-
SIV construct but not in the truncated CAR-SIV construct. Data are representative of three replicates 
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6.2.2 Detection of CAR CT and CAR RmcB antisera binding in 
transfected cells using a proximity ligation assay 
To assess the binding of CAR CT and CAR RmcB antisera in transfected cells, a 
proximity ligation assay (PLA) was employed. PLA requires the close proximity 
of two antisera (within a maximum distance of 30-40nm) to yield a positive signal 
(Chapter 2, section 2.18).  
Briefly, INS-1E cells were transiently transfected with wild-type CAR-SIV or the 
truncated CAR-SIV mutant and immunolabelled with CAR CT and CAR RmcB 
antisera before being subjected to PLA. The cells were also co-stained with anti-
insulin after completion of the proximity ligation assay. Labelling with anti-CAR 
CT and anti-CAR RmcB was detected in cells expressing the wild-type CAR-SIV 
construct (Figure 6.4A). In contrast, no signal was obtained in cells transfected 
with the truncated CAR-SIV mutant construct (Figure 6.4B). Thus, these data are 
consistent with the concept that the C ‘terminal motif “SIV” is essential for anti-
CAR CT binding. In summary, the results obtained using full length wild-type 
CAR-SIV and truncated CAR-SIV mutant constructs have validated the specificity 
of the CAR CT antiserum in a range of different assays (Figure 6.5, Table 6.1). 
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Figure 6.4 Proximity ligation assay demonstrates the binding of CAR CT and CAR RmcB in the different CAR-SIV constructs 
(A) Close proximity binding of CAR RmcB and CAR CT antisera was detected in select INS-1E cells transfected the wild-type CAR-SIV 
construct (red),insulin (green). In contrast, no proximity binding for (B) CAR RmcB and CAR CT antisera binding was detected in cells 
transfected with the truncated CAR-SIV mutant. Nuclei were stained with DAPI (blue). Data are representative of three replicates, Scale 
bar 7.5μm 
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Table 6.1 Summary of the validation of the specificity of CAR CT antiserum with the wild-
type and truncated CAR-SIV constructs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Assays 
CAR CT binding 
(CAR-SIV construct) 
CAR CT binding 
(Truncated CAR-SIV 
mutant construct 
Immunocytochemistry + - 
Western blotting + - 
Flow cytometry + - 
Proximity ligation assay + - 
 
Figure 6.5 Schematic diagram of both CAR constructs 
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Diagram showing the extracellular domains (D1 &D2) with the C terminal end in 
the wild-type CAR-SIV (full length) indicating CAR CT epitope recognition and a 
truncated terminal end in truncated CAR-SIV mutant  
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6.2.3 CAR-SIV colocalises with insulin in wild-type CAR-SIV 
construct in the human pancreatic beta cell line 1.1B4 
To assess the extent of colocalisation of insulin and CAR-SIV in 1.1B4 cells 
expressing the wild-type CAR-SIV construct, triple staining with anti-insulin, anti-
CAR RmcB and anti-CAR CT was employed. This revealed that CAR-SIV isoform 
and insulin were colocalised to a significant extent in 1.1B4 cells (Figure 6.6). 
This therefore prompted us to use a system to assess CAR-SIV’s involvement in 
insulin secretion in the subsequent section. 
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Figure 6.6 CAR-SIV co-localises with insulin in the wild-type CAR-SIV transfected 1.1B4 cells. 
CAR CTNucleus 
CAR RmcB 
Insulin 
Insulin,CARCT&CARRmcB 
Insulin CAR CT Insulin& CAR CTSkin 
(Squamous cell carcinoma) 
Immunocytochemical analysis utilised to detects the expression of (A) insulin (anti-insulin; light blue), (B) CAR-SIV (anti-CAR CT; red) and 
(C)(anti-CAR RmcB; green). Magnified images (Broken lines) displays (D) insulin and (F) CAR-SIV and (G) colocalisation of CAR CT and 
insulin (E) Colocalisation of insulin, CAR CT and CAR RmcB (yellow). Nuclei were stained with DAPI (blue). Data are representative of three 
replicates, Scale bar 5μm 
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6.2.4 Investigating insulin secretion in transfected 1.1B4 cells 
In order to assess the effects of changes in CAR expression on insulin secretion 
from transfected 1.1B4 cells it was necessary to devise a method to distinguish 
between secretions from untransfected vs transfected cells. To achieve this, we 
made use of a previously established human Growth Hormone assay system. 
Human Growth Hormone (hGH) was first used in  rodent beta cells as a means 
to monitor secretory activity and it was shown to be co-sorted and secreted with 
insulin(Iezzi et al., 1999). Cells are transfected with a vector encoding hGH and 
the secreted product is assayed by ELISA in the cell supernatant (Chapter 2, 
section 2.23). This is then taken as a surrogate for insulin release. In order to 
utilise this system, the hGH construct encoding plasmid pXGH5 (Varadi et al., 
2002) provided as a gift by Prof. Guy Rutter (ImperialCollege London) was 
transfected into 1.1B4 cells.  
Inorder to determine the suitable combination of insulin secretion stimuli that 
would provide greatest hGH secretion from 1.1B4 cells, hGH construct was 
transiently transfected and assayed in the supernatant after 1hr. Cells were 
treated with 0mM and 20mM glucose, 25mM KCl alone or together with a 
combination of agents that raise cAMP (200µM IBMX and 10µM forskolin).The 
results revealed that the cells responded with a two-fold increase in hGH 
secretion when exposed to 20mM glucose and 25mMKCl  when compared to 
0mM glucose. Moreover, combinations of (200µM IBMX+ 10µM forskolin+ 20mM 
glucose) and (200µM IBMX+ 10µM forskolin+ 25mM KCl) yielded a further two-
fold increase above than achieved with 20mM glucose or 25mM KCl alone 
(Figure 6.7). This result implies that a combination of 20mM glucose, 25mM KCl, 
10µM forskolin and 200µM IBMX yielded the greatest hGH release.  
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Figure 6.7 Effect of different combinations of insulin secretion stimuli on human 
Growth Hormone (hGH) release in hGH transfected 1.1B4 cells. 
 
 
 
 
 
 
 
 
 
 
 
Transfected hGH 1.1B4 cells were starved for 90mins followed by treatment with 0mM 
or 20mM glucose, 25mM KCl, 200µM IBMX and 10µM forskolin for 60mins. Hgh 
secreted into collected supernatant was determined by hGH ELISA assay. Data 
represents fold change versus control treatment, mean ± SEM (n=3).  
**p<0.01 relative to 0mM glucose (control) 
 ***p<0.001 relative to 0mM glucose (control) 
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6.2.5 Effects of transfection with CAR-SIV on human growth 
hormone (hGH) release from 1.1B4 cells 
To examine whether transfection with  CAR-SIV leads to any change in hormone 
secretion, 1.1B4 cells were co-transfected with 0.7μg of hGH and 0.3μg of either 
wild-type CAR-SIV, truncated CAR-SIV mutant or empty vector prior to 
stimulation of secretion. Growth hormone release into the cell supernatant was 
then assessed. The results demonstrate that hGH release was increased robustly 
(2-3 fold) by the stimulation cocktail (20mM glucose, 25mM KCl, 200µM IBMX 
and 10µm forskolin) in cells transfected with human Growth Hormone alone 
(Figure 6.8A). Surprisingly, co-transfection of hGH with any other DNA species 
resulted in a decrease in absolute hormone release. However, when the values 
were normalised to the relevant control as a means to yield an estimate of relative 
secretion rates with reference to basal secretion, no difference in the extent of 
growth hormone released was evident with any of the constructs tested (Figure 
6.8B). 
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Figure 6.8 Effect of the different CAR-SIV constructs on human growth Hormone (hGH) 
release in 1.1B4 cells 
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Cells were co-transfected with of 0.7μg of hGH and 0.3μg of corresponding constructs 
(empty vector, wild-type CAR-SIV and truncated CAR-SIV mutants and then hGH 
release was assessed with hGH ELISA (A) Total hGH release (B) Fold change in 
reference to basal secretion, values are presented as mean ± SEM (n=3) 
 
A 
B 
279 | P a g e  
 
To explore these relationships further, the ratio of hGHto other vectors was 
varied. Initially, an equal ratio of hGH and the corresponding constructs was 
employed. Thus, 0.5μg of hGH in combination with 0.5μg of wild-type CAR-SIV, 
truncated CAR-SIV mutant or empty vector was transfected and the hGH release 
was monitored. The data show that, using this protocol, a decrease in the 
absolute amount of growth hormone released occurred (78pg/ml vs 550pg/ml; 
when compared to the previous results in Figure 6.8A & Figure 6.9A. However, 
as noted previously, when the “fold change” was measured with reference to 
basal secretion, there was no difference in the amount of growth hormone 
released when comparing cells transfected with the wild-type CAR-SIV, truncated 
CAR-SIV mutant or empty vector (Figure 6.9B).  
Collectively, these results revealed that CAR-SIV does not have a marked effect 
on human growth hormone release under the conditions of these studies. 
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    Figure 6.9 Effect of the equal ratio of human growth hormone (hGH) and 
    different CAR-SIV constructs on hGH release in 1.1B4 cells 
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A 
B 
Cells were co-transfected with of 0.5μg of hGH and 0.5μg of corresponding constructs 
(empty vector, wild-type CAR-SIV and truncated CAR-SIV mutants) and then hGH 
release was assessed with hGH ELISA (A) Total hGH release (B) Fold change in 
reference to basal secretion presented as the mean ± SEM (n=3) 
 
281 | P a g e  
 
6.2.6 Investigation of the human growth hormone (hGH) system 
in the rodent pancreatic INS-1E cell line 
The results obtained with 1.1B4 cells prompted an assessment of parallel studies 
using a rodent beta cell, INS-1E, since earlier reports have utilised the hGH assay 
in rodent pancreatic beta cell lines (da Silva Xavier et al., 2003, Varadi et al., 
2002). INS-1E cells were co-transfected with 0.7μg hGH and 0.3μg empty vector 
and the release of growth hormone was evaluated. The results showed a robust 
increase in growth hormone release compared to control when cells were 
treatedwith the “stimulation cocktail” (Figure 6.10). Thisconcurs with the hGH 
release observed from 1.1B4 cellsshown below in Figure 6.11. 
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Figure 6.10 hGH is released in INS1E cells co-transfected with 0.5μg of hGH 
and 0.3μg empty constructs. 
Transfected hGH construct and empty vector 1NS-1E cells were starved for 90mins 
followed by treatment with 0mM or 20mM glucose, 25mM KCl, 200µM IBMX and 
10µM forskolin for 60mins. The hGH secreted into collected supernatant was 
determined by hGH ELISA. Data are represented as mean ± SEM (n=3) 
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Figure 6.11 The hGH release from the hGH transfected 1.1B4 cells is similar 
to the INS1-E cells. 
 
 
 
 
 
1.1B4 and INS-1E cells were co-transfected with 0.7μg of hGH and 0.3μg of 
empty vector and then hGH release was assessed with hGH ELISA. Fold 
change in reference to basal secretion was assessed in both 1.1B4 and INS1-
E cells. Each data set are presented as mean ± SEM 
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To determine if indeed the hGH and insulin are co-localised in transfected cells, 
immunocytochemical (ICC) analysis was employed by co-staining INS-1E cells 
with anti-hGH and anti-insulin. High resolution confocal microscopy revealed that 
insulin was present in many more cells than expressed hGH (Figure 6.12). 
Moreover, where these were present in the same cells, hGH and insulin did not 
always co-localise (Figure 6.13). These results suggest that insulin and hGH may 
be routed differentially through the regulated secretory pathway in INS-1E cells 
but this remains to be confirmed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12 Insulin is present in many more INS-1E cells than expressed hGH. 
 
hGH Insulin
Representative confocal immunocytochemical imaging showing staining with 
anti-hGH (green) and insulin (light blue). Nuclei were stained with DAPI (blue). 
Data are representative of three replicates.Scale bar 50µm 
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          Figure 6.13 hGH co-localises with insulin in some, but not in all INS-1E cells. 
 
Insulin
hGH
Insulin
hGH
(A) (B)
hGH insulinhGH insulin
Representative immunohistochemical analysis of (A) anti-hGH (green) and insulin (light blue) (B) anti-hGH (green) and anti-insulin 
(red), Magnified images (white broken box) displaying co-localisation. Nuclei are stained with DAPI (blue). Data are representative 
of three replicates. Scale Bar 7.5μm 
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6.2.7. Immunocytochemical detection of human growth hormone 
(hGH) and CAR-SIV in the human pancreatic beta cell line 1.1B4 
To further explore the co-localisation of hGH and insulin in the wild type CAR-SIV 
construct in 1.1B4 cells, cells that had been co-transfected with growth hormone 
were examined by immunocytochemistry using anti-growth hormone, anti-CAR 
CT and anti-insulin. The staining pattern demonstrates that CAR-SIV co-localised 
with human growth hormone in certain regions in some cells but this was not 
always the case (Figure 6.14A). In other cells, that were negative for insulin, CAR-
SIV and growth hormone co-localised partially (Figure 6.14B). 
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                 Figure 6.14 ICC staining reveals hGH partial co-localisation with CAR-SIV in insulin containing beta cells in 1.1B4 cells. 
 
hGH
CAR-SIV
Insulin
hGH
CAR-SIV
Insulin
hGH hGH CAR-SIV insulin
hGH CAR-SIV insulin
hGH CAR-SIV insulin
hGH CAR-SIV insulin
Representative immunocytochemical analysis of (A) hGH (anti-hGH; green), CAR-SIV (anti-CAR CT; red) and insulin (anti-
insulin; light blue) (B) anti-hGH (green), CAR-SIV (anti-CAR CT; red) and anti-insulin (negative). Magnified images displays 
degree of co-localisation, Nuclei is stained with DAPI (blue). Data are representative of images from three replicates. Scale Bar 
5μm, 7.5μm 
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6.3 Discussion 
6.3.1Generation of wild-type and mutant CAR-SIV constructs 
The employment of a site directed mutagenesis strategy resulted in the 
successful generation of wild-type CAR-SIV and truncated CAR-SIV mutant 
constructs. Visualisation of theseconstructs by immunocytochemistry (ICC), 
western blotting and flow cytometry revealed that transfected CAR-SIV was 
robustly detected in the 1.1B4 cells when immunolabelled with the anti-CAR CT 
serum. Indeed, a similar pattern was achieved with either CAR CT or CAR RmcB 
antisera. As expected, the CAR CT antiserum did not detect the truncated CAR-
SIV mutant from which the C terminal “SIV” motif had been removed. This was 
confirmed by ICC, western blotting and flow cytometry. In addition, it was also 
found that attachment of a Myc-tag to the C’ terminal end of wild-type CAR-SIV 
created a molecule in whichsteric hindrance prevented the CAR CT antiserum 
from binding. 
6.3.2 Validation of the specificity of the CAR CT antiserum using 
the mutant CAR-SIV construct 
As demonstrated in this study, the CAR CT antiserum failed to recognise the 
truncated CAR-SIV mutant when tested via ICC, western blotting or flow 
cytometry. Consistent with this, a proximity ligation assay which relies upon the 
close proximity of two antisera provided an independent confirmation since no 
labelling was achieved with a combination of the CAR RmcB and CAR CT 
antisera in cells expressing truncated CAR-SIV.By contrast, a positive signal was 
obtained with these antisera in cells expressing the wild-type CAR-SIV 
construct.This implies that CAR CT and CAR RmcB antisera will only interact 
when the “SIV” residue is intact.  
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Overall, these studies have validated the specificity of CARCT antiserum and 
shown that it does not cross react with other CAR isoforms.  
6.3.3 CAR-SIV overexpression did not impact on insulin granule 
secretion in this model-but is it the right model? 
The wild-type CAR-SIV construct was observed to be localised in a similar 
subcellular compartment to insulin in the 1.1B4 cells (Figure 6.6). Thus, to assess 
whether the presence of CAR-SIV had a functional impact on insulin secretion, a 
human Growth Hormone assay was utilised in the 1.1B4 cells because it has 
been reported that growth hormone is co-secreted with insulin following 
transfection and that hGH secretion is stimulated in a calcium dependent manner 
(Sugita et al., 1999). Interestingly, results of the trial with different stimuli revealed 
that indeed the 1.1B4 cells were responsive in that growth hormone release was 
increased by 2-4 fold under stimulating conditions, by comparison with the basal 
levels. 
One feature of the responses described here is that hGHsecretion appeared to 
be decreased in absolute terms as the amount of DNA was varied in transfection 
experiments. However, when the growth hormone release was normalised by 
reference to the basal level, it was seen that the stimulation index was essentially 
unchanged under conditions when each of the forms of CAR-SIV was introduced. 
This finding is rather disappointing as, when taken at face value, the results 
suggest that CAR-SIV may not be involved in controlling insulin secretion. 
However, we note that thehGH release in these cells is utilised as asurrogate for 
insulin release and examination of the co-localisation of insulin and hGH revealed 
that, inmany 1.1B4 cells and INS-1E cells, the transfected hGH did not fully co-
localise with insulin. This suggests the surprising possibility that the granules 
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containing insulin and growth hormone may be different and as such each 
granule pool could be regulated differentially. Thus, this suggests that it may not 
be completely accurate to measure insulin secretion from growth hormone 
release. 
Another important issue is that many of the 1.1B4 cells were not immunopositive 
for insulin (Figure 6.14B) and may therefore mean that this cell model is not ideal 
for assessing the potential role of CAR-SIV in insulin secretion. An alternative 
human model that could be examined in the future is the EndoC-βH1, however, 
studies from other members from our laboratory utilising this model have shown 
that they are difficult to transfect.  
Together these arguments suggest that the hGH assay might not be an efficient 
system to study insulin secretion and other alternative human pancreatic beta cell 
model would need to be pursued for future experiments in clarifying the CAR-SIV 
functional impact in insulin secretion. 
 
6.3.4 Future work to assess the effect of CAR-SIV in insulin 
secretion 
Initially the first objective would be to confirm more fully whether insulin and 
growth hormone utilise thesame granule pools and this might be best achieved 
by using EM studies to label both insulin and growth hormone in beta cells to 
observe if they are both co-localised in the same pool of granules. 
Unfortunately it may not be ideal to utilise a rodent beta cell line to understand 
the role of CAR-SIV in insulin secretion because immunostaining with anti-CAR 
CT in chapter 3 in murine pancreas suggests that CAR-SIV is not normally 
expressed in the endocrine cells and therefore may not form part of the insulin 
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secretion machinery in rodents. In other words, the rodent beta cell line will not 
be ideal for studying the role of CAR in insulin secretion. 
Potentially, knocking down CAR-SIV in isolated human islets by the transfection 
of siRNA’s and assessment of the impact on insulin secretion would, however, 
be an appropriate approach. In a similar vein, an endogenous regulator of CAR 
has recently been described which is known as “hsa-miR-466d”. This was shown 
to downregulate CAR expression in human A549 cell line (Lam et al., 2015) and 
could be of value in beta cells if similar regulatory mechanisms are present. 
Another option would be to inhibit the interaction between CAR-SIV and PICK1 
in isolated human islets or EndoC-βH1 by utilising a cell permeable, small 
molecule PDZ domain inhibitor (E)-ethyl 2-cyano-3-(3,4-dichlorophenyl 
acryloylcarbamate)which has been shown to specifically target PICK1 PDZ 
domain (Bach et al., 2010).  
However, the above experiments mentioned are problematic in that obtaining 
isolated human islets is not trivial. Moreover, physically knocking down genes in 
a human islet would require significant optimisation. Furthermore, ahuman islets 
would require further isolation of functional beta cells which is intricate as islets 
are a mixed population consisting of both beta islets cells and exocrine cells. 
 In conclusion, this chapter has been able validate the CAR CT antiserum and 
has recommended that a system to assess CAR-SIV role in insulin secretion 
would need to be developed to clarify the functional importance. 
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                    CHAPTER 7 
Conclusion 
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7.0 Summary 
This is the first study to comprehensively investigate which CAR isoforms 
areexpressed in the human pancreas. Immunological and molecular approaches 
reveal the selective expression of a specific CAR isoform “CAR-SIV” in the human 
pancreatic beta cell, at both the RNA and protein level. The specificity of the CAR 
antiserum (CAR CT), used for the characterisation of CAR-SIV was validated and 
proven not to react with other CAR isoforms by site-directed mutagenesis. 
Unexpectedly, we discovered that the subcellular localisation of CAR-SIV in the 
human pancreatic beta cell was not at the plasma membrane. Rather, it was 
found to be intracellular within a granular distribution in the cytoplasm suggesting 
a distinct physiological role. Intriguingly, assessment of a human microarray 
revealed that CAR-SIV was expressed in a variety of other tissues that have a 
biological secretory function and in these cells it tended to have a granular 
localisation. In the pancreatic beta cell, CAR-SIV colocalised with insulin and 
other insulin secretory granule proteins ZnT8 and PC1/3 but less so with 
proinsulin. It was also found to interact and co-localise with PICK1, a cytosolic 
protein involved in the budding, maturation and trafficking of insulin secretory 
granules. Direct confirmation by Cryo-immuno EM revealed that CAR-SIV is 
localised to both maturing insulin secretory granules and to fully mature, dense 
core (insulin) secretory granules. These intriguing findings may have several 
implications in type 1 diabetes which are discussed below. 
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7.0.1The localisation of CAR-SIV may explain the susceptibility 
of human beta cells to enteroviral infection 
Coxsackie B viruses (1-6) have been associated with the pathogenesis of 
autoimmune type 1 diabetes although, the mechanisms by which these viruses 
could contribute to type 1 diabetes are not fully understood. CVB can gain entry 
into cells via CAR and therefore I propose that CAR-SIV localisation to the mature 
dense core insulin granules may facilitate enteroviral entry into the beta cells 
during exocytosis, which is summarised in Figure 7.1.  
I predict that the orientation of CAR-SIV is such that the C’ terminus (with the 
PDZ binding domain) is located in the cytoplasm environment making it available 
to other proteins containing PDZ domains while the extracellular domain 
(important for virus binding) is in the lumen of the granule. Thus, during 
maturation of the granule, the extracellular domain of CAR is in the interior of the 
granule and only becomes available to the external face of the plasma membrane 
during exocytosis. This would suggest that enteroviral entry into the beta cells 
might be facilitated when secretory exocytosis occurs, leading to increased 
externalisation of CAR-SIV and therefore increased viral entry. In support of this, 
Ylipaasto et al (2004) demonstrated that pre-treatment of human islets with a 
CAR blocking antiserum (CAR RmcB) directed towards epitopes in the 
extracellular domain of CAR attenuated Coxsackie virus infection (Ylipaasto et 
al., 2004). This is consistent with the present study where the majority of CAR is 
localised intracellularly in the islet cells implying that externalisation of CAR-SIV 
facilitates viral entry. 
Furthermore, Hodik et al (2016) demonstrated that stimulation of insulin secretion 
3 days after infection of isolated human islets with CVB-5 led to the formation of 
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enterovirus replication complexes and CVB-5 viral particle lattices on or near 
insulin secretory granules (Hodik et al., 2016b). This evidence supports the 
hypothesis that CAR-SIV localisation in the beta cells may enhance their 
susceptibility to enteroviral infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEY: 
Proinsulin CAR-SIV 
CVB 
Insulin 
Mature granule 
CAR ECD 
CAR CT 
Figure 7.1 Proposed model of enteroviral entry in the beta cell through CAR-SIV. 
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7.0.2 CAR-SIV may have a role in vesicle maturation and 
trafficking in human pancreatic beta cells 
This study revealed that CAR-SIV is expressed in a variety of tissues involved in 
exocytotic secretion; for example the testis and brain. Previous work has 
demonstrated that the testis secretes proacrosomal granules that are involved in 
fertilisation (Berruti and Paiardi, 2011) while neuronal cells secrete 
neurotransmitters by exocytosis(De Camilli and Jahn, 1990). 
In this study, CAR-SIV was reported to co-localise and interact with the PDZ 
domain cytosolic protein PICK1 in human beta cells. PICK1 has a unique 
combination of  PDZ and BAR domains (Xu and Xia, 2006) and plays a specific 
role in budding and trafficking of immature secretory granules from the trans-
Golgi network (Holst et al., 2013). Electrophysiological and Cryo-EM analysis in 
adrenal chromaffin cells from PICK1 KO mice revealed aberrant biogenesis of 
secretory granules and impaired catecholamine secretion (Pinheiro et al., 2014). 
Furthermore, PICK1 knockout mice demonstrated impaired trafficking of 
proacrosomal granules in the testis and abnormal acrosome formation in sperm, 
directly affecting male infertility (Xiao et al., 2009). These studies provide strong 
evidence to support a role for PICK1 in the trafficking and maturation of secretory 
granules. It is conceivable from our study that CAR-SIV orientation in the insulin 
granule enables PICK1 interaction and this association with the insulin secretory 
granules could facilitate the maturation of the insulin secretory granules after their 
emergence from the trans-Golgi network (see Figure 7.2, below)  
Furthermore, via its BAR domain PICK1 interacts with a microtubule trafficking 
associated protein, syntabulin, which functions as a linker molecule for the 
attachment of cargo vesicles to the molecular motor, conventional kinesin 1, 
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mediating vesicle transport (Su et al., 2004). In rat hippocampal neuronal cells, 
time lapse live imaging demonstrated that syntabulin regulates the trafficking of 
PICK1 containing vesicles along axons (Xu et al., 2016). Since, syntabulin is 
expressed in beta cells and was shown to mediate glucose stimulated insulin 
secretion (Ying et al., 2012), we speculate that PICK1 and CAR-SIV may interact 
in the insulin granules to favour syntabulin binding to the PICK1 and CAR-SIV 
complex thereby promoting the tethering of insulin secretory granules to 
microtubules. CAR-SIV has also been shown to have high affinity for 
microtubules and it was revealed that its cytoplasmic domain is required for the 
interaction with microtubules(Fok et al., 2007). Thus, microtubule dependent 
ATPases such as kinesins could then assist in the transport of tethered insulin 
granules along microtubules to the cortical F actin filamentous web located near 
the cell periphery, in preparation for exocytosis (docking and SNARE protein 
complex formation) (Thurmond et al., 2003). At this point, we suspect that PICK1 
is lost as it is not required for exocytosis (Cao et al., 2013, Pinheiro et al., 2014) 
with CAR-SIV still intact in the secretory granule. Depolymerisation of the F-actin 
network at the plasma membrane occurs disrupting it’s interaction with the 
SNARE protein complex leading to the mobilisation of the insulin granule for 
exocytosis. 
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Figure 7.2 CAR-SIV and PICK1 interaction in the beta cell may be involved in the 
maturation and trafficking of the insulin secretory vesicle.  
Hypothesis: PICK1 interacts with CAR-SIV through its PDZ domain to facilitate the 
maturation of the insulin secretory granules after their emergence from the trans-Golgi 
network. PICK1 then interacts via it’s BAR domain with syntabulin, mediating insulin 
vesicle transport on microtubules to F-actin near the cell periphery. In preparation for 
exocytosis, PICK1 is lost and there is depolymerisation of the F-actin network at the 
plasma membrane, allowing mobilisation of the insulin granule for exocytosis. 
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7.1 Limitation of study 
Whilst this work predominantly focuses on the expression of CAR-SIV in the 
human pancreatic beta cell, the other transmembrane isoform CAR-TVV is also 
present as shown by RNA analysis in either isolated human islets or from laser-
captured microdissected islets. The use of less selective antisera (CAR RmcB 
and CAR ECD) cannot differentiate between these isoforms, therefore the 
possibility that CAR-TVV is present and functional in beta cells cannot be 
excluded. Unfortunately, a specific CAR-TVV antiserum is neither commercially 
available nor was I able to obtain it from authors of publications describing such 
antisera.  
 
7.2 Future Work 
To test the models presented in this thesis in isolated human beta cell or a 
suitable pancreatic beta cell line by;  
 Assessing the impact on insulin secretion of wild-type CAR-SIV and 
truncated CAR-SIV constructs  
 Knocking down the CAR-SIV isoform and studying the effects on insulin 
secretion. 
 Examining if the level of viral infection under high and low glucose 
conditions is impacted by treatment with a CAR blocking antibody. If my 
model is correct, high glucose treatment should enhance viral infection 
and if CAR is mediating this, treatment with the blocking antibody should 
reduce infection. In addition, to confirm that viral infection of beta cells can 
be mediated by CAR-SIV, I would transfect cells with both the wild-type 
CAR-SIV and the truncated CAR-SIV constructs, to demonstrate that CAR 
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is mediating the infection. This will also confirm the importance of the 
terminal three amino acids in this process.  
 Disrupting the interaction between CAR-SIV and PICK1 by utilising a small 
cell permeable PDZ domain inhibitor (E)-ethyl 2-cyano-3-(3,4-
dichlorophenyl acryloylcarbamate), which has been shown to specifically 
target PICK1 PDZ domain (Bach et al., 2010). This could be used to 
confirm the importance of the CAR-SIV and PICK1 interaction in mediating 
both insulin secretion and/ or viral infection. 
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APPENDIX 
Table 8.1  Tissue Samples, Patient Information 
Case ID Case Type Cohort Age Sex Duration of 
disease 
12425 No diabetes EADB Neonate   
8582 No diabetes EADB 1 N/A  
150/88 No diabetes EADB 3 F  
274/91 No diabetes EADB 6 M  
245/90 No diabetes EADB 6 M  
8651 No diabetes EADB 6 N/A  
12229 No diabetes EADB 10 N/A  
540/91 No diabetes EADB 11 M  
6099-06 No diabetes nPOD 14.2 M  
PM146/66 No diabetes EADB 18 F  
PAN 8 No diabetes EADB 19 N/A  
PAN 1 No diabetes EADB 22 N/A  
6160-06 No diabetes nPOD 22.1 M  
329/72 No diabetes EADB 24 M  
191/67 No diabetes EADB 25 M  
PM132/67 No diabetes EADB 46 M  
330/71 No diabetes EADB 47 M  
186/74 No diabetes EADB 55 F  
77/6/87 No diabetes EADB 57 F  
332/66 No diabetes EADB 59 M  
6098 No diabetes nPOD 17.8 M  
6153 No diabetes nPOD 15.2 M  
6027 AAb+ nPOD 18.8 M  
6167 AAb+ nPOD 37 M  
E236 T1D EADB 7 F 'Recent' 
SC41 T1D EADB 4 F 3 weeks 
11746 T1D EADB 6 M <1 week 
11713 T1D EADB 3 M 3mth 
E375 T1D EADB 11 F 1 week 
E560 T1D EADB 42 F 18mths 
6041 T1D nPOD 26.3 M 23y 
6087 T1D nPOD 17.5 M 4y 
6113 T1D nPOD 13.1 F 1.58y 
6161 T1D nPOD 19.2 F 7y 
EADB – Exeter Archival Diabetes Biobank; AAb+ - Autoantibody positive no diabetes; 
N/A – not available 
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                          Figure 8.1 Map of the pCMV6 vector  
 
 
 
 
 
  
                                      
 
The vector map depicts where CAR-SIV Myc-tag is inserted (green).           
This vector was purchased from ORIGENE. Map was created with version 
4.1.2 SnapGene.com software 
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                Figure 8.2 Map of the pCMV6 empty vector 
   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
This vector was purchased from ORIGENE. Map was created with version 4.1.2 
SnapGene.com software 
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Table 8.2  Primers used for site directed mutagenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target sequence Primers 
Wild-type CAR-SIV  
Exon 7Fd (stop codon insert) Shown 
in bold italics above 
 
GTCTATAGTAtaGCGTACG 
 
Exon 7Rv 
 
CCATCCTTGCTCTGTGCT 
 
Truncated CAR-SIV mutant  
Exon 7Fd (stop codon insert) Shown 
in bold italics above 
 
 
GAGCAAGGATtaGTCTATA 
 
Exon 7RV 
 
TGTGCTGGAATCATCACAG 
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Figure 8.3 Site directed mutagenesis strategy creating the Wild-type CAR-SIV and truncated CAR-SIV mutant construct 
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